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Abstract 
 
 
The research presented in this thesis focuses on the study of the reaction between 
boronic acids and diols and its evaluation as a possible “click” reaction, possibly 
applicable in bioconjugation and drug delivery. A key feature of this reaction is its 
reversibility at acidic pH, which could allow the release of a diol-containing drug from a 
bioconjugate in the acidic environment of late endosome/lysosome, possibly after 
undergoing receptor mediated endocytosis.  
 
Over the last two decades various studies have focused on the study of the conjugation 
of boronic acids to diols using Alizarin Red S as a fluorescence reporter. In this research 
we have presented an alternative method based on the batochromic shifts of Alizarin 
Red S absorbance; this method is particularly advantageous in complex systems with an 
elevated scattering, such as colloidal dispersions or for binding to complexed active 
compounds. We have therefore demonstrated that this method allows the determination 
of equilibrium constants between diols (e.g. catecholamines) and boronic acids.  
 
We have also demonstrated that the method allows to follow the kinetics of enzymatic 
reactions involving catechols; in particular, we have focused on cytochrome P450-
mediated reactions such as the conversion of estradiol to 2-hydroxyestradiol using 
CYP1A2, or the demethylation of 3-methoxytyramine to dopamine using CYP2D6.  
 
Once we have established a reliable method for following this reaction on low 
molecular weight compounds, we have applied it to polymeric bioconjugates. 
Specifically, we have selected hyaluronic acid (HA) as a biocompatible and 
biodegradable polymeric backbone and produced derivatives containing boronic acids, 
catechols and dimethylated catechols (as negative controls). The resulting polymers 
where characterised via UV-Vis, 
1
H NMR and SLS, also qualitatively evaluating their 
cytotoxicity and enzymatic degradability. The conjugates with boronic acids showed the 
lowest cytotoxicity, and the highest degradability. The complexation of HA-boronic 
derivatives was then studied; using the same library of diols previously used with low 
molecular weight compounds, evaluating the effect of the presence of the 
polysaccharidic macromolecular chain. 
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1. Introduction and scope of the thesis 
1.1 Bioconjugation 
 
Bioconjugation is generally referred to as the formation of a chemical linkage between a 
biologically active component (protein, peptide or drug) and a polymer whereby the 
biologically active component provides the biofunctional properties, and the polymer 
component improves the stability, solubility and biocompatibility of the active 
component
1-5
.  
Bioconjugation with polymers provides several advantages to the bioavailability of the 
drug such as: 
 
A) Shielding effect. Polymers usually protect the conjugated components from 
chemical and enzymatic degradation and can mask their antigenic sites, thereby possibly 
reducing their antigenic/immunogenic properties. For example, poly(ethylene glycol) 
(PEG) has a shielding effect on conjugated drugs from thermodynamic effects like 
temperature, pH and ionic strength, attack by immunoglobulins, degradation by 
enzymes, and adhesion to surfaces due to its high mobility, associated and 
conformational flexibility, and water-binding ability
2, 5-8
. 
 
B) Reduction in renal excretion. The increase in volume following bioconjugation 
may allow reducing the elimination through kidneys, which is known to be size-
sensitive, with a threshold generally assumed to correspond to the size of serum 
albumin. Since, however, the size depends not only on the molar mass, but also on the 
hydration of the bioconjugate, the threshold may occur at molar masses considerably 
lower than that of albumin. For example, PEG threshold occurs roughly at a molecular 
mass of one third of the protein one
2, 5, 9, 10
. 
 
C) Enhanced permeability and retention. Polymers can be conjugated with drugs to 
promote targeted delivery to sites characterised by increased capillary permeability, like 
tumoural or inflamed tissues. For example, this may increase the so-called Enhanced 
Permeation and Retention effect (EPR effect) that is based on the preferential 
accumulation of colloids in cancer tissues due to the higher permeability of blood 
capillaries along with a reduced lymphatic drainage of the tumour
2, 4, 5, 10-13
.  
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D) Receptor-mediated-endocytosis. Macromolecular characteristics such as solubility, 
stability and recognition by receptors of the bioconjugates in blood are responsible for 
the drug‟s entrance into the cell through adsorption or receptor-mediated-endocytosis 
and cleavability intracellularly. There are various linkages like acetals and boronic-diols 
which are acid-sensitive i.e. stable in blood at physiological pH and cleavable only 
intracellularly due to the acidic pH or enzymes of the endosomes and lysosomes
2, 6, 13
.  
 
Depending on the application, bioconjugates can be synthesised in various ways ranging 
from a head-to-tail design where the polymer serves as one block and the biomolecule 
as the other; to a comb shaped structure with biomolecules as side chains which grants 
high stability from denaturation due to its multi-point attachment sites; or high 
throughput dendrimeric structures which can either encapsulate functional molecules 
and isolate their active site or covalently link their functional peripheral groups to 
biomolecules
1, 2
. The various applications and techniques used for bioconjugation are 
mentioned in the following sections.  
 
1.1.1 Applications of Bioconjugation 
 
Discovery of Biological Interactions. An essential task for understanding biological 
processes is to discover and characterise natural ligands of biopolymers. Coupling 
biomolecules of interest with small synthetic molecules capable of ligand binding is one 
of the upcoming approaches for ligand discovery. These small synthetic molecules 
(fluorescent molecules
2, 14
, biotin
15, 16
 or NMR probes
15
) act as probes for ligand 
binding. Some popular examples of this approach are DNA microarrays
15, 17
 and protein 
microarrays
14, 15
 which enable a high-throughput screening of ligands. 
 
Biochemical Assays. Bioconjugation of small molecules to biomolecules can serve as 
probes for biochemical analyses for example; in Förster resonance energy transfer 
(FRET) which generates signals sensitive to molecular conformational changes in the 1-
10 nm range and can be used to characterise protein and RNA folding
16
. FRET works 
by attachment of a pair of fluorescent molecules to different regions of a biomolecules 
whereby, one fluorophore serves as a donor and the other an acceptor of energy, and the 
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acceptor then emits radiation at its own frequency reporting the distance between the 
fluorophores
15, 18
.  
 
Diagnostic Applications. Qualitative and quantitative detection of analytes in clinical 
samples is crucial for the early diagnosis of disease. The most common biosensors used 
commercially consist of biomolecules attached to surfaces via robust bioconjugation 
linkages for example; glucose sensors
8
 (for monitoring glucose levels in diabetics) 
which record digital signals when glucose oxidase is converted to hydrogen peroxide by 
an immobilised enzyme
2, 8, 15, 19
.  
Some of the other biosensors use optical techniques such as surface plasmon resonance 
(SPR)
15
 to evaluate the binding of analytes to biomolecules immobilised on a surface.  
 
Imaging in vivo. Magnetic resonance imaging (MRI)
13, 15, 20
, radioimaging
15, 21
 and 
positron emission tomography (PET)
15
 are some of the most common techniques which 
are used for imaging in vivo. MRI requires contrast agents such as magnetite or 
Gd(III)
15, 20
 to be conjugated to antibodies while radioimaging uses isotopes of iodine 
(
123
I and 
131
I) introduced into tyrosine residues of proteins
15, 16
. PET is used to map 
normal human brain and heart function
15
 as well as for the clinical diagnosis of certain 
diffuse brain diseases such as the ones causing dementias
15
 by sensing the gamma rays 
emitted indirectly by a positron-emitting radionuclide (
18
F fluoro group attached to 
glucose).    
 
Polymer-Protein/Drug linkages. Bioconjugation of biodegradable polymers like 
poly(ethylene glycol) and hyaluronic acid with proteins and drugs is well known in 
literature. The linkage of proteins/drugs to these polymers is essential as it can provide 
desirable advantages such as reduced immunogenicity
22, 23
, improved circulating half-
life in vivo
2
, enhanced water solubility
15
, enhanced proteolytic resistance
2
, reduced 
toxicity
22
 and improved thermal and mechanical stability
23
.   
 
Industrial Applications. Immobilised enzymes are widely used as industrial catalysts 
in the pharmaceutical, food and chemical industry
8
. In the food industry they are used in 
the isomerisation of fumeric acid to malic acid
15
. In the pharmaceutical industry they are 
used for synthesis of drugs like 6-aminopenicillanic acid which uses immobilised 
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penicillin amidase and in the chemical industry for preparation of acrylamide from 
acrylonitrile
2, 15
.   
  
1.1.2 Bioconjugation Techniques 
 
A) Grafting to using natural functionalities 
 
i) Amine conjugation (PEGylation). One of the oldest and most common 
bioconjugation techniques is the reaction between the activated hydroxyl group of PEG 
chains and primary amines from proteins
2, 24, 25
. Functionalisation by alkylation which 
maintains the positive charge of the protein at physiological pH and acylation which 
involves loss of charge at the conjugation site is possible due to the high numbers of 
primary amines present on the surface of proteins in both lysine residues and N-
terminus
1, 15
.  
This method is mainly employed to reduce the limitations of protein-based drugs which 
have a short half-life and are immunogenic for example, PEG-bovine adenosine 
deaminase (ADAGEN)
1, 2, 5, 9
. One of the main limitations is in the use of high 
molecular weight PEG since it accumulates in the liver
1
. 
One of the oldest PEGylation methods uses cyanuric chloride to be linked to PEG 
firstly, followed by the second chloride of the PEG dichlorotriazine derivative linking to 
amines from a protein or drug at room temperature and pH 9 to form a secondary amine 
linkage (Scheme 1-1, left). The main problem with this type of linkages is multiple side 
reactions as well as the toxicity of cyanuric chloride and its derivatives 
1, 2, 24
. 
Polymers like PEG can also be linked with amines using N-hydroxysuccinimide (NHS) 
esters by acylation
1, 5, 15, 26, 27
. The carboxylic acid group of succinylated PEG reacts 
with NHS ester to form succinimidyl succinate PEG which readily reacts with amines at 
physiological pH and hence can form amide bonds with drugs or proteins (Scheme 1-1, 
right). The main issue with this reaction is the hydrolysis of the ester bond of 
succinylated PEG which can be resolved by coupling of NHS to PEG via a carbonate 
group
1, 2, 19, 26, 28
. One of the examples of this type of linkage is the generation of 
controlled-release nanoparticles from PLA-PEG block copolymers with a terminal 
carboxylic acid group attached to PEG conjugated with primary amine terminated 
aptamers
27
. Well-defined NHS α-functional polymers (poly(PEGMA)) for 
bioconjugation with biomolecules can also be synthesised using ATRP and RAFT
25
. 
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Brocchini has shown the polymerisation of diamino PEG and a bis(N-
hydroxy)succinimide macromonomer derived from PEG and cis-aconitic acid leads to a 
water soluble polymer which degrades in acidic pH
29
. 
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Scheme 1-1. Left: Bioconjugation showing reaction of PEG dichlorotriazine derivative with amines via 
alkylation Right: Conjugation of succinimidyl succinate PEG with amines via acylation.  
 
Polymers can also be coupled with peptides or drugs using a single step method by the 
use of a carbodiimide (N,N‟-diisopropyl carbodiimide (DIC) or 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide hydrochloride (EDC)) which activates the polymer 
in situ. Using these methods there is a high loss of bioactivity due to the reaction being 
non-specific and hence having no control over the final bioconjugates
1, 16, 28, 30
.  
To increase the selectivity of the conjugation the active site of the enzyme or 
recognition area of a drug or protein can be shielded using an inihibitor, substrate or 
ligand during the reaction for example; avidin is PEGylated in the presence of biotin-
PEG conjugate which acts as a shield
1, 15
. Another way to increase the selectivity is to 
limit the availability of the reactive groups in the protein by replacing reactive amino 
acids by non-reactive ones, using mutagenesis
1, 30
. 
Another method which can provide specific conjugation is reductive alkylation in which 
an aldehyde reacts with the polymer first, followed by coupling to an amine to form a 
Schiff base
1, 2, 31, 32
. Sodium cyanoborohydride can then be used to reduce this 
intermediate to a stable secondary amine. The main advantage is the functionalisation of 
the N-terminal amines, leaving the lyside side chain amines untouched
1
. Instead of 
using cyanoborohydride in acidic pH, an iridium-catalysed reaction can be carried out at 
pH 7.4 with a high yield
16, 25, 32
. 
 
ii) Cysteine conjugation. Cysteine containing compounds can very well be targeted for 
forming bioconjugates with polymers since the free cysteines are usually low in number 
and hence it leads to a more site specific binding and does not result in a loss of 
biological activity. The main cysteine targeting reactions are thioether and disulphide 
forming
1, 16
. 
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Thioether bioconjugates. Michael type addition involves a cysteine reactive reagent 
(vinyl sulphone) to react with thiols to form thioethers (Scheme 1-2). This is a very slow 
and selective reaction and even the presence of other nucleophiles like amines does not 
affect it. It has been used to link PEG derivatives to RNase and also to immobilise RGD 
proteins on surfaces
1, 7, 15, 16, 33
. 
Chain transfer free radical polymerisation is another method which is used together with 
cysteine conjugation for example; polymerisation of N-isopropylacrylamide (NIPAAm) 
which induces thermo-responsiveness due to its lower critical solution temperature 
(Scheme 1-2) followed by modification of the terminal hydroxyl group with divinyl 
sulphone leads to the production of a thiol-reactive polymer which can conjugate with 
cysteines. These stimuli-responsive materials are referred to as smart materials and can 
be used for diagnostic assays as in this reaction the polymer chains can be linked close 
to the active site of the proteins without hampering its activity
1, 13, 24, 25, 31, 34-38
.   
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Scheme 1-2. Bioconjugation based on reaction of vinyl sulphone with thiols to form thioethers, for 
example; using poly(N-isopropylacrylamide).  
 
Instead of vinyl sulphone, maleimide is a better suited and more commonly used 
Michael acceptor as it reacts faster with thiols as well as is capable of reacting in 
slightly acidic conditions (Scheme 1-3, top). The main drawback is its products (imido 
groups) have low stability in water and undergo spontaneous hydrolysis, which results 
in heterogeneity
1, 2, 15, 19, 27, 28, 33, 39
. One of the reactions using this chemistry involves 
reacting first an amine-terminated PEG with maleic anhydride which forms an 
intermediate, followed by dehydration and ring-closure by acetic anhydride and sodium 
acetate (Scheme 1-3, bottom). This PEG-maleimide can then react with thiols to form 
thioethers
1, 5, 39
.  
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Scheme 1-3. Top: Bioconjugation based on reaction of maleimide with thiols Bottom: Synthesis of PEG-
maleimide using maleic anhydride  
 
Disulphide bioconjugates. A disulphide bond is a covalent linkage which is formed by 
the oxidation of two sulphhydryl (SH) groups of cysteines or other SH-containing 
material. They are usually found in secretory proteins and exoplasmic domains of 
membrane proteins in bacterial and eukaryotic cells
24, 40
. Bioactive compounds 
containing cysteines can be linked to polymers by reacting the thiol group of cysteine to 
an activated disulphide group on a polymer leading to a new disulphide bond. The main 
advantageous points of this reaction are that it can occur in a broad pH range of 3 – 10 
and the newly formed disulphide bond is reversible using reducing agents like 
dithiothreitol (DTT) and β-mercaptoethanol1, 12, 15, 24, 28, 40, 41. The disulphide linkage is 
an interesting delivery tool because of the presence of a high redox potential difference 
between the oxidizing extracellular space and the reducing intracellular space
40
.  
Various activated disulphides like o-pyridyl disulphide, p-pyridyl disulphide, 
alkoxycarbonyl and o-nitrophenyl can be used for this reaction. The most common and 
effective one is o-pyridyl disulphide since it does not take part in the reaction and gets 
sidelined as a nonreactive compound (Scheme 1-4). Polymers like PEG can be 
functionalised with o-pyridyl disulphide either by using an NHS-activated o-pyridyl 
disulphide or by first activating the terminal hydroxyl groups of the polymer by p-
nitrophenyl chloroformate, followed by linking with 2-(2-pyridyldithio)ethylamine
1, 5, 12, 
40
. One of the first disulphide link containing drugs is Mylotarg developed by Celltech 
Group and American Home Products and is anti-CD33 antibody-S-S-calicheamicin, for 
treatment of acute myeloid leukemia
40
.  
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Scheme 1-4. Bioconjugation of bioactive compounds to polymers by reaction of o-pyridyl disulphide 
modified polymer with thiol containing bioactive compound to form a hetero-disulphide bond.  
 
Instead of using the above modifications, pyridyl disulphide-functionalised initiators 
can be used during atom transfer radical polymerisation (ATRP) to form o-pyridyl 
disulphide-functionalised polymers
1, 25
. Disulphide-crosslinked hyaluronic acid 
nanogels have been developed by Park and co-workers physically encapsulating green 
fluorescence protein siRNA for targeting tumours
20, 42
. Disulphide linking chemistry has 
also been used for the preparation of DNA-protein conjugates
17
. 
 
Bridged disulphide bioconjugates. Proteins (leptin, interferon α-2) which have 
cysteines in disulphide bridges on their surfaces can be conjugated with polymers like 
PEG by selectively reducing the surface accessible disulphide bridges using mild 
reducing conditions without denaturants. The two thiols which are liberated are treated 
with a bis-alkylating PEGylation agent which leads to the addition of the first thiol and 
elimination of a sulphinic acid, followed by the addition of the second thiol due to the 
double bond (Scheme 1-5)
1, 41, 43, 44
.  
This addition-elimination-addition reaction ensures that the disulphide is bridged in the 
end linking it to the polymer and hence stabilizing the peptide
1, 41
. 
 
+
=  Polymer
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Scheme 1-5. Formation of three-carbon bridge between polymers like PEG and proteins containing 
disulphide surface bonds by using addition-elimination-addition reaction. 
 
B) Grafting to using unnatural functionalities (Click reactions) 
 
Click chemistry is defined by Sharpless et al. as a chemistry inspired by nature tailored 
to generate substances reliably and quickly by joining small units together
45, 46
. The 
reactions in click chemistry must (or would be desirable)
45, 46
: 
 be modular 
 be wide in scope 
 give high chemical yields 
 generate only inoffensive byproducts 
 be stereospecific 
 physiologically stable 
 exhibit a large thermodynamic driving force to favour a reaction with a single 
reaction product 
 high atom economy 
 have simple reaction conditions 
 use readily available starting materials and reagents 
 use no solvent or a solvent that is benign or easily removed (preferably water) 
=  Polymer
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 provide simple product isolation by non-chromatographic methods 
(crystallisation or distillation) 
 
These are the requirements for a reaction to be classified as a click reaction. The 
following are few examples of click reactions: 
 
i) Copper-catalyzed azide-alkyne Huisgen 1,3-dipolar cycloaddition (CuAAC). 
Azides and alkynes usually react by 1,3-dipolar cycloaddition at high temperatures 
(Scheme 1-6, top). However scientists like Huisgen have demonstrated that this reaction 
can be performed at room temperature and accelerated by using a copper catalyst 
(Scheme 1-6, bottom). It is commonly used because of its high yield, mild reaction 
conditions and ease of introduction of the groups to polymers and bioactive molecules
1, 
14-16, 19, 21, 23, 31, 34, 47-50
. It converts organic azides and terminal alkynes into the 
corresponding 1,4-disubstituted 1,2,3-triazoles, whereas the uncatalyzed reaction which 
requires much higher temperatures leads to the formation of mixtures of 1,4- and 1,5-
triazole regioisomers
31, 46, 49-52
. One of the good examples of the use of triazoles is in the 
antibiotics field where they have been used to improve the pharmacokinetic properties 
of drugs, for example; cephalosporins endowed with good oral availability were 
obtained by conjugation of triazoles to cephalosporin core
14
.  
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Scheme 1-6. Top: Azide-alkyne reaction at high temperature produces 1-4- and 1-5-triazole Bottom: 
Azide-alkyne reaction using copper catalyst at room temperature produces 1,2,3-triazole 
 
Alkyne groups can be introduced into polymers like PEG by coupling propargylamine 
with a NHS activated PEG. Bioactive molecules like superoxide dismutase-1 (SOD) can 
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be modified with azide by linking with p-azidophenylalanine. The CuAAC reaction is 
then carried out in a phosphate buffer at pH 8 to form PEGylated SOD
2
. Clickable 
polymers can also be synthesised by using ATRP, ring-opening polymerisation (ROP) 
or reversible addition-fragmentation chain transfer polymerisation (RAFT) by using 
alkyne or azido functional initiators
1, 21, 22, 31, 50, 52, 53
. 
Tirrell et al. have used this technique for selectively labelling expressed recombinant 
proteins or membrane proteins in living E. coli bacteria in their native environment. 
Others, like Rutjes have conjugated alkyne-functionalised bovine serum albumin to 
azide-functionalised polystyrene
16, 21, 46, 54
. Fokin and Finn have showed how this 
reaction can be carried out in water and the conjugation of fluorophores to virus 
particles
19, 21, 52
.  
The main disadvantages of this reaction are the toxicity of copper to cells as well as the 
denaturation of proteins induced by copper
1, 15, 19, 34, 54
.  
 
ii) Hydrazone and oxime ligation. Ketones and aldehydes can be used for conjugating 
peptides or drugs with polymers as they react with hydrazides and hydroxylamines 
respectively to form hydrazones and oximes (Scheme 1-7). These reactions are well 
suited for bioconjugation since the groups need no protection while conjugation since 
the reaction can be carried out successfully in slightly acidic conditions to prevent the 
side reactions (formation of Schiff base by reaction between amino groups and ketones 
or aldehydes)
1, 15, 32, 45, 46, 51
. 
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Scheme 1-7. Left: Bioconjugation using Ketone-hydrazide reaction forming hydrazone bond Right: 
Ketone-hydroxylamine reaction forming oxime bond.   
 
Polymers like PEG can be modified with hydrazides and then conjugated with bioactive 
molecules containing ketones or aldehydes by a hydrazone bond under acidic 
conditions. This link is thermodynamically unstable and reversible and needs to be 
reduced by sodium cyanoborohydride to form a stable alkyl hydrazide. Similarly, a 
ketone or aldehyde-functionalised bioactive molecule can be linked to a hydroxylamine-
bearing polymer by an oxime bond which is more stable than the hydrazone bond
1, 15, 19
. 
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The half-life of alkylhydrazones and acylhydrazones is only about an hour at 
physiological pH while the half-life of oximes is nearly a month
15
. Since many proteins 
are unstable at low pH, the reaction can be performed at neutral pH by the addition of p-
methoxyaniline which acts as a nucleophilic catalyst and accelerates the rate of 
reaction
1, 19
.  
Controlled hydroxylamine radical initiators can be used for synthesis of polymers with 
hydroxylamine groups using ATRP, for example; tert-butyloxycarbonyl (Boc) protected 
hydroxylamine initiators can be used for synthesis of HEMA and poly(ethylene glycol) 
methacrylate (PEGMA)
1
. 
 
iii) Copper-Free cycloaddition reaction with azides. Literature45, 47 has shown that 
activated alkynes can undergo cycloaddition reactions with azides in the absence of a 
metal catalyst. Alkynes with at least one electron-withdrawing group can react with 5-
azidovalerate at room temperature in water giving a yield of 67 – 94% (Scheme 1-8)34.  
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Scheme 1-8. Click reaction between azides and electron-deficient alkynes (R‟ = H, CH3, or COOEt, R” = 
Me or Et, and N3-X = 5-azidovalerate or 5‟-azido-DNA). 
 
This click reaction has also been performed to couple an azido-DNA molecule to prove 
that functional groups can be introduced to DNA under physiological conditions
34
.  
 
iv) Thiol based click reactions. The radical based addition of thiols to double bonds is 
a well known method used for polymerisation, curing reactions and for the modification 
of polymers. One of the most simple thio-click reactions was shown by Schlaad et al. 
for a post-polymerisation modification of poly[2-(3-butenyl)-2-oxazoline] (Scheme 1-
9). This reaction was performed under an inert atmosphere by exposure to UV light for 
24 hours, but can also proceed under irradiation with direct sunlight. Various other 
thiols like fluorinated thiols and acetylated glucose thiols have also been used in this 
reaction
34
. 
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Scheme 1-9. Thio-click modification of poly[2-(3-butenyl)-2-oxazoline]. 
  
Another thiol based click reaction was performed by Hawker et al. for the synthesis of 
fourth generation dendrimers by using thiol-ene chemistry. The reaction between an 
alkene and a thiol was performed without a solvent under ambient conditions by 
irradiation with a UV lamp for 30 minutes (Scheme 1-10). Trace amount of 
photoinitiator was added to increase the concentration of radicals, and purification was 
carried out by precipitation in diethyl ether
34
.  
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Scheme 1-10. Thiol-ene click chemistry for the synthesis of a dendrimer. 
 
v) Diels-Alder reaction. Diels-Alder reactions involve the simultaneous formation and 
destruction of carbon-carbon bonds. They require very low energy and can carried out 
even below room temperature. One of the most common types of Diels-Alder 
bioorthogonal reactions was reported by Fox et al. for the reaction between tetrazines 
and cyclooctynes (Scheme 1-11). This is based on the inverse electron demand Diels-
Alder reaction, and the subsequent retro-[4+2] cycloaddition produces nitrogen as the 
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only byproduct. The reaction takes 40 minutes at 25 °C to give a high yield and can be 
performed in water
34
.  
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Scheme 1-11. Retro-Diels-Alder reaction of trans-cyclooctene and tetrazine. 
 
C) Grafting to using non-covalent interactions 
 
Bioconjugates can also be formed without covalent coupling, by using coordination 
strategy between polymers and bioactive compounds by the use of cofactors. Cofactors, 
which are present in the active site of proteins and responsible for protein activity can 
be removed and attached to polymers. These polymer-functionalised cofactors when 
mixed with proteins lead to the formation of bioconjugates as the cofactor is 
reconstituted in the protein
1, 17, 31, 37
.  
One of the examples of this type of bioconjugation is the biotin-(strept)avidin system. 
Biotin is a cofactor which has a very high affinity for avidin and streptavidin. Biotin 
contains a carboxylic acid group which can easily link with various polymers and hence 
bioconjugates can be synthesised using avidin or streptavidin. This linkage is one of the 
strongest and hence it is used for constructing materials such as DNA or protein 
microarrays. Biotin can also be incorporated into the initiators for ATRP and RAFT 
thereby leading to biotin-functionalised polymers
1, 17, 28, 31, 37
.   
In drug delivery, PEG-based heparin-functionalised star-polymers have been cross-
linked with dimeric protein vascular endothelial growth factors (VEGF) to form 
hydrogels. VEGF can bind to heparin and also acts as a crosslinker for the gel 
formation. When particles covered with VEGF receptors bind to VEGF proteins, 
erosion of the hydrogel is triggered and this could release the incorporated drugs
1
.  
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D) Grafting from using polymer macroinitiators 
 
There are lots of techniques for bioconjugation of preformed polymers to bioactive 
molecules; however a polymer can also be grown from these bioactive molecules which 
can act as initiators. The main advantages of using this strategy are the need for a small 
amount of initiator, lower steric hindrance during functionalisation and simple 
purification due to removal of only the monomer
1, 25, 31, 37, 51, 53
.  
One of the main strategies for growing a polymer bioconjugate is using a primary 
amine-functionalised initiator, for example; primary amine-functionalised initiators are 
used for ring opening polymerisation (ROP) of amino acid N-carboxyanhydrides 
(NCAs) forming poly(amino acids) (Scheme 1-12, top). This reaction is not controllable 
due to chain-breaking and termination reactions in normal conditions, but can be 
controlled by using high vacuum or by replacing the primary amine initiator by its 
hydrochloride salt
1, 25, 54, 55
.  
An alternative reaction to the above uses a zero-valent nickel complex as initiator to 
carry out NCA polymerisation (Scheme 1-12, bottom). Through an oxidative addition-
reductive elimination mechanism, nickel allows the addition of monomers to the active 
polymer chain-end and also prevents any side termination reactions
1, 37, 54, 55
.  
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Scheme 1-12. Top: ROC of NCAs using a primary amine initiator Bottom: ROC of NCAs using a nickel 
catalyst [2,2‟-bipyrydine – Nickel – 1,5-cyclooctadiene]. 
 
Other more complex macroinitiators containing arms of amines can also be used for the 
growing polymers, for example; star-shaped PEG with four terminal amine groups has 
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been used for ROP of γ–benzyl-ʟ-glutamate NCA to yield poly(γ–benzyl-ʟ-glutamate)1, 
25, 37, 54
. 
Börner has investigated the interactions of ATRP systems with oligopeptide 
macroinitiators using homogenous solution-phase ATRP for the synthesis of poly(n-
butyl acrylate) as well as used RAFT polymerisation for synthesis of bioconjugates
53, 54
.  
 
E) Grafting through 
 
Bioconjugates can also be prepared in comb-like structures with a polymer backbone 
and bioactive side chains by linking the bioactive molecules to the monomers and then 
carrying out polymerisation. The main advantage of this strategy is quantitative 
functionalisation, while the disadvantage is that there might be compatibility issues 
between the bioactive molecule and the polymerisation technique
1, 25, 37
.  
An example of this strategy is the ATRP polymerisation of a methacrylate coupled to a 
pentapeptide (Val-Pro-Gly-Val-Gly) derived from the structural protein tropoelastin 
using the initiator Ebib (ethyl-2-bromo-2-methyl-propionate) (Scheme 1-13). This 
polymerisation is controllable and yields polymers with low polydispersity index
1, 37
. 
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Scheme 1-13. ATRP polymerisation of a methacrylate coupled to a pentapeptide using Ebib initiator. 
 
F) pH Sensitive linkages 
 
In the body, tumours and inflammatory tissues have a pH more acidic than blood and 
normal tissue. The endocytic pathway of cells has a range of pH, whereby it starts from 
7.4, and then lowers down to 5.5 – 6 in the endosomes and finally a pH of 4.5 – 5 in the 
Chapter 1 
33 
 
lysosomes. This drop in pH can be used as a favourable aspect for drug delivery systems 
which are pH responsive
2, 11, 13, 56-59
.   
 
Acetal links. Acetal linkages are acid-sensitive linkages for linking polymers with 
hydroxyl groups of bioactive compounds and are reasonable for drug delivery since 
their hydrolysis rate follows first order kinetics relative to hydronium ion, in other 
words they hydrolyse 10 times faster with each unit of decrease in pH
56, 60-62
. They can 
be formed using various different types of hydroxyl groups such as primary, secondary, 
tertiary, syn-1,2- and -1,3-diols. Also depending on the structure of the acetal, the 
hydrolysis rate can be controlled
56, 61-64
. 
Ketones react with hydroxyl groups from alcohols to form an intermediate (hemiacetal) 
which becomes protonated and further reacts with alcohols to form acetals (Scheme 1-
14)
60, 65
. This reaction also leads to the production of water which needs to be removed 
to prevent hydrolysis of the acetal. These acetals hydrolyse very quickly with a half-life 
of 90 seconds at pH 5 and 6 hours at pH 7.4 at 25 °C and are mostly used for rapid 
targeting to tumours where they can release the bioactive compound even in slightly 
acidic extracellular tumour pH
56
.  
One of the examples of this ketone-alcohol reaction to form acetals is shown by Fréchet 
where he shows the bioconjugation of activated poly(ethylene oxide) (PEO) to 5-fluoro-
2‟-deoxyuridine (anticancer drug) by forming an acetal link56.  
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Scheme 1-14. Synthesis of acetals from ketones by using alcohols. 
 
Aldehydes react with alcohols as well to form acetals, and these acetals are much more 
stable and slow hydrolysing than the acetals formed from ketones because of the 
absence of the second electron-donating methyl group which stabilises the carbocation 
intermediate during hydrolysis
64
. The acetal obtained from acetaldehyde and primary 
alcohol has a half-life of 100 hours at pH 5 and 3 years at pH 7.4, and hence these 
acetals can be used for applications where they need to be stable at physiological pH for 
long periods
56
. An example for drug delivery by using this strategy is by synthesising 
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ATRP based poly(ethylene oxide)-block-poly(glycerol monoacrylate) (PEO-b-PGA) 
and then coupling with drugs like 1-pyrenecarboxaldehyde using acetal linkage
66
. 
Acetal linkages have also been used for formation of responsive gels, for example; PEG 
has been grafted on a polyacetal backbone to form a temperature/pH-sensitive gel which 
disintegrates at acidic pH
63
. For drug delivery, acetalated-dextran which is hydrophobic 
has been used for encapsulating hydrophobic and hydrophilic drugs since it is acid-
sensitive and biocompatible
67
. Fréchet has synthesised acid-sensitive micelles made 
from PEO-dendrimer hybrids which incorporate hydrophobic groups linked to the 
periphery of the block by acetal links; such that upon hydrolysis, the hydrophobic 
groups are lost, resulting in destabilization of the micelle and hence release of drug
57, 59
.  
Another very interesting strategy has been used by Duncan, where oestrogen 
diethylstilboestrol (DES - anticancer drug) has been incorporated into the mainchain of 
water-soluble polyacetals synthesised using co-monomers of PEG resulting in a drug 
release system by degradation of the polymer backbone in the lysosomes of the 
tumour
68
. Duncan and Brocchini have also shown the preparation of polyacetyl-
doxorubicin conjugates for tumour targeting by synthesising amino-pendent polyacetals 
and coupling with doxorubicin by using EDC
62
. Brocchini has also prepared polyacetals 
by the reaction of a diol (e.g., PEG) with divinyl ether (e.g., tri(ethylene glycol) divinyl 
ether) using an acid catalyst
69
.  
 
Boronic acid – Diol links. Boron containing molecules have been found to have 
biochemical functions in plants, algae and microorganisms but are not known for any 
significant role in mammalian cells
70
. Boronic acids bind with diol containing 
compounds through a reversible reaction leading to boronate ester formation (Scheme 
1-15). Various methods have been used in the past for the detection of boronate ester 
formation such as by appending a fluorophore to the boronic acid, nuclear magnetic 
resonance, circular dichroism, and pH titration. The problem associated with appending 
a fluorophore directly to the boronic acid is that it could greatly affect the binding 
affinity of the artificial receptor for the target sugar in a negative fashion while the issue 
with NMR is that, it usually lacks the desired sensitivity to evaluate the binding 
strengths
71
. The stability of this link is pH dependant and it affects the binding affinities 
of boronic acids towards various diols. This property of pH responsiveness enables 
boronic acids to be used for creating sensors for saccharides which contain cis-diol 
moieties and for delivery of bioactive substances when linked with polymers
71-77
.  
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Boronic-diol conjugation can be regarded as a click reaction since it meets most of the 
criteria (see Section 1.1.2 Part B) for it, for example: the joining of small units quickly 
and reliably, wide in scope, give high yield, generate only inoffensive byproducts, 
physiologically stable – as these links are stable at pH 7, simple reaction conditions – as 
it can be performed at room temperature, use readily available starting materials and 
regents, use a solvent like water, provide simple product isolation – as they can be 
separated easily especially when one is linked with a polymer. Since it meets a lot of the 
desirable criteria, we can claim the boronic-diol conjugation to be a click reaction.  
They have also been used in new technologies like BASE (boronate affinity in 
saccharide electrophoresis) which relies on reversible diol binding to modulate 
saccharide mobility
78
. Hydrogels made from this technology are common as well since 
they possess self-healing property i.e. under high shear stress the boronate-diol network 
breaks up (shear thinning) but reheals quickly when it comes to rest
77, 79
.  
The optimal pH of binding where the equilibrium binding constant is the highest is the 
average of the pKa‟s of the boronic acid and diol
72, 74, 80
. As shown by Wang, the Keq 
(equilibrium binding constant) values for ᴅ-glucose, ᴅ-fructose and catechol rise from 
acidic pH till pH 8.5. The Keq values for ᴅ-fructose at pH 5.8, 7.4, and 8.5 are 4.6, 160, 
and 560 M
-1
. Wang also shows that, boronic acids like phenylboronic acid have an 
increasing affinity for diols like alizarin red-S (ARS) when increasing pH from 4-7 and 
that the maximum binding obtained is at pH 7 (Keq = 1100). On increasing the pH from 
7-10 a drop in the binding affinity is found probably due to change in ionization states 
when it changes from trigonal to tetrahedral form. It is well known in literature
71
 that 
boronate-ester complexes have decreased stability under acidic conditions which results 
in a high concentration of the quenched free form of ARS (Keq = 190 at pH 4.6) at low 
pH (<5). Therefore, ARS displays a dramatic change in fluorescence intensity and 
colour in response to the binding of a boronic acid and is used as a general reporter for 
studying carbohydrate-boronic acid interactions, both quantitatively and qualitatively
71, 
72, 81
.  
This property of boronic acids to bind strongly only at physiological or basic pH, and 
showing reversibility at acidic pH could be used efficiently to delivery drugs when 
coupled with a degradable polymer. The idea would be that a boronic acid could be 
linked by a non-reversible bond to a degradable, high molecular weight biopolymer, 
followed by reversibly conjugating with a diol based drug at physiological pH, the 
conjugate would then be purified to remove any excess unbound drug, and will then be 
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injected into the bloodstream where the conjugate would be stable due to the 
physiological pH and would circulate through the body, until it arrives at the site of 
cancer/tumour/inflammatory tissue, where the conjugate would be endocyted by the cell 
(due to cell surface receptors) and the drug would be released in the late 
endosome/lysosome of the cell where there is an acidic pH (due to acidic pH the 
boronic acid-diol reaction reverses, releasing the drug) whereas the polymeric carrier 
would be degraded by enzymes.   
An example of this is provided by Gan et al. who have prepared a magnetic and 
reversible pH-responsive mesoporous silica nanoparticles-based (MSNs) nanogated 
ensemble by anchoring superparamagnetic Fe3O4 nanoparticles on the pore outlet of 
MSNs via a reversible boronate ester linker. They have studied the in vitro release of an 
entrapped model dexamethasone at different pH values which indicated that at acidic 
pH (<5) the hydrolysis of the boroester bond took place and it resulted in a rapid release 
of the drug. In vivo studies were also carried out to evaluate the cytotoxicity of the cells 
with the nanoparticles, but no release profiles were shown
82
.  
The binding of boronic acids to diols has been studied in detail in Chapter 2. 
Polymers can be functionalised with boronic acids and can be used for drug delivery by 
bioconjugation to bioactive compounds like drugs or peptides containing diols. This is 
studied in detail in Chapter 3.  
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Scheme 1-15. Reversible linkage of phenylboronic acid to a diol-functionilised moiety showing the 
trigonal and tetrahedral forms.  
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1.2 Hyaluronic acid (HA) and its functional derivatives 
 
Hyaluronic acid (HA) also known as hyaluronan or hyaluronate is a naturally occurring 
glycosaminoglycan found in the extracellular matrix in the body
83, 84
. It is known as 
hyaluronic acid due to its location in the body and its chemical nature. It was first 
discovered in the vitreous humour of the eye and therefore the name hyaloid which 
means vitreous and it contains uronic acid, therefore the name hyaluronic acid. HA 
exists in the body as a polyanion and not in the acid form and is therefore usually 
known by the name of hyaluronan
85, 86
.  
 
1.2.1 Structure of HA 
 
HA is a high molecular weight polysaccharide with disaccharidic repeating units 
composed of D-glucuronic acid and N-acetyl-D-glucosamine monomers (Scheme 1-16). 
These units are linked together by a 1-4 β glycosidic bond, while the disaccharides are 
connected by 1-3 β bonds in the polymer chain87, 88. 
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Scheme 1-16. Structure of hyaluronic acid 
 
The main difference of HA from other glycosaminoglycans is the absence of sulphate 
groups
89
. HA usually has a molecular weight of a few million g/mol and a broad 
molecular weight dispersity. The end to end distance in a linear conformation in HA is 
approximately 2-25µm
83
.  
The carbon-hydrogen bonds in the saccharidic repeating units are all in axial 
configuration; therefore they form a hydrophobic face, while the equatorial, polar 
Chapter 1 
38 
 
residues form a hydrophilic face, providing therefore a two-face, two-polarity ribbon-
like structure. 
Although the HA molecule looks like a straight rigid rod, however when magnified it is 
a coiled structure. Since it is very rigid, the coils take up more number of units per turn 
and therefore the structure has a lot of empty spaces, which are filled up with water. The 
structure has alternating apolar faces which might interact with the apolar faces on 
another molecule but all the apolar faces cannot couple up because there will be a 
drastic loss in the entropy.
90
 
 
The molecule has a coil-like structure when in solution
88, 90-92
. This coil-like structure is 
produced by the occurrence of hydrophobic and hydrophilic groups in the solution. This 
structure allows smaller molecules to pass through, however large molecules like 
proteins will have restricted access
85, 91
.  
Usually in tissues high molecular weight HA at high concentration can form entangled 
molecular networks. Such networks can be formed if the hydrophobic face on a section 
of HA interacts reversibly with the hydrophobic face on another molecule of HA or 
another region of the same molecule. These networks can exhibit elastic properties by 
distributing the load and shear forces within the network and thereby resisting rapid and 
short duration fluid flow through the network. They can exhibit viscous properties by 
separating and aligning their molecules and thereby allowing slow fluid flow of longer 
duration
85
. 
 
1.2.2 Occurrence, Functions and Commercial Products of HA 
 
Hyaluronan was first found to be present in the vitreous humour of the eye
93
. Since then 
it has been located in many places such as the skin and in some joints (Figure 1-1)
94
. It 
is present in reasonable quantities in aortic smooth muscle cells and chondrocytes and 
also in the nuclei and cytoplasm of cells of some of the tissues
95
.  
 
Figure 1-1. Occurrence of hyaluronic acid in Joints, vitreous humour of the eye and skin (Taken from 96) 
Chapter 1 
39 
 
HA is present in tissues such as vocal folds, synovial fluid, umbilical cord, dermis, 
subcutaneous tissue and cartilage where it performs a number of functions
89, 97, 98
. In 
tissues where HA is present, it performs a role of contributing towards tissue viscosity, 
tissue flow, tissue osmosis, shock absorption, wound healing and space filling
97
. HA is 
also metabolically active and cells focus attention on the processes of its synthesis and 
catabolism
99
. So basically this leads us to the conclusion that HA performs 2 main 
functions: one where there is a high concentration of HA it performs various functions 
by interactions and second where there is a low concentration of HA it acts as a 
structural element
85
. 
The companies which produce HA commercially and their products are detailed in the 
pie chart below, with the major producer being the Japanese company Seikagaku 
(Figure 1-2). 
 
 
Figure 1-2. Market share of companies manufacturing HA products and their uses (Data obtained from 
Fidia Farmaceutici market report 2009). 
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1.2.3 Receptors of HA 
 
HA plays an important role in cell proliferation and migration. Cells interact with 
hyaluronan through cell surface receptor with an intermediate known as hyaluronan 
binding proteins. The hyaluronan binding proteins are known as hyaladherins
100
. The 
two most common known receptors which have been characterised are CD44 and 
RHAMM (receptor for HA mediated motility)
101-103
. Some of the other known receptors 
are Layilin, ICAM-1, IVD4 and LEC
103, 104
. 
 
CD44. CD44 is a proteoglycan and one of the most common receptors of HA which has 
been characterised. It belongs to a family of leukocyte antigens which are known as 
clusters of differentiation (CD)
104-106
. CD44 is expressed by almost all cells of 
neurectodermal origin where majority of primary cells, except epithelial cells express 
the standard form of CD44. Malignant derivatives of many cells also express variant 
isoforms of CD44
103
. 
Many primary cells like leukocytes do not bind to HA until they are activated, whereas 
fibroblasts, smooth muscle cells and most primary tumour cells have CD44 which is 
always activated
103
.  
Certain experiments have shown that CD44 can bind to HA in vitro and that it has a 
higher affinity to larger molecules of HA
101
. CD44 is also responsible for growth factor 
and chemokine binding and presentation
107
. 
CD44 has four functional domains – namely the distal, proximal, transmembrane and 
cytoplasmic domains (Figure 1-3)
104
. 
 
Figure 1-3. The Functional Domains of CD44 Receptor (Taken from 104) 
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The distal domain is responsible for binding hyaluronan while the proximal domain is 
responsible for the alternate splicing of mRNA. The CD44 gene contains 19 exons out 
of which 10 are variably spliced. Several isoforms arise due to this alternate splicing 
which range in size from 80 to 250kDa
103, 104, 107, 108
.  
CD44 undergoes modifications like phosphorylation, glycosylation and attachment of 
glycosaminoglycan chains. These modifications are known as post-translational 
modifications and they contribute to binding of hyaluronan
103, 104
. There are three states 
of CD44 activation: active CD44 which is least glycosylated, inactive CD44 (does not 
bind to HA even in the presence of inducing factors) which is most glycosylated and 
inducible CD44 (activated by inducing factors like cytokines) which is partially 
glycosylated
106
. 
Some studies have suggested that the presence of basic amino acids in the distal domain 
is essential for the binding of CD44 to hyaluronan. Also arginine 41 was discovered as a 
critical component required for the binding
104
. 
CD44 has a variety of functions ranging from cell-cell aggregation, retention of 
pericellular matrix, matrix-cell and cell-matrix signalling, receptor mediated 
degradation of hyaluronan, and cell migration
104, 107
. Apart from its function as a HA 
receptor, it also acts in lymphocyte activation and lymphogenesis
101, 109
. 
 
RHAMM. RHAMM belongs to the family of itinerant hyaladherins. RHAMM is 
another common receptor of HA which occurs on the cell surface, in the cytoskeleton, 
in the mitochondria and in the nucleus of cells. Both the forms of RHAMM, the surface 
RHAMM and intracellular RHAMM are required for cell motility and cell proliferation 
in both normal as well as tumour cells. RHAMM has also been found on ras-
transformed cells which increase cell motility by the use of antibodies
101, 110-113
.  
There are 3 basic forms of RHAMM – Long RHAMM, alternatively spliced RHAMM 
and short RHAMM. They differ in their sizes and their reactions with antibodies. The 
structure of RHAMM is divided into various domains namely D1, D2, D3, D4 and D5 
(Figure 1-4). These Domains are required for cell motility and they contribute to various 
interactions including activation of kinases and binding with hyaluronan
110, 112
. 
Intracellular RHAMM proteins may connect actin and microtubule cytoskeleton due to 
their ability to form coils as well as it limited homology with proteins that link 
microtubules and actin filaments
113
. 
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Figure 1-4. The Functional domains of RHAMM (Taken from 110) 
 
RHAMM, like CD44 also contains sites for post-translational modifications like N-
glycosylation sites and phosphorylation sites
110
. Although it is known that CD44 and 
RHAMM can participate individually in proliferative and migratory functions, they 
have overlapping functions in some situations and hence their individual roles cannot be 
clearly specified
112
. 
Studies on animal models for metastases have shown the dependence of hyaluronan on 
it; especially in the case of tumour cells which have been treated with soluble RHAMM 
are unable to form long metastases
112
. Using biotinylated HA, RHAMM has been 
shown to be the main HA binding protein in cell lysates of ras transformed fibroblasts 
and smooth muscle cells responding to wound injury
114
.  
 
Layilin. Layilin is a widely expressed integral membrane hyaluronan receptor which 
binds to HA through its extracellular domain and is present in various cell types and 
tissues. It is capable of mediating cell adhesion. Though the exact function of layilin 
remains unclear, it is hypothesised that it might mediate early interactions between 
spreading cells and the ECM. Apart from binding to HA it can also bind to cytoskeleton 
membrane like proteins through its cytoplasmic domain
115, 116
. 
 
ICAM-1. The intercellular adhesion molecule is expressed by various cell types like 
leukocytes and endothelial cells. It is easily inducible by cytokines like interferons and 
inhibited by glucocorticoids. Hyaluronan is one of the main ligands for ICAM-1 which 
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plays a role in inflammatory processes and in T-cell mediated host defence system
117-
120
.  
 
1.2.4 Synthesis of HA 
 
Hyaluronan synthesis is a high energy consuming process for cells as it requires a 
reasonable number of NAD cofactors, acetylCoA and monosaccharide groups. HA is 
the only glycosaminoglycan which is synthesised in the plasma membrane
121
. 
The HA synthases or HASs are glycosyltransferases, present in the plasma membrane 
which regulate the polymerisation of HA and its transfer into the extracellular matrix. 
There are three types of HASs: HAS1, HAS2 and HAS3
121
. 
The three hyaluronan synthases are synthesised during different stages of development 
and their functions/expressions are highly dependent on the tissues/cells
122, 123
. 
HAS1 is responsible for the formation of both HA and chitin. Chitin is important for the 
formation of two distinct glycosidic linkages to form the repeating unit of the 
disaccharide
121
. HAS1 is independent and can synthesise HA without the use of any 
proteins
122
. HAS1 has a lower rate of production of HA as compared to the other HASs. 
This means that the there is lower concentration of HA in the matrix around the cells. 
This is also proved due to the fact that the half life of HAS1 is lower than the other 
HASs
123
. 
The growth of the HA chain takes place by addition of alternating monosaccharides to 
its reducing end. In this process the growing HA chain remains covalently attached to a 
terminal uridine 5‟-diphosphate (UDP) and the new monosaccharide is attached to a 
second UDP on the reducing end, which then displaces the terminal UDP. As the HA 
chain grows, the end opposite to where the new monosaccharides are added is pushed 
through a pore outside the plasma membrane
99, 122
. With this process the HA does not 
have limited growth and can proceed to form long HA chains
99
. However increased 
synthesis of HA is usually linked to cancerous tumours
123
. 
HAS2 is responsible for the synthesis of hyaluronan required for the development of 
extracellular proteoglycan complexes in the cartilage like the valves of the heart
102, 122
. 
HAS3 is responsible for the production of hyaluronan which is of a lower molecular 
weight (1×10
5
 to 1×10
6
 Da) than the hyaluronan produced by HAS2 (2×10
6
 Da) and 
HAS1 (2×10
5
 to ~2×10
6
 Da)
123
. This low molecular weight hyaluronan can be used 
more effectively for cell signalling than higher molecular weight hyaluronan
102, 122
. 
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1.2.5 Endocytosis, Degradation and in vitro and in vivo studies of HA and its 
conjugates 
 
Endocytosis is the widespread cellular function that regulates the quantal uptake of 
exogenous molecules from the cell‟s environment via plasma membrane-derived 
vesicles and vacuoles since most substances important to cells are large polar molecules 
that cannot pass the hydrophobic plasma or cell membrane
124
. There are four main 
categories of endocytosis pathways:  
 
Clathrin-mediated endocytosis. It is mediated by vesicles which are approximately 
100nm in diameter and have a characteristic crystalline coating made up of a complex 
of proteins which are mainly associated with the cytosolic protein clathrin. These 
vesicles are found in almost all cells and form domains of the plasma membrane termed 
clathrin-coated pits which can concentrate large extracellular molecules that have 
different receptors responsible for the receptor-mediated endocytosis of ligands, for 
example: transferrin, growth factors, antibodies, etc
124, 125
.  
 
Caveolae. They consist of the cholesterol-binding protein caveolin with a bilayer 
enriched in cholesterol and glycolipids. They are flask shaped pits in the membrane 
approximately 50nm in diameter. They can take up almost a third of the plasma 
membrane area of the cells of some tissues, and are found mainly in smooth muscle, 
fibroblasts, adipocytes, endothelial cells and type 1 pneumocytes. They are believed to 
be responsible for the uptake of extracellular molecules
124-126
.  
 
Macropinocytosis. It usually starts from the plasma membrane and is the folding of the 
cell membrane to form a pocket, which then pinches off into the cell to form a vesicle 
(0.5 – 5 µm in diameter) filled with large volumes of extracellular fluid and molecules 
within it. The vesicle then travels into the cytosol and fuses with endosomes and 
lysosomes
124, 125, 127
.  
 
Phagocytosis. All particulate matter which is larger than 0.75 µm in diameter is 
internalised by phagocytosis. This includes small dust particles, cell debris, 
microorganisms and even apoptotic cells
124, 125, 128
.  
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The principal components of endocytic pathway are: early endosomes, late endosomes, 
and lysosomes. Early endosomes are the first in line and receive most of the vesicles 
coming from the cell surface, they have a mildly acidic pH and they are the sorting 
organelles for separating the ligands from their receptors. Late endosomes receive 
internalised material which is en route to lysosomes, usually from the early endosomes 
in the endocytic pathway, from trans-golgi network in the biosynthetic pathway, and 
from phagosomes in the phagocytic pathway. They contain lysosomal membrane 
glycoproteins and acid hydrolases, and they have a pH of approximately 5.5. Lysosomes 
are the last compartment of the endocytic pathway with a pH of about 4.8 and appear as 
large vacuoles with a high content of lysosomal membrane proteins and active 
lysosomal hydrolases. It principally serves to break down cellular waste products, fats, 
carbohydrates, proteins and other macromolecules into simple compounds by using 
about 40 different kinds of hydrolytic enzymes; which are then recycled to the 
cytoplasm as new cell-building materials
124, 126, 127
.  
Endocytosis of HA usually takes place either within the tissue where it is synthesised or 
in the lymph nodes and the liver so as to be replaced with fresh HA
122, 129
. The 
degradation of HA takes place by binding of an HA molecule to an HA receptor (like 
CD44), followed by the receptor complex being taken into the cell via endocytosis, and 
finally the HA molecule is degraded into its monosaccharide units by hyaluronidase in 
the lysosome
88, 97, 105, 130
.  CD44 can mediate HA endocytosis during morphogenesis of 
tissues such as the lung and skin, during long bone growth, and in adult tissues such as 
cartilage
100
. However, the most efficient HA receptor responsible for internalisation and 
degradation is the liver endothelial cell receptor that forms a large molecular mass 
complex of several subunits. LYVE-1, a lymph vessel-specific receptor has also been 
shown to participate in the endocytosis of HA in the lymphatics
86, 88, 122
.  
The mechanism of HA uptake by cells appears unique and is still being researched on 
because clathrin-coated pits and caveolae, the most common vehicles for endocytosis, 
seem not to work in this case
84, 100
. The exact reasoning for why some HA-CD44 
interactions signal, some promote endocytic uptake, and other permit retention of HA 
on the cell surface has not yet been resolved
122
. A few investigators have related the 
cellular capacity for CD44-mediated endocytosis and degradation of HA as assessed in 
vitro to tumour metastatic aggressiveness
104
. 
The degradation of HA in vivo is carried out by three classes of enzymes: 
Hyaluronidase, β-D-glucuronidase and β-N-acetyl-D-hexosaminidase. Basically, 
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hyaluronidase degrades the HA and the oligosaccharides produced by the degradation 
are degraded by the other two enzymes. The minimum degraded unit by this mechanism 
is the disaccharidic repeating unit
88, 131
. 
Hyaluronidase is an enzyme which breaks the β-N-acetyl-D-glucosamine bonds of the 
HA separating the polysaccharides N-acetyl glucosamine and glucuronic acid. The 
activity of Hyaluronidase depends on the density of carboxylate (COO
-
) groups. For 
example, non-esterified HA and partially esterified HA can be degraded by 
hyaluronidase, while completely esterified HA cannot be degraded
131, 132
. 
The degradation of HA is reduced in the presence of chondroitin sulphate and heparin as 
they can bind to hyaluronidases and reduce their activity on HA
131, 133
. 
HA can be hydrolysed by mammalian hyaluronidases to form tetra and hexasaccharides. 
There are six gene sequences related to hyaluronidase: HYAL1, HYAL2, HYAL3, 
HYAL4, PHYAL1 and SPAM1. Their correspondence to the Hyaluronidase is 
mentioned in the Table below:
84
 
 
Table 1-1. Gene sequences and their corresponding Hyaluronidase 
Gene Corresponding Hyaluronidase 
HYAL1 Hyaluronidase-1 
HYAL2 Hyaluronidase-2 
HYAL3 Hyaluronidase-3 
HYAL4 Hyaluronidase-4 
PHYAL1 Transcribed but not translated in human 
SPAM1 PH-20 
 
Hyal-1 found in lysosomes, can degrade HA to tetrasaccharide units or smaller 
disaccharides and can suppress tumours as it can act as a TSG (Tumour Suppressing 
Gene) as eradication of hyaluronidase activity is an important step in the development 
of some cancers
84, 122
. 
Hyal-2 is attached to the plasma membrane and can degrade HA to a molecular weight 
of about 20kDa. Hyal-2 can act either as a TSG or as an oncogene
84, 122, 133
. 
Hyal-3 has been found in the chondrocytes but its responsibilities/activities have not yet 
been identified. It is widely present and its expression is enhanced during chondrocyte 
differentiation
84, 133
. 
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Hyal-4 is a peculiar hyaluronidase enzyme that can degrade HA but its activity on HA is 
minimal as it can attach to chondroitin and chondroitin sulphate which inhibit it
84, 133, 
134
. 
The gene PHYAL1 is not translated into an enzyme in humans however in other species 
it does translate. It is a pseudogene with multiple deletions and contains an abnormal 
stop codon, however not much is known about it
84, 133
. 
PH-20 plays a variety of roles and has been found distributed in various regions of the 
body. One of its main occurrences is in the testes, however it is also found in the 
epididymis, the female genital tract, breast, placenta and fetal tissues. PH-20 also plays 
an important role in fertilization. It also expresses itself in some cancers
84, 122, 133, 134
. 
Various types of tumours like epithelial, ovarian, colon, stomach and acute leukaemia, 
over produce HA such that elevated HA contents are prognostic for malignant 
progression
135
. CD44 and RHAMM are overexpressed in many types of cancer cells, 
demonstrating enhanced binding and internalisation of HA
136, 137
.  
The delivery of doxorubicin (DOX) to several cancer cell lines (human breast, ovarian 
and colon) has been shown in-vitro by N-(2-hydroxypropyl)-methacrylamide (HPMA) 
polymer grafted with both DOX and low molecular weight HA by using a lysosomally 
degradable spacer. They showed selective toxicity towards cancer cells overexpressing 
HA receptors whereas free doxorubicin as well as HPMA-DOX conjugate were toxic to 
both cancer cells and to fibroblasts
138
.  
Paclitaxel (Taxol) has been linked at 2‟-OH by a succinate ester spacer to low molecular 
weight HA since the drug is poorly soluble in aqueous media. This conjugate was 
targeted in vitro to human cancer cell lines (HBL-100, SK-OV-3 and HCT-116) and 
only CD44 overexpressing cells internalised the conjugate after 20 minutes of 
incubation. The ester linkage was found to be stable in the media with cells while in the 
presence of esterase it rapidly released the drug, which bought forward the conclusion 
that the conjugate is first internalised by receptor-mediated endocytosis, followed by 
esterase-catalysed drug release in the lysosomal compartment. The human cancer cells 
were selectively killed, while the fibroblasts were unaffected
139, 140
.  
Quantum dots have been conjugated to HA backbone by first modifying HA with adipic 
acid dihydrazide followed by coupling the quantum dots to the carboxyl groups of HA 
through an amide linkage. They were then studied in vivo for the effect of the chemical 
modification of HA on its cellular uptake and distribution. Real time imaging of the 
quantum dots was performed (they emit at 800nm) by injecting them either 
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subcutaneously or in the vein of the tail of the mice. The distribution of the quantum 
dots was observed to depend on the amount of modification of the carboxyl group: the 
ones which were 35% derivatised had sufficient binding to HA receptors accumulated 
mainly in the liver (liver has high specificity towards HA molecules), while the ones 
which were 68% derivatised and had lost most of their binding sites were distributed 
evenly to the tissues in the body
141
. 
HA-poly(ethylene glycol)-poly(lactide-co-glycolide) [HA-g-PEG-PLGA]
142
 and HA-
poly(ethylene glycol)-polycaprolactone [HA-g-PEG-PCL]
143
 nanoparticles have been 
prepared by Yadav et al. and have been tested in vivo for biodistribution. The DOX 
loaded HA-g-PEG-PLGA and HA-g-PEG-PCL particles accumulated mainly in the 
liver and kidney will still quite substantial amounts localised in the tumour, whereas the 
free DOX was almost evenly distributed in the blood, heart, lung, liver, spleen and 
kidney. Control studies performed by substituting HA with methyl poly (ethylene 
glycol) showed that the particles delivered DOX to the tumour tissue much less 
efficiently than the HA
142, 143
. 
Also, polycations such as poly(L-lysine) have been covalently grafted with short HA 
fragments for subsequent complexation with DNA for delivering DNA to the liver 
sinusoidal endothelial cells in vivo
144
. 
Following the above examples, a HA-boronic derivative conjugated with a diol drug 
would also follow a similar pathway, whereby it would undergo receptor mediated 
endocytosis, followed by going through the early endosome where the receptor would 
get separated, followed by the late endosome and finally the lysosome where due to the 
acidic pH of 4.8, the drug would get released (boronic – diol links are unstable in acidic 
pH) and the HA-boronic would be degraded by the hyaluronidase enzymes. 
 
1.2.6 Chemical Modifications in HA 
 
Principal Targets. Hyaluronan, having limited biomechanical properties is not used for 
biomedical applications on its own. It is usually combined with other materials to 
improve its mechanical and chemical strength. Usually the non-toxicity and 
biodegradability of hyaluronan is retained after these chemical modifications. The 
carboxylic acid and hydroxyl groups are the two main groups which are used for 
chemical modifications in HA (Scheme 1-17). These modifications to HA allow it to be 
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used for various applications such as, space filling, drug delivery and tissue 
regeneration
145
. 
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Scheme 1-17. Principal Sites for Chemical Modifications in HA 
 
HA can be modified specifically for different purposes. If it is required to function as a 
gel or a hydrogel, it can be cross-linked
146
. This makes it extremely viscous and elastic, 
thereby providing the properties of a gel. If it is required for drug delivery, tethering 
groups can be attached to hyaluronan which allow the attachment of drugs and their 
controlled release
147
. Hyaluronan can be grafted onto other polymers to make composite 
biomaterials
148
. It can also be grafted onto liposomes for drug delivery
145
. 
 
A) Modifications to carboxylic acid group 
 
There are two important reactions that can take place with the carboxylic acid group of 
HA: Esterification and Carbodiimide-mediated reactions
145
. 
  
Esterification. Esterification is a reaction in which carboxylic acids react with alcohols 
to form esters through a condensation reaction. Alkylation of tetra (n-butyl) ammonium 
salt of HA with an alkyl halide in DMF is one of the processes for preparing esterified 
hyaluronan biomaterials (Scheme 1-18). These materials have good mechanical strength 
when dry, but on combining with water they lose this strength. The degree of 
esterification plays an important role, whereby it varies the size of the hydrophobic part 
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of the biomaterial. This hydrophobic part modifies the polymer network, making it 
strong and stable. Also it defers the degradation of the material by enzymes
145, 149
. 
 
HA-COON(BU
4
)
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RCH
2
OH HA-CO2CH2R+
 
 
Scheme 1-18. Esterification of tetra (n-butyl) ammonium salt of HA 
 
Another common esterification reaction is the formation of HA-N-succinimide (HA-
NHS) active ester (Scheme 1-19). This is an important intermediate for bioconjugation 
with reporter and effector molecules. Like the previous reaction, tetra (n-butyl) 
ammonium salt of HA reacts with N-hydroxysuccinimido diphenyl phosphate (SDPP) 
to form HA-N-succinimide active ester
150
. 
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Scheme 1-19. Esterification of HA to form HA-NHS active ester 
 
A couple of HA-esterified biomaterials are commercially available (Scheme 1-20). 
These are known as HYAFF and are biomaterials with higher stability than pure HA 
and are produced by esterification of the free carboxyl group present in the HA chain 
with different alcohols
149, 151
. 
 
 
 
 
 
Scheme 1-20. Principal Structure of HYAFF Biomaterials 
 
There are 2 variants present in this type of reaction – (i) using different alcohol groups 
(ii) changing the degree of esterification. These 2 variants ultimately lead to the 
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production of a variety of HYAFF biomaterials. HYAFF 7 and HYAFF 11 are two of 
the well known HYAFF biomaterials
151
. 
 
Carbodiimide-mediated reactions. Carbodiimide compounds react with carboxylic 
acid group of HA to produce carbodiimide-activated HA which can be used for 
derivatisation with drugs, for biochemical probes and for cross linking agents
145, 147, 152
. 
Another use for carbodiimide-activated HA is hyaluronan microspheres
153
. These have 
also been prepared using ADH and HA especially because HA possess structural 
integrity and has ease of removing unreacted reagents
154
. 
EDC [3-(dimethylamino)propyl] ethylcarbodiimide is one of the common carbodiimide 
compounds used to react with HA. Carbodiimide-mediated reactions might be 
performed with or without the use of primary amines. The additions of primary amine 
results in the production of O-acylisourea adduct. If there is no presence of nucleophile, 
then there is formation of stable N-acylurea, while in the presence of a nucleophile, the 
nucleophile attacks the O-acylisourea to form an amide linkage between the amide and 
the acid (Scheme 1-21)
146, 152, 155
. 
 
 
Scheme 1-21. Amidation of carboxylate group of HA 
  
Nucleophilicity is an important issue in carbodiimide-mediated reactions where the 
hydrazides need to retain their nucleophilicity in order to couple efficiently to 
carbodiimide-activated HA (Scheme 1-22). Hydrazides such as adipic dihydrazide 
(ADH) have more than one hydrazide groups which can be used for further reactions 
such as for derivatisation with drugs and for cross-linking agents
145, 156, 157
. 
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Scheme 1-22. Carbodiimide-mediated reaction showing coupling of carboxylic acid group of HA with 
ADH to form carbodiimide-activated HA which further uses the free hydrazide groups to incorporate a 
drug.  
 
The formation of carbodiimide-activated HA requires an acidic pH i.e. 4.75 because the 
amine base needs to have a certain percentage of itself in nucleophilic form for the 
reaction to occur successfully
145, 156
. 
The degree of derivatisation of HA can be varied depending on the nucleophile used. 
Also the conditions used for derivatisation should be mild in order to maintain high 
molecular weight of HA, since low molecular weight HA can cause inflammation
155
. 
 
B) Modifications to Hydroxyl group 
 
There are four important reactions that can take place with the hydroxyl group of HA: 
(1) Esterification (2) Sulphation (3) Isourea coupling and (4) Periodate oxidations
145
. 
 
Esterification. Esterification, as mentioned before is the reaction between carboxylic 
acids and alcohols to form an ester. In this case, the hydroxyl group of HA is the alcohol 
and can react with different carboxylic acids to form various esters
145, 149, 158
. 
One of the common reactions is between butyric acid and the hydroxyl group of HA in 
the presence of DMF to form hyaluronan butyrate (Scheme 1-23). This HA butyrate can 
be used as a drug delivery system especially for tumour cells, since butyric acid is a 
well known compound which can stop cell differentiation in tumours
145, 158
. 
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Scheme 1-23. Esterification reaction between hydroxyl group of HA and butyric acid to form HA 
butyrate. 
 
Sulphation. Sulphation, in the simplest terms, can be explained as the addition of 
sulphur group to any chemical group. In the case of hyaluronan, the hydroxyl group can 
be reacted with sulphur trioxide-pyridine complex to give HASx where x can be 
anything from 1 to 4 per disaccharide (Scheme 1-24). X Represents the degree of 
sulphation. Also, this reaction is carried out in the presence of DMF
145, 159-161
. 
 
 
 
 
                            x = 1 to 4 per disaccharide 
 
 
Scheme 1-24. Reaction between hydroxyl group of HA and sulphur trioxide-pyridine complex to form 
sulphated HA. 
 
Sulphated HA surfaces show less cell adherence and low bacterial growth as compared 
to native HA surfaces. These properties can be quiet helpful in certain applications like 
for medical devices.
145
 
 
Isourea Coupling. Isourea coupling is basically used for coupling antibiotic drugs to 
HA. Firstly the HA must be activated using cyanogen bromide. Only after the HA has 
been activated, can the drug be coupled with HA by urethane bonds
145, 162, 163
. 
The reaction of the hydroxyl group with cyanogen bromide leads to the production of an 
isourea intermediate. This intermediate has a high affinity for antibiotic drugs and can 
couple with them easily (Scheme 1-25). The drugs attach via a urethane bond to one of 
the hydroxyl groups of the HA
145, 162, 164
. 
The only drawback this process has is that this reaction can affect the integrity and 
biocompatibility of the HA
145
. 
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Scheme 1-25. Activation of HA by cyanogen bromide and isourea coupling of drugs. 
 
Periodate oxidations. Oxidation of the hydroxyl group of HA by sodium periodate 
results in the formation of periodate-activated HA. This periodate-activated HA can 
couple with primary amines and either cross-link, attach peptides to itself or immobilise 
materials (Scheme 1-26)
145, 165-167
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Scheme 1-26. Oxidation of hydroxyl group of HA by sodium periodate 
 
This is a 2 step process in which the HA is first activated and then by the process of 
reductive coupling, primary amines are attached to HA. The drawback of this process is 
that this oxidation technique might break the chain and introduce immunogenic linkages 
into the HA chain
145, 166
. 
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C) Crosslinking techniques 
 
Hyaluronan has 4 reactive groups (carboxyl, hydroxyl, reducing end and amide) which 
participate in crosslinking of HA either with itself or other polymers
168
. 
The crosslinking techniques basically involve the modifications used above, but are 
aimed for the purpose of achieving a mechanically strong material
145
. 
Various experiments have suggested that a high degree of crosslinking and therefore 
high stability can be achieved by carrying out the process of crosslinking in 2 stages. In 
both the stages the same crosslinking agent is used, however the different functional 
groups are used by altering the reaction conditions
168
. 
Some of the crosslinking techniques are described below: 
 
Carbodiimide crosslinking. Carbodiimide‟s react with carboxyl group to form an 
unstable O-acylisourea, which in the absence of a nucleophilic agent forms N-acylurea 
which is stable. If a primary amine is introduced, it acts as a nucleophilic agent, and the 
O-acylisourea does not form N-acylurea and instead leads to the formation of an amide 
linkage between the amine and the acid. This is a desirable product in the case of cross-
linking. In this reaction, amide linkages are formed which couple to the HA which make 
the substance chemically stable. Also, there are no undesirable side-products formed
145, 
146
. 
The carboxyl group of HA reacts with a biscarbodiimide in aqueous isopropanol to form 
carbodiimide crosslinked HA (Scheme 1-27). This leads to the production of a low 
water content hydrogel. Hyaluronan films can also be made using carbodiimide‟s in the 
same way
145, 146
. 
The chemical properties of this type of cross-linked HA depends on the ease of 
availability of the carboxyl groups to the carbodiimide‟s and not merely on its 
functional groups
146
. 
 
 
Scheme 1-27. Crosslinking of HA using carbodiimide 
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Hydrazide crosslinking. HA can be cross-linked using hydrazide compounds such as 
bishydrazide, trishydrazide and polyvalent hydrazide. HA-ADH which is formed by 
reaction of adipic dihydrazide with carboxylic group of HA can be cross-linked using 
small molecule homobifunctional cross-linkers such as disuccinimidyl suberate (DSS) 
(Scheme 1-28)
145, 169
. 
HA-ADH can be also be cross-linked using EDC. This cross-linked HA can be used as a 
drug delivery vehicle.  HA-ADH can also be cross-linked for hydrocortisone release 
using hydrocortisone hemisuccinate solution
147, 154
. 
The gels formed from this technique can range from soft gels to rigid gels. The 
mechanical properties of the gels can be varied, by changing the reaction conditions and 
molar ratios of the reactants
145, 147, 170
. 
PEG cross-linkers and PVA cross-linkers are also used for making gels. Experiments 
have shown that PVA cross-linkers have better gelation capacity than PEG cross-linkers 
since PVA is polyfunctional and PEG is just bifunctional
171
. 
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Scheme 1-28. Crosslinking of HA using hydrazide 
 
HA-ADH can also be cross-linked with PEG-dialdehyde, which is a macromolecular 
cross-linker (Scheme 1-29). This leads to the formation of a hydrogel with considerable 
strength
145, 169
. 
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Scheme 1-29. Crosslinking of HA using PEG-dialdehyde 
 
PEG can also be grafted on HA and be used for drug delivery. This leads to the 
formation of an aqueous polymer two phase system which can incorporate bioactive 
peptides like insulin. When a peptide such as insulin is inserted in pure PEG, it gets 
entangled with the PEG, however in this case when PEG is grafted onto HA, it remains 
separate. This type of system can be used for injectable formulations
172
. 
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1.3 Biological relevance of catechols 
 
1.3.1 Catecholamines 
 
Catecholamines are sympathomimetic “fight-or-flight” hormones secreted by the 
adrenal glands in response to stress and belong to the sympathetic nervous system. They 
are derived from the amino acid ʟ-tyrosine and contain a catechol or 3,4-
dihydroxylphenyl group and an ethylamine moiety. The main catecholamines which 
circulate in the blood but cannot cross the blood-brain-barrier are epinephrine 
(adrenaline), norepinephrine (noradrenalin) and dopamine (Scheme 1-30)
173, 174
. 
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Scheme 1-30. Structure of catecholamines 
 
Dopamine. Dopamine is a neurotransmitter bridging the nervous and immune systems. 
Dopaminergic neurons mainly exist in the mid-brain and partly in the hypothalamus
175
. 
It regulates behaviour, movement, endocrine, cardiovascular, gastrointestinal, renal, and 
immune functions
176-178
.  
Dopamine acts through 5 main G-protein coupled receptors D1, D2, D3, D4 and D5 in 
normal human leukocytes. D1 and D5 receptors are classified as excitatory binding (D1 
type, positively coupled to adenylate cyclase) while D2, D3 and D4 are classified as 
inhibitory binding (D2 type, negatively coupled to adenylate cyclase). Human dendritic 
cells and lymphocytes have shown to contain dopamine receptors as well. Changes in 
the expression of dopamine receptors and their signalling pathways alter immune 
functions in disorders such as schizophrenia and Parkinson‟s disease176-179.  
Chapter 1 
59 
 
Dopamine is generated by a 2 step conversion: firstly ʟ-tyrosine is hydroxylated to ʟ-
dopa by the enzyme tyrosine hydroxylase followed by decarboxylation of ʟ-dopa to 
dopamine by the enzyme ʟ-amino acid decarboxylase173-175.  
Dopamine can be formed by hydroxylation of endogenous neurochemical substrate 
tyramine by CYP2D6 (a CYP2D isoform)
175
. CYP2D belongs to the most important 
cytochrome family which is capable of metabolizing various drugs such as 
antidepressants, neuroleptics, antiarrhythmic agents, the drugs of abuse – codeine and 
amphetamine, carcinogens and various neurotoxins
180
. CYP2D are also present in the 
brain and regulate the variations in response to centrally acting drugs and toxins. Since 
dopamine cannot cross the blood-brain-barrier, CYP2D6 synthesises dopamine from 
tyramine in the liver as well as in the brain separately
175, 180
.  
Dopamine has been shown to form strong bonds with various organic/inorganic surfaces 
and hence self-polymerisation of dopamine is a useful way for applying multifunctional 
coatings onto surfaces like noble metals, metal oxides, ceramics and polymers
181
. One 
example of this is the report by Park where dopamine-derivatised heparin was anchored 
on the surface of a cobalt-chromium alloy along with paclitaxel encapsulated in HA-g-
PLGA micelles and poly-ʟ-lysine to form a drug-eluting stent for coronary artery 
disease
182
. Another example is shown by Messersmith where polydopamine surfaces 
were engineered for specific biomolecular interactions by forming an ad-layer of 
partially thiolated hyaluronic acid
183
.  Dopamine has also been incorporated in 
intracranial nano-enabled scaffold devices for site-specific delivery to minimize the 
side-effects of conventional forms of Parkinson‟s disease therapy184. Levodopa, a 
precursor of dopamine has also been used in minitablets with extended release times
185
. 
Also, HA-dopamine mixed with thiol end-capped Pluronic F-127 copolymer has been 
used to produce a lightly cross-linked composite temperature dependant gel for drug 
delivery
186
.  
 
Epinephrine. Epinephrine is localized in the adrenal medulla and in the brain
187, 188
. 
Epinephrine is synthesised from norepinephrine by phenylethanolamine N-methyl-
transferase in the brain
188-191
.  
Epinephrine acts by binding non-selectively to various adrenergic receptors like α1, α2, 
β1, β2 and β3 receptors. Binding to α receptors inhibits insulin secretion by pancreas, 
stimulates glycogenolysis in liver and muscle, and starts glycolysis in muscle. Binding 
to β receptors triggers glucagon secretion in pancreas, increases adrenocorticotropic 
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hormone secretion by the pituitary gland, and increases lipolysis by adipose tissue. This 
leads to increased blood glucose and fatty acids for energy production within cells
192, 
193
.  
It is released during sudden frightening or life-threatening situations and affects 
sympathomimetically innervated structures all across the body.  The heart rate rises 
increasing the force of cardiac contractions and increasing the blood pressure. The 
blood flow is also redistributed from the skin and subcutaneous tissue to the skeletal 
muscles, splanchnic circulation, and brain. The bronchi and pupils also dilate with 
increase in oxygenation and blood glucose to „fight or flight‟187, 193. 
Epinephrine is metabolized by catechol-O-methyl transferase (COMT - ubiquitously 
expressed enzyme that metabolizes catecholamines) to produce metanephrine in the 
presence of the cofactor S-adenosylmethionine
194-196
.  
Epinephrine is used for treatment of postintubation croup and viral croup by face masks 
and nebulizers. Dilute solutions of epinephrine are used in surgery to provide 
hemostasis and/or prolong the duration of action of concomitantly administered local 
anesthetics. It is also largely used for treatment of anaphylaxis
187, 195
 and septic shock
197
. 
Epinephrine has also been encapsulated in alginate based microspheres
198
 and coloaded 
in biocompatible polymer implants
199
 to ensure vasoconstriction at delivery at various 
rates.  
 
Norepinephrine. Norepinephrine is a major monoamine neurotransmitter which is 
synthesised in both the adrenal medulla and in the brain
189, 200, 201
. Mainly it regulates 
arousal and stress responses and any dysregulation with this system leads to anxiety and 
depressive disorders
202
. Norepinephrine also regulates various other processes such as 
decision-making, attention response, sleep, memory encoding, and fear-learning
203, 204
.  
The main norepinephrine receptors are the same as epinephrine receptors α1, α2 β1, β2 
and β3 which carry out its modulatory activities
203, 205
.  
Norepinephrine is synthesised in the brain by hydroxylation of dopamine (using enzyme 
dopamine-β-hydroxylase) which is synthesised by decarboxylation of 
dihydroxyphenylalanine (using enzyme dopa decarboxylase) which is synthesised from 
tyrosine (using enzyme tyrosine hydroxylase)
201, 206, 207
.  
The metabolism of norepinephrine in humans could be either: o-methylation which 
forms normetanephrine, deaminition by monoamine oxidase which forms 
dihydroxyphenylethylene glycol (DHPG) and dihydroxymandelic acid (DOMA), or 
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combined deaminition and o-methylation by catechol-O-methyltransferase which forms 
vanillylmandelic acid and 3-methoxy-4-hydroxyphenylglycol
200, 205
.  
Norepinephrine is mainly used in reversing hypotension in patients with septic shock as 
it is more effective than dopamine
208
. It has also been used in spinal injections along 
with opiods for reducing chronic pain
209
 and in biodegradable microspheres for 
treatment of CNS neurodegenerative disease
210
.  
 
1.3.2 Other catechols (2- and 4-hydroxyestradiol) 
 
Estradiol, the primary female sex hormone responsible for sexual differentiation and 
development, arterial vasodilation, maintenance of bone density and neuroprotective 
actions is eliminated from the body by metabolic conversion to inactive metabolites that 
are excreted in the urine and/or feces
211
. Estradiol is converted to 2- and 4-
hydroyxestradiol (Scheme 1-31) in the endoplasmic reticulum by NADPH-dependent 
(nicotinamide adenine dinucleotide phosphate dependent) cytochrome P450-linked 
mono-oxygenase system
212-214
. Conversion to 2-hydroxyestradiol is carried out by 
CYP450 1A1/1A2/3A4 whereas to 4-hydroxyestradiol is carried out by CYP450 1B1
211, 
213
. 
  
OH
H
OH
H H
OH
H
OH
H
OH
H
OH
H
OH
H H
OH
2-hydroxyestradiol
4-hydroxyestradiol
CYP 1A1/1A2/3A4
CYP 1B1
 
 
Scheme 1-31. Metabolism of estradiol to 2- and 4-hydroxyestradiol by CYP450. 
 
Unconjugated 2-hydroxyestradiol concentration is low in blood and several tissues 
because of its instability and its rapid O-methylation by COMT to form 2-
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methoxyestradiol which has negligible estradiol receptor binding affinity and targets 
actively dividing cells disturbing cell proliferation (antitumourigenic)
211, 213-215
. 
It has been shown that catechol metabolites of estradiol (mainly 4-hydroxyestradiol) 
may lead to carcinogenesis possibly due to their rapid oxidation leading to production of 
quinines and reactive oxygen species which can lead to deoxyribonucleic acid damage 
and mutations. This has been shown in the study of breast cancer
211, 213, 214, 216
.  
Catecholestrogens have been proved to be better antioxidants than estradiol
217, 218
. The 
administration of 2-hydroxyestradiol has shown to suppress the increase in lipid 
peroxide levels caused by ovariectomy in women. This capability of 2-hydroxyestradiol 
could also be used to prevent cardiovascular disease
217, 219, 220
. 
 
1.3.3 Flavonoids (Quercetin, Taxifolin, etc.) 
 
Flavonoids are polyphenolic compounds found in common foods we eat. Over 4000 
different ones have been identified, the major sources being apples, berries, onions, 
chocolate, red fruits, citrus fruits, nuts, and drinks such as beer, tea and wine
221-223
. The 
basic structure of flavonoids consists of a heterocyclic ring fused to an aromatic ring, 
attached to a third ring system at C3 or C4 position
224, 225
. Some of the most common 
catechol containing flavonoids are quercetin, taxifolin, myricetin, fisetin, luteolin and 
epicatechin (Scheme 1-32)
223
. Quercetin is one of the main flavonoids as it is present 
abundantly in onions and apples and it is proven to prevent diseases associated with 
oxidative stress such as cancer and cardiovascular diseases
224-226
.  
Flavonoids have a positive influence on various cardiovascular diseases due to their 
antioxidant activity, metal interactions (iron and/or copper chelation), decrease in 
expression of inflammatory signaling molecules, inhibition of platelet aggregation, 
vasodilatory action and their capability to inhibit radical-forming enzymes like NADPH 
oxidase, xanthine oxidase and lipoxygenases
221, 223, 224, 227
.  
In the brain, they have a potential to protect neurons against injury by neurotoxins, 
suppress neuroinflammation, and promote memory, learning and cognitive functions
228
.  
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Scheme 1-32. Catechol containing flavonoids. 
 
Flavonoids have been described as CYP1 inhibitors due to their inhibition potential of 
carcinogenic product formation and blockage of the initiation stage of carcinogenesis 
(over expression of CYP1 in tumours). However they are also responsible for CYP1-
mediated bioactivation, for example; kaempferol is a inhibitor of CYP1A1 but, in doing 
so, it is transformed to quercetin
222
.  
Some of the flavonoids like quercetin have been encapsulated in nanoparticles
229
, 
microcapsules
230, 231
, vesicles
232
 and micelles
233
 for anticancer drug delivery. Taxifolin 
has also been used for its anticancer, antioxidant and anti-inflammatory properties by 
encapsulation in polyvinylpirrolidone nanoparticles
234
. Troxerutin gels have also been 
synthesised for topical treatments as antioxidants, and as protective agents on the wall 
of veins for prevention of varicose veins
235
.  
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1.4 Scope of this thesis 
 
In the current investigation we aim at: a) Studying the pH based reversible 
complexation of boronic acids with diols using the batochromic shifts of the reporter 
alizarin red S (ARS) in simple and complex systems. This is purely a new analytical 
method to evaluate their binding constants and to give an idea of how easy/difficult 
would it be to release a diol. b) Studying the synthesis, characterisation, cytotoxicity and 
degradability of a HA-boronic based drug delivery carrier and other HA derivatives. c) 
Studying the reversible complexation of HA-boronic with diols using batochromic 
shifts of ARS in simple and complex systems and to evaluate the effects/advantages of 
using a polymeric chain. d) Studying the bioconjugation of HA-boronic with diols and 
vice versa using static light scattering.  
Bioconjugation has several advantages, however the few constraints which need to be 
focussed on for good bioconjugate development are: a) To have the perfect conditions 
for binding so as not to affect the stability of the polymer. b) To ensure adequate and 
successful detachment of the drug at the target site in endosomes and lysosomes. c) To 
develop methods for characterisation of the constructs as a whole. d) To obtain a well-
characterised biodegradable polymeric carrier. e) To choose a polymer which can be 
easily approved by the FDA.  
In Chapter 2 we have presented the study of complexation of boronic acids with 
various diols using the batochromic shifts of the optical reporter ARS. Since the 
complexation of polymeric compounds with diols is more complicated, we have initially 
analyzed the equilibrium constants of the reactions between 3-aminophenylboronic acid 
and various diols (catecholamines, sugars, flavonoids, etc.) in order to test the feasibility 
of the new analytical technique as well as to establish a benchmark for the binding 
constants which can later be used to compare with those obtained by using polymeric 
compounds. The main advantage of using this method over literature methods of using 
fluorescence is that it can be employed to complex systems such as colloidal dispersions 
or complexed active compounds. In order to evaluate the other uses and advantages of 
this method, we have also studied the action of enzymes on catechols, focussing on 
cytochrome P450-mediated reactions which could be used as a reporter for these 
reactions in a biological environment. One such reaction studied is the conversion of 
hormones such as cyclodextrin-complexed estradiol to 2-hydroxyestradiol using 
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CYP1A2. The other reaction studied is the demethylation of 3-methoxytyramine using 
CYP2D6 to dopamine which is a major drug for Parkinson‟s disease.   
 
 
Scheme 1-33. Design of a HA based responsive polymeric carrier 
 
In Chapter 3 we have presented the synthesis, characterisation, cytotoxicity and 
degradability studies of three HA derivatives (HA-boronic, -dopamine and -
veratrylamine) synthesised using an amidation reaction. We have also studied the 
reaction and its side effects in detail. We have specifically focused on HA-boronic since 
it appears to be a suitable drug carrier, due to its low toxicity and the complexing ability 
towards diol-containing molecules (Scheme 1-33). We have therefore studied the 
complexation of HA-boronic with the same library of diols (soluble, in colloidal form, 
enzymatically generated) as in Chapter 2 and have provided a comparison. In addition 
we have also studied the complexation of HA-boronic with other polymers (HA-
dopamine, PEG-dopamine, etc) in order to evaluate the binding of HA-boronic with 
large molecules. Future work will establish whether HA-boronic diol-containing-drug 
complexes will be able to release the drug selectively in the acidic environment of the 
late endosome or lysosome 
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2. New tricks for an old dog: boronic-diol “click” reactions in 
complex media. Applications to enzyme kinetics and 
catecholamine metabolism 
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2.1 Summary 
 
The complexation of boronic acids and diols is an interesting “click” reaction, used both 
in natural and synthetic systems. These reactions are often monitored through the 
fluorescence developed by Alizarin Red S upon complexation with boron derivatives. 
We here describe an alternative method based on the batochromic shifts of this reporter; 
the distinct advantage of this method is the possibility to be applied also to complex 
systems, such as colloidal dispersions or complexed active compounds. This is purely a 
new analytical method to study the conjugation between boronic acids and diols by 
evaluating their binding constants and to give an idea of how easy/difficult would it be 
to release the diol. To evaluate the new analytical method we have successfully 
employed the batochromic shifts of ARS to the determination of the equilibrium 
constants of the reactions between a number of diols, several with catecholamine 
structure, and a model boronic derivative. Since the complexation of polymeric 
compounds with diols is more complicated, we have initially followed the complexation 
of a small molecule (APBA) with diols in order to test the feasibility of the new 
analytical technique as well as to establish a benchmark for the binding constants which 
can later be used to compare with those obtained by using polymeric compounds. Most 
interestingly, in order to present the other advantages and uses of this method, we have 
showed that this method allowed to follow the kinetics of enzymatic reactions involving 
catechol structures; we have focused on cytochrome P450-mediated reactions and, 
besides demonstrating the possibility to follow enzymatic modification on complexed 
steroids (cyclodextrin-complexed estradiol2-hydroxyestradiol), we have for the first 
time shown the enzymatic (CYP2D6) reversibility of dopamine methylation, which is a 
catechol O-methyltransferase (COMT)-mediated process presiding to the inactivation of 
drugs for Parkinson‟s disease (PD). This last result may open new perspectives in PD 
treatment, where both COMT and CYP2D6 polymorphism may have to be taken into 
account. 
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2.2 Introduction 
 
2.2.1 Significance of boron-diol complexation 
 
Boric acid and organic boronic derivatives are well known to interact with diol-
containing molecules with high affinity, reversibly forming cyclic esters in a sort of 
“click” reaction, orthogonal to most biochemical pathways.  
These reactions occur in nature: in the plant or fungal world such complexes are found 
in cell walls
1
 and have an important function in the stabilization of plant cell 
membranes
2
, and have also been shown to mediate the biological mobility of boron
3
. 
Another interesting example of the biological role of boron-diol (catechol) complexes is 
offered by certain bacterial quorum-sensing molecules
4-6
, whose activity can be 
modulated or inhibited by the formation of complexes with boronic/boric acid, then 
affecting bacterial virulence and capacity of swarming or of forming biofilms
6, 7
. 
These reactions are also selective: due to their preferential interaction with 1,2 diols in a 
chelating configuration, and specifically with cis sugars, boronates have been proposed 
as synthetic analogues of lectins, as suggested by Wang
8, 9
. Due to this selective 
recognition of carbohydrates, as reviewed by Striegler
10
, boron-based sugar sensors 
have been developed, for example conjugating boronic acids with fluorescent 
reporters
11, 12
. Boronate-displaying solid supports have also been used for the 
purification/extraction  and analysis (chromatography
13-15
, electrophoresis
16, 17
) of 
carbohydrate-containing low MW or polymeric compounds, such as glycoproteins; the 
reverse approach has also been employed, and supported diols have been used for the 
extraction of boronic acids
18
 or for performing solid state chemistry on them
19
. 
In synthetic polymer chemistry, the boronate/diol complexation has been used as a 
“click” reaction, e.g. to provide functional ends20, or to fine tune the nano-structure of 
self-assembling macromolecules
21
; this reaction has also been employed as a reversible 
polycondensation reaction
22
, e.g. to provide self-repairing macromolecules
23
. Finally, 
and most interestingly, the mild conditions of boronate/diol complexation and its 
insensitivity to most biomolecules has also allowed its use for the derivatisation of 
biological surfaces, such as those of living cells
24, 25
. 
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2.2.2 Details of boron/diol complexation 
 
Following complex formation, boron is readily quaternarised by OH ions, leading to a 
pH decrease
26
; inter alia, this phenomenon has been extensively used for the titration of 
H3BO3 with bases
27, 28
, otherwise much too weak an acid. However, since the free 
boronates can be quaternarised by OH ions too, one can consider two different constants 
for the boronate/diol copmlexation: one (
trigK ) for the reaction from the trigonal form 
(R-B(OH)2) and one ( tetK ) for the tetrahedric, quaternarised form (R-B(OH)3
-
). 
However, the higher acidity of the complex causes  tetK >> trigK
29
, and it is therefore 
possible to group the formation of the cyclic product and its quaternarisation into one 
single complexation event. The acidity and therefore also the tetK  of the boron/diol 
complex appears not to have a strong dependence on the pKa of the boronic precursor
30
, 
but it does depend on that of the diol; for example cathecols are more acidic than 
aliphatic alcohols and bind more strongly than them. There are exceptions to this rule: 
the binding constants of-hydroxyacids to boronic acids are only marginally higher 
than those of aliphatic diols
31
.   
A variety of methods have been employed for the quantification of boronic/diol 
equilibria. In the vast majority, they exploit spectral changes produced by the 
complexation/decomplexation of a chromophoric reagent, such as electron-rich 
(hyperbranched) polyphenylenes
32
 or naphtyl residues
33, 34
. Probably the most effective 
and popular reporter is alizarin red S (ARS), an aromatic diol capable of intense 
fluorescence only when bound to a boronic acid
20
. If a second diol is added, two 
competing equilibria are established (Scheme 2-1): in the first one the ARS reacts with 
the boronic acid, in our case 3-aminophenyl boronic acid (APBA) as a model of 
functional boronic acids. Upon addition of another diol (DI), an APBA – DI adduct can 
be formed, with the contemporaneous liberation of ARS. A lot of literature in the past 
has been focused on the use of phenylboronic acids with ARS since they are water 
soluble and can easily complex with diols at neutral pH due to their pKa
8, 9
. However, in 
this study we have specifically used APBA since its amine group can be linked with the 
carboxylate group of HA to form HA-BA which could be used as a carrier for diol 
based drugs. So, in order to evaluate the complexation between HA-BA and diols, a 
benchmark using the new analytical technique was required, which was provided by 
studying the complexation between APBA and various diols. Knowing the equilibrium 
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constant for the first equilibrium (KARS) and monitoring the concentration of ARS, it is 
possible to calculate the second equilibrium constant (KDiol). Due to their favourable 
characteristics, these equilibria have also been employed to build chemical gates, 
linking saccharide sensing to molecular computing
35
. 
 
 
 
 
Scheme 2-1. The spectral changes of ARS allow to evaluate the equilibrium constants a) of its binding to 
a model functional boronic acid, APBA, ( ARSK ) and b) of the competitive binding to APBA in the 
presence of another diol ( EXCK ). From these constants, it is possible to calculate that of the equilibrium 
between the diol and APBA ( DiolK ). Please realize that for simplicity the protonation equilibria have 
been omitted and all free boronic acids have been represented in their protonated form, their complexes in 
their deprotonated one. 
 
2.2.3 Validation of the analytical method 
 
In this study, we have developed a parallel method based on the changes in the ARS 
absorption spectrum: a peak shift of about 40 nm is observed using 0.56 mM ARS and 
0.56 mM APBA (519 nm – 480 nm) i.e. a colour change from red to orange is 
associated to complex formation, while the liberation of free ARS determines a colour 
shift back to the red region. This absorbance-based method is considerably less sensitive 
than any fluorescence-based assay, but is applicable to far more concentrated and 
possibly inhomogeneous samples and is also much less sensitive to the presence of 
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scattering objects and quenchers. The absorbance method, therefore, would be suitable 
to follow diol/boronic equilibria used as “click” reactions in complex, e.g. 
heterogeneous or self-assembled systems, where scattering or aggregation (self-
quenching) may provide unreliable fluorescence readings. Here, we have first validated 
the use of absorbance for the evaluation of the constants for the equilibria between 
APBA and a number of aromatic diols (catechols) and aliphatic ones 
(monosaccharides), which are listed in the Scheme 2-2.  
The main reasons for using these diols are to prove the usability of the analytical 
technique with various diols, to compare the binding constants between similar types of 
diols (catechols, aromatic polyols, aromatic negative controls and sugar diols) and to 
investigate whether the different positioning of diols in various substances has any 
effects on their binding constants. 
 
 
 
Scheme 2-2. Structures of diols used in this study.  
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Another important reason for using these substrates is to provide a benchmark value of 
binding constant for each substrate with APBA so as to be able to compare with the 
binding values for HA-3-APBA which would help in determining any effect a polymer 
would have on the binding strengths and hence on the ease of binding and release of 
these diols – thereby contemplating on the use of a boronate – polymer as a drug 
delivery carrier.  
Pyrocatechol, dopamine, norepinephrine and epinephrine present a simple 1,2-
dihydroxybenzene structure and have been chosen as main substrates; it is noteworthy 
that the last two are metabolites of dopamine. The study of dopamine is also carried out 
since we expect HA-3-APBA and HA-Dopamine when mixed to form pH responsive 
nanoparticles which could be used for the delivery of hydrophobic drugs to 
cancer/tumour cells. Pyrogallol has been used as a positive control: it bears an 
additional OH group that can speed up the kinetics of complexation (two positions of 
attack) but it should not dramatically influence its equilibrium constant. As negative 
controls, i.e. non-complexing but structurally similar reagents, we have used 
phloroglucinol, where the spacing betwen OH groups does not allow the formation of 
cylic esters, and veratrylamine, a dimethylated analogous to dopamine Finally, as 
“sugar” diols we have used glucose and mannose, and ascorbic acid, an enediol derived 
from glucose. 
We have then employed this assay to equilibria occurring in complex and possibly 
phase-separated environments: 
 
Colloidal dispersions. Flavonoids have attracted attention as promising active 
principles in the prevention of cancer
36, 37
 and inflammation
38
, possibly due to the 
radical scavenging and reducing
39
 activity of their catechol-containing structure. 
Quercetin is the most common naturally occurring flavonoid and possibly the most 
investigated one, but its scarce water solubility
40
 determines the need of solubilisers, 
which on the other hand may affect its physico-chemical properties. Here we have used 
a surfactant already known to effectively disperse quercetin, Tween 20
41
, verifying the 
availability of quercetin‟s catechol group through the absorbance test. The main reason 
is to prove the usability and advantage of this method for determining the binding 
constants of hydrophobic substrates containing diols with boronic acids as most of the 
anti-tumour/cancer drugs are usually hydrophobic. 
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In situ enzymatically produced substrates. A number of metabolic pathways involve 
catechols and the availability of a reporter to continuously monitor these reactions in a 
biological and possible heterogeneous environment would be very beneficial. We have 
used two different enzymatic pathways to prove this and it was carried out to purely 
present the various instances in which this method might be useful, especially for 
monitoring the metabolic effects of CYPs on drugs. We have specifically focused on the 
human Cytochrome P450 enzymes (CYPs), a vast family of enzymes whose very wide 
metabolic activity is directed to both endogenous and exogenous molecules
42, 43
. CYPs 
are best known for their oxidative activity
44, 45
, which is often essential for drug 
metabolism and makes them one of the most important targets of rational drug design. 
Four main classes of chemical reactions are typically performed by CYPs, i.e. carbon 
hydroxylation, heteratom release, heteroatom oxygenation and epoxidation
46
.  
 
A) The conversion of phenolic substrates to catechols belongs to the first class of 
reactions (hydroxylation) and is often related to tumour initiation and progression: for 
example, the CYP-mediated oxidation of estrogens to the corresponding catechols and 
further to quinonic structures are well established steps in hormonal cancerogenesis
47, 48
. 
Here we have focused on estradiol (17-estradiol) hydroxylation, a reaction whose 
regiochemistry is critical in tumour development: the 2-hydroxy derivative has a 
catechol structure and is known to be non-cancerogenic and possibly tumour-inhibiting 
because of its rapid monomethylation by catechol O-methyltransferase (COMT); the 4-
hydroxy derivative has a much richer REDOX chemistry and high tumourigenic 
activity
49
. Our method may allow to selectively follow the production of the 2-
derivative, allowing to compare possibly tumourigenic conditions. Here we have 
employed the P450 variant 1A2 (CYP1A2), one of the three variants known to operate 
the 2-hydroxylation reaction
49, 50
. Since both estradiol and 2-hydroxyestradiol, are 
substantially water insoluble, we have used a sulphonated β-cyclodextrin to solubilise 
them. Cyclodextrins are good complexing agents for estradiol, even inhibiting its 
hormonal activity that is based on its hydrophobic character
51
; on the other hand, 
compared to most common excipients, they have a very low inhibitory activity on 
CYPs
52
. We have chosen a sulphonated cyclodextrin because preliminary experiments 
have showed that it allows for a higher maximal concentration of estradiol, while the 
sulphonation of OH groups reduces the interference of the cyclodextrin diols in the 
complexation of APBA.  
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B) Some members of the CYP superfamily are specifically active in performing the 
second class of reactions (heteratom release) by demethylating or demethylenating 
phenolic and catecholic substrates: for example, cytochrome P450 variant 2D6 
(CYP2D6), which is estimated to be responsible for the metabolism of at least a quarter 
of the drugs used today
53
, has a significant O-demethylase activity. CYP2D6 appears to 
be the main enzyme responsible for the dealkylation of methylated phenols yielding, 
e.g. serotonin (from 5-methoxytryptamine)
54
, morphine (from codein)
55
, desvenlafaxine 
(from venlafaxine, a serotonin-norepinephrine reuptake inhibitor)
56
, harmalol and 
harmol (respectively from harmalin and harmin, two psychoactive alkaloids inhibting 
monoamine oxidase A)
57
, dextrorphan (from dextromethorphan, a cough suppressant)
58
, 
O-desmethyl-tramadol (from tramadol, a common analgesic)
59
. CYP2D6 exhibits a 
similar dealkylating activity on methylene dioxolane catechol derivatives (e.g. 3,4-
methylenedioxy-amphetamine (MDMA, ecstasy))
60
 converting them into catechols. 
Although this enzyme can also perform hydroxylation reactions on phenolic substrates, 
converting them to catechols (for example p- or m-tyramine to dopamine
61
), in the 
presence of methyl ethers it has predominantly a dealkylase activity
62
 and hydroxylation 
is only a less likely second step catalyzed by the same enzyme
63
. Due to its 
demethylating activity, CYP2D6 may help countering the role of COMT in the therapy 
of Parkinson‟s disease (PD): COMT is one of the main contributors to the inactivation 
of exogeneous neurotransmitters, such as L-DOPA, dopamine, epinephrine, etc, used to 
treat PD
64, 65
. As a result, COMT inhibitors (entacapone, tolcapone, etc.) are now used 
in combined therapy with L-DOPA to increase dopamine concentration in the brain
66-68
. 
CYPD26 may partially counter COMT action, for example demethylating 3-
methoxytyramine, which is the mono-methylated derivative of dopamine produced by 
COMT; however, we have not found any report in the literature about this reaction. We 
have therefore applied our batochromic shifts method to investigate whether CYP2D6 
could produce dopamine from 3-methoxytyramine. 
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2.3 Experimental Section 
 
2.3.1 Materials 
 
Alizarin red S (ARS), 3-aminophenylboronic acid hydrochloride (APBA), 
phenylboronic acid (PBA), dopamine hydrochloride (DOPA), D-(+)-mannose, D-(+)-
glucose, pyrogallol, phloroglucinol, L-ascorbic acid, quercetin, estradiol, pyrocatechol, 
(±)-epinephrine hydrochloride, D,L-norepinephrine, veratrylamine, β-Nicotinamide 
adenine dinucleotide 2′-phosphate reduced tetrasodium salt hydrate (β-NADPH), 
recombinant human cytochrome P450 1A2 (1000 picomol/mL solution), Tween 20, 
sodium hydroxide pellets and tris(2-carboxyethyl)phosphine hydrochloride (TCEP) 
were supplied as high purity reagents (purity always ≥ 98%) by Sigma-Aldrich (U.K.) 
and used without further purification.  
Sodium dihydrogen orthophosphate dihydrate, and disodium hydrogen orthophosphate 
dihydrate were supplied by BDH (U.K.). Human Cytochrome P450 2D6 Yeast 
reductase (500 picomol/mL solution) was manufactured by SPI-Bio (France) and 
supplied by Immuno diagnostic systems (U.K.). β-cyclodextrin sulphobutylether 
(Captisol) was supplied by Cydex Pharmaceuticals (U.S.).  
All solutions were prepared in 100 mM PBS obtained by dissolving sodium dihydrogen 
orthophosphate dihydrate, disodium hydrogen orthophosphate dihydrate and sodium 
chloride, supplied by BDH (U.K.), in concentrations respectively of 2.3 g/L, 11.8 g/L 
and 9 g/L in water purified in a Milli-Q system (Millipore, U.K.). 
 
2.3.2 UV-Vis and fluorescence measurements 
 
A BioTek Synergy 2 multi-mode microplate reader was employed to record absorbance 
spectra (generally in the range 400-800 nm) and fluorescence readings (filters at 
exc 485±20 nm and em 620±40 nm); temperature was generally kept at 25°C, 
except for the spectra of enzymatic reactions which were recorded at 37°C.  All the 
spectra were corrected by subtracting the possible scattering component of the buffer 
solution using appropriate blanks. 
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2.3.3 Binding experiments 
 
General conditions: For competitive binding experiments in each well of a 96 well 
plate (total volume of each sample = 250 L) 48 L of a 1 mg/mL ARS solution and 55 
L of a 0.44 mg/mL APBA solution (both in 0.1 M PBS) were mixed to obtain a 0.56 
mM final concentration for both reagents and were allowed to react for 30 seconds; the 
colour of the solution correspondingly changed from red to orange. An amount of diol 
corresponding to 3-APBA/diol molar ratios ranging from 1:0.5 to 1:1000 was then 
added, producing a clear orange to red chromatic change at high 3-ABPA/diol molar 
ratios. The highest APBA:diol molar ratio for veratrylamine and for phloroglucinol was 
1:10 (0.0056 M) and 1:100 (0.056 M) respectively, due to their limited solubility in 
water. All the absorbance values and the concentrations of the reagents were then 
corrected for the dilution. In simple binding experiments the same protocol was used, 
but the volumes of APBA or PBA solutions were varied in a series of experiments and 
the absorbance or fluorescence values were monitored to obtain the intensities as a 
function of amount of added boronic acid.  
 
Reaction with pyrogallol: Owing to the quick oxidation of this electron-rich polyol, 
TCEP was added to the stock solution of pyrogallol in a molar ratio pyrogallol/TCEP 
1:1.5. Due to the decrease in pH following TCEP addition, a few drops of 0.1 N NaOH 
were added to the pyrogallol stock solution until pH = 7.4. 
 
Reaction with ascorbic acid: Due to the acidic nature of this diol, 1M PBS buffer was 
used to raise the pH to 7.4. 
 
Reaction with quercetin. Owing to the very poor solubility of quercetin in a water 
environment a Tween 20 (a oligo(ethylene glycol) (polyoxyethylene) derivative of 
sorbitol monolaurate widely employed in bioassays and pharmaceutical formulations) 
was used. For quercetin concentrations up to 1 mM a 1:1 Tween/quercetin molar ratio 
was sufficient to completely solubilise it in 0.1 M PBS buffer, since its UV-Vis 
absorbance reaches a plateau and does not increase with larger amounts of surfactant. 
The highest concentration of Tween 20 used is limited by its ability to hamper the 
binding reaction.  A maximum of 8% w/w of Tween 20 can be used without affecting 
the reaction kinetics.  
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Enzymatic Reactions. Typical experiments were performed in 96 well plates at 37 
O
C 
sealed with the help of PCR plate adhesive seals to prevent evaporation; three 
repetitions were carried out per sample in 0.1M PBS buffer. 
 
- Demethylation of 3-Methoxytyramine. 3-methoxytyramine can bind to boronic acid 
only upon removal of its methoxy group, which can be carried out by cytochrome P450 
variant 2D6. A stock solution of CYP2D6 was prepared by diluting 20 L of a 500 
pmol/mL solution with 520 L of 0.1 M PBS. To this CYP solution, 8.34mg of 
NADPH was added which is needed for activation of the enzyme.  
The reaction of ARS with APBA was conducted as described above. Appropriate 
amounts of 3-methoxytyramine, ranging from a APBA : 3-methoxytyramine molar ratio 
of 1:0.5 to 1:3.2, were then added to each well, followed by 27 l of the CYP2D6 stock 
solution (corresponding to 0.5 pmoles of CYP2D6 + 2mM final concentration of 
NADPH). 
 
- Hydroxylation of estradiol. Estradiol can bind to boronic acid only upon the 
introduction of a second alcoholic function, which can be carried out by cytochrome 
P450 variant 1A2. Estradiol is barely soluble in the water medium that we have used for 
the diol/boronic reaction (0.1 M PBS) and thus requires a solubilising agent; since most 
surfactants would impair the activity of cytochrome P450, we have employed β-
cyclodextrin sulphobutylether, (i.e an anionic, very water soluble cyclodextrin: neutral 
cyclodextrins did not provide sufficient solubilisation, while most surfactants do) in 1:1 
molar ratio with estradiol. A stock solution of CYP1A2 was prepared by diluting 30 L 
of a 1000 pmol/mL solution with 375 L of 0.1 M PBS. To this CYP solution, 7.8mg of 
NADPH was added for its activation. 
48 L of ARS solution (final concentration: 0.56 mM) was added to each well, followed 
by 55 L of APBA (final concentration: 0.56 mM); the mixture was allowed to react for 
30 seconds (stable change in colour from red to orange). On completion of this reaction, 
a calculated amount of estradiol (APBA : estradiol molar ratios ranging from 1:0.1 to 
1:4.5) was added to each well, followed by 27 L of the CYP1A2 stock solution 
(corresponding to 2 pmoles of CYP1A2 + 2.5mM final concentration of NADPH). 
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Relevance of NADPH. NADPH (Scheme 2-3) is a coenzyme responsible for 
transferring electrons to cytochrome P450 for carrying out its various metabolic 
activities such as hydroxylation and demethylation
69, 70
. CYP450 needs NADPH in 
order to act on its substrate since without it, its activity is seriously reduced (see 
appendix, Figure 2-10). In the abovementioned enzymatic reactions, both estradiol and 
3-methoxytyramine do not possess a 1,2-diol and hence cannot link to any boronic acid 
moiety. The CYP1A2 and CYP2D6 using NADPH, help by hydroxylating
71
 and 
demethylating their respective substrates, thereby producing their respective 1,2-diols 
which can then link to APBA. 
Control experiments without NADPH with all other parameters unchanged were carried 
out initially. Also control experiments without CYP450 and without NADPH were also 
carried out which showed no shift in wavelength due to the absence of any 1,2-diol.  
 
PO
O
O
O
OH O
PO O
O
N
N
NH
2
N
N
O
PO
O
O
O
OH OH
N
NH
2
O
 
Scheme 2-3. Structure of NADPH. 
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2.3.4 Analytical methods used for the calculation of binding constants 
 
It is noteworthy that in this study we have not differentiated between the equilibria 
leading to the formation of the trigonal or the tetragonal form of the diol-boronic esters. 
Whenever binding constants are provided for the diol-boronic equilibria, they are 
overall affinities at pH=7.4 in 0.1 M PBS. 
 
1) Determination of ARS/boronic acids binding constants through batochromic 
shifts  
 
When using boronic acids such as APBA (here identified as B), that lack a significant 
absorption in the visible or near UV spectral region, the only absorbing species are ARS 
(here identified as A) and the ARS-boronic ester (here identified as AB), i.e. ARS in the 
free and bound form. As a result, the spectra of ARS with different amounts of boronic 
acid show a clear isosbestic point, ensuring the presence of only two species in the 
equilibrium (Figure 2-1, left). Since the spectra of ARS alone and of its complex, 
obtained from ARS in the presence of a large excess of APBA, can be accurately fitted 
with Gaussian equations (see appendix, Figure 2-6), it is possible to recreate the 
absorption spectrum of any mixture of ARS with its boronic ester, expressing it as a 
linear combination of the spectra of the two pure substances (see appendix, Figure 2-7): 
 
2
2
2max2
1
1max
}
)(2
{
2
}
)(2
{
1 )1(






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where the absorbance A depends on the molar concentrations of the two products 
[expressed as the product of their molar fractions (xA – molar fraction of ARS, 1 - xA – 
molar fraction of ARS-APBA) times the total concentration of ARS species (CA)], and 
on parameters obtained from the spectra of the two pure products, 1max and 2max , 1 and 
2 , 1 and 2 , which are, respectively, the wavelengths of the maxima of the spectra of 
ARS and of its boronic ester, the corresponding extinction coefficients and parameters 
related to the band width. 
By plotting the wavelength of the absorbance maxima of these calculated spectra vs. Ax
one obtains a sigmoidal graph (Figure 2-1, right); this graph is, in essence, a master 
curve, which allows to relate the location of the absorption maximum for a given 
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ARS/APBA mixture to the fraction of free ARS in that mixture. It is worth pointing out 
that this master curve is necessary, due to the non-linear nature of the relationship 
between the max of the solution and Ax . 
 
 
 
Figure 2-1. Left: UV-Vis spectra of 0.56 mM ARS in the presence of increasing content of APBA. The 
isosbestic point is clearly visible at 497 nm.   Right: the max of the curves obtained as linear 
combinations of the spectra of ARS and of the ARS/APBA complex show a sigmoidal dependence on 
Ax ; by fitting it with a Boltzmann equation, it is possible to directly relate the experimental max  of a 
mixture to the molar fraction of free ARS. 
 
It is possible to express Ax  as a function of the constant 1K  of the equilibrium between 
ARS and APBA and of the initial concentrations of ARS and APBA, AC  and BC : 
 
])[])([(
][
]][[
][
1
ABCABC
AB
BA
AB
K
BA 
        (2) 
 
2
4)
1
(
1
][
2
11
BABABA CC
K
CC
K
CC
AB

      (3) 
A
BABABA
A
A
C
CC
K
CC
K
CC
C
AB
x
2
4)
1
(
1
1
][
1
2
11

     (4) 
 
It is then possible to calculate 1K  by applying a nonlinear least square regression to a set 
of experimental values imax,
~
 from mixtures prepared at different initial concentrations of 
ARS and APBA ( iAC , and iBC , ,respectively).  This is obtained by taking into account 
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that the vector ( nAA xx ,1,  ) can be expressed as function of 1K , iAC , and iBC , (equation 4) 
and minimizing the sum of the squares of the offsets 2,max,,max ))(
~
)(( 
n
iAiiA xxS  .Using 
a fixed concentration iAC , = AC = 5.6×10
-4 
M and varying iBC ,  in a range between 5.6×10
-
5 
M and 5.6×10
-3 
M, the nonlinear least square regression (performed using a 
MATLAB-written routine) returned a value of  the equilibrium constant 1K  = 5150 M
-1
 
with a coefficient of determination 2R =0.9937. An example of the convergence 
between the master curve )(max Ax and the set of ),
~
( ,max, iAi x  points ( iAx ,  obtained from 
the optimization of 1K ) is presented in appendix, Figure 2-8. 
 
2) Determination of ARS/boronic acids binding constants through fluorescence  
 
The binding of ARS to phenylboronic acid (PBA) and 3-aminophenlboronic acid 
(APBA) was also studied using the emission of the ARS boronic esters, recording the 
increase in fluorescence intensity of an ARS solution upon addition of the boronic acids, 
a method pioneered by Wang
72
. In those reports, fluorescence data were fitted according 
to 
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where 0I is the total concentration of ARS (in our model it is called AC ),  and ][L should 
stand for the concentration of free boronic acid (in our model ][B ). Although this is not 
explicitly described in the paper, we are induced to believe that the total concentration 
of boronic acid ( BC ) was used instead of ][B : indeed by replacing BC  with ][B )  our 
fluorescence data for the ARS/PBA equilibrium provide a constant substantially 
identical to that given by Springsteen et al.
72
 (see Table 2-1). We have, on the contrary 
used the expression of ][AB provided by equation 3 to fit the fluorescence data through 
the model provided by equation 6 
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Where the fluorescence intensity FI dependence on BC  is used to calculate the unknown 
parameters A and 1K  ( AC  being constant). 
 
3) Determination of diol/boronic acid binding constants through competitive 
binding with ARS 
 
The gradual addition of a diol (identified as D) to an ARS boronic ester determines an 
increasing batochromic shift due to the production of free ARS (Figure 2-2, left; see 
appendix, Figure 2-9, for a picture of the typical colour changes during the test). 
 
 
 
Figure 2-2. Left: Shifts in max  produced by the addition of increasing amounts of pyrogallol to a 
solution of ARS/APBA (both 0.56 mM). Right: Using equations 7 and 8 it is possible calculate the values 
of K  for any experimental point of the curve on the right, although we have generally limited this 
calculation to the points of the initial linear region of the curve. The average of these values is then used 
to calculate 2K , i.e. in this case the binding constant of pyrogallol to APBA. 
 
The corresponding competitive equilibrium ADBDAB   is governed by a constant 
K  which can be expressed as the ratio of the two equilibrium constants for the 
formation of the individual boronic esters, AB and DB (equation 7), but can also be 
expressed as a function of the concentration of free ARS as the only variable (equation 
8). 
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For each given amount of diol, one obtains a max value from which it is then possible to 
calculate the fraction of free ARS Ax , as shown in the previous section; the application 
of equation 8 allows then to obtain K  and finally, through equation 7, the equilibrium 
constant of interest 2K .The values of 2K were averaged through a range of 
concentrations (Figure 2-2, right). 
 
4) Enzymatic reactions 
 
In general, all enzymatic tests were based on the in situ production of a diol in the 
presence of the ARS/APBA complex, taking part to a competitive equilibrium of the 
kind described in the previous section. Correspondingly, the main UV-Vis band of the 
solution undergoes a time- and concentration-dependent batochromic shift (Figure 2-3, 
left); the dependence on time provides information about the kinetics of the enzymatic 
conversion and that on the concentration of the precursor information about the binding 
constant of the diol. 
 
 
Figure 2-3. Left: example of the dependence of the batochromic shifts on time and concentration of the 
enzyme substrate for the enzymatic conversion of 3-methoxytyramine by CYP2D6 in the presence of the 
ARS/APBA complex (0.56 mM). Right: time dependence of the 3-methoxytyramineconcentration [S]                 
( 0][S = 0.84 mM, [ARS/APBA] = 0.56 mM), compared to its fit with a simple exponential decay. 
 
In this part of the study we have always assumed that the enzymatic conversion is the 
rate-determining step of the test, i.e. the competitive equilibrium is established in an 
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instantaneous fashion as soon as new diol is produced. This assumption is reasonable, 
since the diol-boronic equilibria are established in a matter of seconds, while tenths of 
minutes are required to obtain quantitative yields in diols. We have also assumed that 
complete substrate conversion was obtained when the batochromic shifts reached their 
asymptotic values; in this way it is possible to replace DC in equation 8 with the initial 
substrate concentration 0][S , therefore allowing the calculation of the diol-boronic 
equilibrium constant 2K .  
It is then possible (see appendix, Additional information about enzymatic reaction 
experiments) to use 2K  to express the substrate concentration ( ][S ) as a function of the 
molar fraction of free ARS ( Ax ), which can be calculated from the batochromic shift; 
from the time dependence of ][S  it is possible to calculate the initial rate of the 
enzymatic reaction. In order to reduce the experimental error, this was done by fitting 
the time-dependent data as an exponential decay ( )exp(][][ 0 ktSS  , where the slope at 
t=0 is approximated to be –k); this approximation is rather coarse, but legitimate73.The 
initial reaction rate v  was then plotted vs. 0][S and fitted using a Michaelis-Menten 
realationship
0
0max
][
][
Sk
Sv
v
M 
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2.4 Results and Discussion 
 
2.4.1 Comparison absorbance vs. fluorescence assays 
 
The UV-Vis spectrum of ARS is heavily affected by complexation: the absorption 
maximum of ARS in water is located at 519 nm (red colour), but it shifts to 480 nm 
(orange colour; see appendix, Figure 2-9) in the presence of a stoichiometric excess of 
boronic acids; this finding has been extensively reported in the literature
72
. Analogously 
to what happens for the fluorescence intensity, also these batochromic shifts can be used 
to monitor the binding equilibrium; a detailed description of the method is provided in 
the experimental section.  
We have compared the use of spectral shifts with that of fluorescence intensity the 
reactions of ARS with phenylboronic acid (PBA) and 3-amino phenylboronic acid 
(APBA) (Figure 2-4). An expected asymptotic behaviour was recorded for both assays 
with excess boronic acid; however, above all for ARS/APBA, the batochromic shifts 
provided better defined plots, possibly because of the fluorescence emission to 
aggregation/scattering at higher APBA concentrations.  
 
 
Figure 2-4. Comparison of the variations in fluorescence intensity (right axes, data corrected for dilution) 
and location of the absorbance maximum (left axes) for a 0.56 mM ARS solution in 100 mM PBS as a 
function of the amount of added boronic acid. Please realize that the max data are related to the 
concentrations of the two chromophores (ARS and ARS boronic esters) in a non-linear fashion. Left: 
addition of phenyl boronic acid (PBA). Right: addition of 3-aminophenyl boronic acid (APBA). The 
max data appear to depend less than fluorescence ones on the nature of the boronic acid (possibly the 
introduction of the amino group in APBA provides a different quantum yield) and in the case of APBA 
show a better defined concentration dependence. 
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Although the equilibrium constants calculated with the two methods showed a 
statistically significant difference, their values were reasonably close; most importantly, 
the ARS/APBA K1 was about 1.5-fold larger than that of ARS/APBA for both methods. 
We therefore concluded that the two methods were well comparable. 
It is worth pointing out that the equilibrium constant for ARS/PBA calculated on the 
basis of the fluorescence measurements showed a significant difference from the 
literature value 
72
. This may be due to a certain variability caused by aggregation of the 
boronic acid at high concentration, but we cannot rule out a difference in calculation, as 
discussed in the Experimental Part, section “Determination of ARS/boronic acids 
binding constants through fluorescence” (Analytical methods, point 2). This is evident 
from Figure 2-4, Right which shows that the absorbance maximum reaches a plateau at 
a low concentration of APBA, while the fluorescence intensity keeps rising almost 
linearly in the concentration range tested.  
 
Table 2-1. Comparison of K1 values obtained using fluorescence intensity or batochromic shifts of ARS 
 
System 
K1 (M
-1
) 
Fluorescence  (Fluoresc. lit. method
 a
) Batochromic shifts 
ARS + PBA 2430 ± 110 (1245 ± 30; 1300
72
) 3600 ± 150 
ARS + APBA 3652 ± 415 (1474  ± 280) 5150 ± 200 
a here we report the K1 value from ref. 72 for the ARS/PBA system and those calculated by us replacing 
the free boronic acid concentration with its total concentration, as described in the experimental section 
(Analytical methods, point 2). 
 
2.4.2 Overall affinities (K2) of different diols for APBA 
 
As a model for possibly functional boronic acid, we have further investigated the 
binding strength of APBA with the compounds listed in Scheme 2-2 (Table 2-2). Since 
APBA has been rarely employed in diol/boron complexation equilibria, this choice does 
not allow a perfect comparison with literature data; however, we can qualitatively 
compare our data with those available for PBA (Table 2-2, 3
rd
 column). 
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Table 2-2. Binding strength of various diols with APBA at pH 7.4 in 0.1M PBS buffer. The binding 
constant of ARS – APBA (K1) is 5150 ± 200 M
-1. Literature values for the binding strengths of some 
diols to PBA are reported for comparison. SD are calculated over n =3.  
Diol K2 (M
-1
) Opt. pH 
a 
 K2 (PBA) (M
-1
) 
b
 
Negative 
controls 
Phloroglucinol 0 8.7  
Veratrylamine 0 =  
Aromatic diols 
Pyrocatechol 1490 ± 70 8.8 830
72
 
Dopamine 1555 ± 66 8.9  
Dopamine from 3-
methoxytyramine 
1550 ± 73 8.9 
 
Epinephrine 1445 ± 65 8.7  
Norepinephrine 1545 ± 66 8.8  
2-hydroxy estradiol 
from estradiol 
c
 
955 ± 38 9.2 
 
Aromatic 
polyols 
Pyrogallol 
d
 1796 ± 78 9.0  
Quercetin
 e
 1240 ± 98 8.3  
Sugar diols 
Mannose 5.85 ± 1.2 10.5 13
72
 
Glucose 3.75 ± 0.4 10.6 4.6
72
 
Ascorbic acid 6.4 ± 0.94 10.4  
a the optimal pH was calculated according to ( ( ) ( )) / 2
optimal a a
pH pK boronic pK diol   
b literature values of PBA shown for comparison 
c  in the presence of sulphonated -cyclodextrin to solubilise the steroid. The end point of the enzymatic 
reaction (see later) was used to calculate the value of the equilibrium constant, assuming complete 
conversion of estradiol. 
d  in the presence of TCEP to avoid pyrogallol oxidation 
e in the presence of Tween 20 to solubilise quercetin 
Chapter 2 
97 
 
First of all, it is noteworthy that the two negative controls did not show any binding to 
APBA. The absence of competitive equilibria with veratrylamine, i.e. dimethylated 
dopamine, and phloroglucinol, with hydroxyl groups all in meta positions, ensured that 
the isolated OH groups and primary amines did not interfere with the assay. 
All aromatic diols and polyols exhibited very similar binding affinities to APBA, and all 
were significantly lower than that of ARS, showing therefore a negligible influence of 
the nature, size or polarity of the residues present in para position. The overall lower 
binding strength of catechols in comparison to ARS can be explained on the basis of 
their pKa. The optimal pH of binding is generally calculated as the average of the pKa 
of the two reactants. ARS has a pKa of 4, APBA of 8.9, which brings the optimal pH of 
binding to 6.45. Catechols have pKa values in the region of 9.2, thus an optimal pH 
value for binding should be in the proximity of 9.05. It is therefore not surprising that at 
neutral pH the binding strength of APBA with these catechols is considerably lower 
than that of ARS. 
Among the aromatic diols/polyols only 2-hydroxyestradiol showed a significantly lower 
K2 value; this can be ascribed to both to the steric hindrance of the sulphonated -
cyclodextrin/2-hydroxy estradiol complex and the electrostatic repulsion between the 
reaction partners: both ARS/APBA and the cyclodextrin are negatively charged. Since 
in the case of quercetin the use of a non-ionic solubiliser did not appear to dramatically 
depress the binding affinity of the catechol, we are inclined to ascribe the lower K2 of 2-
hydroxyestradiol mostly to the electrostatic effect. 
The low binding constants recorded for sugar diols, in accordance to literature data, can 
be explained on the basis of the lower pKa of these compounds, in addition to a less 
favourable conformation of the vicinal OH groups. Indeed, the relative ranking of these 
compounds reflect the fact that mannose presents a more accessible cis diol and 
ascorbic an even more easily accessible enediol group. 
The batochromic shift method has therefore allowed a rather precise estimation of the 
binding constant for a wide range of diols; further, it was successfully applied also on a 
heterogeneous sample (quercetin solubilised with Tween 20). This helps us in proving 
the usability of the method in various systems, especially in heterogeneous systems, and 
in having a benchmark for evaluating the binding strengths of these substances/drugs 
with a polymeric carrier. The binding constants of 2-hydroxyestradiol and quercetin are 
both reasonable at physiological pH showing that they can be coupled with boronic 
acids with ease using low amounts and would be easy to separate at acidic pH.   
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2.4.3 Enzymatic Reactions 
 
We have successfully implemented the batochromic shift method to follow the kinetic 
of enzymatic reactions involving catechols. The plots of the initial reaction rates vs. 
substrate concentration for both the demethylation of 3-methoxytyramine by CYP2D6 
and the hydroxylation of estradiol by CYP1A2 showed rather accurate Michaelis-
Menten-type kinetics (Figure 2-5), which provided maxv = 49.4 ± 3.2 nmol/(min×pmol of 
CYP2D6) and MK = 281 ± 64 M for the first reaction, maxv = 65.2 ± 18.7 
nmol/(min×pmol of CYP1A2) and MK = 3.8 ± 1.7 mM for the second one. The activity 
of both enzymes, i.e. CYP2D6 as a demethylase
74
 and CYP1A2 as a hydroxylase
75
, are 
NADPH-dependent; indeed the batochromic shift method allowed to verify that the 
absence of NADPH profoundly altered the enzymatic kinetics (see appendix, Figure 2-
10). 
 
 
Figure 2-5. Michaelis-Menten plots for the two enzymatic reactions followed in this study. Left: 
demethylation of 3-methoxytyramine. Right: hydroxylation of estradiol.  
 
From a qualitative point of view, the most significant result is the verification that 
dopamine can be produced through the CYP2D6-mediated demethylation of 3-
methoxytyramine, which on its turn is produced by COMT during the deactivation of 
dopamine, proving therefore the possibly antagonistic action of the two enzymes.  
In quantitative terms, we do not have a direct literature comparison for the enzymatic 
parameters obtained through the batochromic shift method for this reaction; however, 
our maxv  and above all MK data are broadly comparable to literature examples the 
CYP2D6-mediated demethylation of O-methylphenols (Table 2-3). It is worth focusing 
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more on MK  than on maxv , since the values of the latter are heavily affected by the 
purity of the enzymes, which varies considerably from microsomal preparations to 
recombinantly expressed molecules. The rather low MK  value can be in part ascribed to 
molecular features: the presence of a vicinal OH group in the 3-methoxytyramine 
structure may decrease the affinity of the enzyme for the substrate; however, the 
sourcing of CYP2D6 is also likely to play a role. A more accurate comparison of the 
batochromic shift method with other reports would appear to be possible for the kinetic 
parameters of the enzymatic 2-hydroxylation of estradiol. For most literature reports, 
MK  values clustered in the proximity of 20 M (Table 2-4). It must be pointed out these 
literature studies were performed with substrate concentrations as high as 200 M, 
while the solubility of estradiol in water or water buffers is lower than 20 M76; 
therefore, it is not unlikely that the reported data reflect the reactivity of an at least 
partially phase separated estradiol. In this study, on the contrary, we have used 
considerably higher estradiol concentrations, in the range 500-2500 M, where the 
steroid was kept in a molecularly dispersed state by the use of a sulphonated 
cyclodextrin. Normal cyclodextrin has 1,2-diols present which can link with boronate 
species, and hence on performing a preliminary experiment with APBA and 
cyclodextrin, complexation was noticed (data not shown). Therefore, we used β-
cyclodextrin sulphobutylether, which has the advantage of being highly water soluble as 
well as  not containing the 1,2-diol groups, and hence showed no linkage with the 
boronate species when the control experiment without estradiol and CYP1A2 was 
carried out. We have observed a dramatically lower affinity of CYP1A2 for the 
substrate, with MK  about two orders of magnitude higher than literature values. We 
attribute this major difference primarily to the effect of the high anionic charge and of 
the steric hindrance of estradiol/cyclodextrin complex, which surely detrimentaly affect 
binding. However, we cannot exclude literature reports to overestimate the affinity of 
CYP1A2 for estradiol: since the steroid was frequently used at concentrations 
considerably above its solubility in water, the affinity may be influenced by its 
aggregation and increased local concentration. 
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Table 2-3. Comparison of the kinetic parameters for the CYP2D6-mediated demethylation of some O-
methylated phenols (literature data, see appendix, Figure 2-11, for the structures of the compounds) and 
of 3-methoxytyramine (this study). 
 
Substrate 
MK  (enzyme 
isoform)
 a
 
(M) 
maxv  
(pmol/pmol 
P450/min) 
Demethylase 
activity 
(CLint)
b
 
(L/pmol 
P450/min) 
Ref 
Pinoline 
(6-hydroxy-1,2,3,4-
tetrahydro-β-
carboline) 
0.74 (CYPD26.1) 
2.3 (CYPD26.2) 
3.06 (CYP2D6.1) 
1.75 (CYP2D6.2) 
4.13 
0.76 
77
 
1.8 26
 c
 15
 c
 
78
 
5-methoxytryptamine 
(5-MT) (serotonin) 
17 43 2.5 
78
 
5-methoxy-N,N-
dimethyltryptamine 
(5-MDMT) 
(bufotenine)79 
29.3 (CYP2D6.1) 
85.0 (CYP2D6.2) 
947 (CYP2D6.10) 
12.3 (CYP2D6.1) 
14.4 (CYP2D6.2) 
10.3 (CYP2D6.10) 
0.42 
0.17 
0.011 
7
 
Dextromethorphan 
(dextrorphan) 
2.7 (high affinity) 
757 (low affinity) 
2.8
d
 (high affinity) 
136
d
 (low affinity) 
 
80
 
3.4 10200
 d
  
81
 
Omeprazole (5-O-
desmethylomeprazole) 
13.6 (high affinity) 
139 (low affinity) 
= 
= 
 
82 
3-methoxytyramine 281
 e
 49.4 0.18 
This 
study 
a  in bracket the name of the specific isoform used (if specified) or the definition of the enzymatic form if 
the kinetic analysis showed bienzymatic activity. 
b CLint (intrinsic clearance = MKv /max ) is a common measure of the enzymatic activity in the cell. 
c catK  and 
M
cat
K
K
 values, respectively expressed in min-1 and min-1 /M. 
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d expressed in pmol/mg protein/hour for the conversion operated by rat cerebellar membranes with an 
unspecified concentration of CYP2D6. 
e Mixture of low-affinity recombinant human and yeast CYP2D6 (producer: SPI-Bio, Montigny-le-
Bretonneux, France) 
  
Table 2-4. Comparison of the kinetic parameters for the CYP1A2-mediated 2-hydroxylation of estradiol 
(literature data and this study) or similar steroidal compounds (literature data). 
 
Substrate 
MK  
(M) 
maxv  
(pmol/pmol 
P450/min) 
Hydrolase 
activity (CLint) 
(L/pmol 
P450/min) 
Ref 
Estrone 
7.7 0.17 = 
83
 
19.0 9.2 0.48 
84
 
Ethinyl estradiol 73 1.30 0.018 
85
 
Estradiol 
27.5 17.4 0.65 
86
 
20.6 11 0.53 
84
 
~19 ~7 0.3-0.4 
87
 
52.1 1.02 0.019 
83
 
3800 65 0.017 
This 
study 
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2.5 Conclusions 
 
The use of ARS as an absorbance reporter allowed to accurately determine the 
equilibrium constants of a number of diol/boronic couples and the results were 
comparable to those obtained using fluorescence-based assays. The batochoromic shift 
method, on the other hand, allowed to study also more concentrated and possibly 
heterogeneous samples, allowing for example to monitor this “click” reaction in a self-
emulsifying system (Tween 20 + quercetin) and during enzymatic kinetics, also 
performed on solubilised active principles (cyclodextin + estradiol), showing promise as 
a reporter for performing diol/boronic “click” reactions even in biological 
environments. 
As a side result of this study, we have also for the first time demonstrated that CYP2D6 
is able to demethylate the monomethyl ether of dopamine (3-methoxytyramine). One of 
the major drawbacks of Parkinson‟s disease (PD) therapies based on the use of 
catecholamine drugs or pro-drugs (e.g. L-DOPA) is the inactivation of exogenous 
catecholamines through methylation (catechol O-methyltransferase, COMT) or 
deamination (monoamine oxidases, MAOs). The first pathway is countered using 
combinations of catecholamines with COMT inhibitors and it is complicated by the 
COMT functional Val158Met polymorphism
65, 88, 89
, whose incidence is so high that is 
also used as an index of dopamine bioavailability
90
. CYP2D6 is highly expressed in the 
brain
91
; there, it can produce dopamine via 2-hydroxylation of tyramine
92
, but it has also 
been shown to have a demethylating activity
93
. CYP2D6 has an extended 
polymorphism, which is well known e.g. to affect opioid efficacy
94
 (O-demethylation of 
codein to morphin). Several studies have also suggested a relationship between 
CYP2D6 polymorphism and incidence of PD, although there are also conflicting reports 
as reviewed by BenMoyal-Segal and Soreq
95
, and this possible effect has been mostly 
attributed to the catabolism of xenobiotics, e.g. pesticides.  
Here we have shown that CYP2D6 is able to regenerate dopamine from its COMT-
derived inactivation product, 3-methoxytyramine. This suggests that the efficacy of a 
catecholamine-based PD therapy may be influenced by the interplay between these two 
enzymes and by their polymorphisms; for example, high CYP2D6 metabolizers may 
require lower dosages of COMT inhibitors to achieve high dopamine concentrations in 
the brain. 
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2.6 Appendix 
 
 
 
Figure 2-6. UV-Vis spectra of Alizarin Red S and its complex with APBA (10-fold excess of APBA) 
compared to the corresponding single-peak Gaussian fits. The experimental and fitted curves are almost 
perfectly superimposable throughout the investigated spectral range. 
 
 
 
 
 
Figure 2-7. Calculated absorption spectra of ARS solutions with different molar fractions of APBA. The 
spectra were generated as a linear combination of the spectra presented in Figure 2-6. 
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Figure 2-8. Example of agreement between “master curve” and the calculated data points.  
 
 
 
 
 
 
 
 
Figure 2-9. Typical competitive assay test run in a 96-well plate. For each experiment of 
diol/ARS/APBA equilibrium 24 wells were used for assessing different diol/ARS molar ratios. In the 
picture, the well plate shows three experiments (two rows each) and the two controls, i.e. ARS alone and 
its complex with APBA. 
 
 
 
Chapter 2 
105 
 
 
 
Figure 2-10. Comparison of Michaelis-Menten plots and of the corresponding kinetic parameters for the 
two enzymatic reactions performed in the presence and in the absence of NAPDH. 
 
 
 
 
 
 
 
 
Figure 2-11. CYP2D6-mediated demethylation reactions considered in Table 3. 
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Additional information about enzymatic reaction experiments 
 
Considering the contemporaneous presence of ARS (A), APBA (B), a diol precursors, 
which is also the enzyme substrate (S) and the diol (D), the overall mass balance of the 
enzymatic reactions coupled to the diol/boronic equilibria comprises the following 
equations: 
 
            
 
                 
 
            
 
                
Therefore 
                  
Since     
    
     
, one obtains         
 
     
        
Since     
    
     
 and                 ,  
then         
     
      
       
    
     
       
Rearranging the expression, one obtains 
                 
 
     
     
     
      
    and,  
since           and              , it is finally possible to express the 
concentration of the enzyme substrate as a function of the molar fraction of free ARS, 
which is measured through the batochromic shift method:  
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3. Bioconjugation of hyaluronic acid using boronic/diol coupling 
as a “click” reaction 
 
3.1 Summary 
 
This study focuses on the development of a bioconjugation strategy based on 
boronic/diol complexation, which was used as a sort of reversible “click” reaction to 
derivatise hyaluronic acid (HA) as a model biomolecule. Boronic- and catechol-
functionalised HA derivatives were thus prepared and characterized in terms of 
cytotoxicity (on L929 fibroblasts and J774 macrophages) and enzymatic degradability. 
Due to a better cytotoxicity evaluation, boronic acid derivatives were chosen for further 
investigation, focusing on a derivative where 25% of repeating units were derivatised 
with boronic acid. The binding strength of this polymer with a library of low molecular 
weight or polymeric diols showed this macromolecular derivative to perform slightly 
better than a low molecular weight model compound (3-aminophenyl boronic acid, 3-
APBA), with equilibrium constants generally averaging 2×10
3
 M
-1
 (Kd<500 µM) with 
catechols. 
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3.2 Introduction 
 
We here present a bioconjugation approach based on the use of boronic acid/diol 
complexation as a reversible “click” reaction. 
The reaction between boronic acids and cis diols, in particular catechols, is quantitative 
and selective
1, 2
 and orthogonal to most biochemical reaction pathways. Boronic acids 
have therefore been widely employed for the selective recognition of sugars
3
, 
expressing a behaviour substantially analogous to lectins
4, 5
. Inter alia, this reaction has 
allowed also the decoration of the surface of living cells (their glycocalyx) with 
synthetic polymers
6, 7
. Through an appropriate choice of the diol reactand, e.g. a 
catechol, this reaction is characterized by low dissociation constants < 1 mM 
(equilibrium constants >10
3
 M
-1
) at physiological pH, and it is reversible at acidic pH. 
Probably, the most popular experimental method for the determination of boronic/diol 
equilibrium constants is the use of competitive equilibria Alizarin Red S (ARS), which 
is an aromatic diol exhibiting large spectral changes upon binding to boronic 
derivatives: for example, ARS develops a strong fluorescence in the boron-bound form 
1, 2
. In our previous studies
8
, we have preferred to use the shifts of the absorbance 
maximum of ARS, which are less sensitive to scattering and also to the possible 
presence of quenchers, and therefore can be employed also in complex (biological) 
environments. This method has allowed to measure the equilibrium constants between 
3-aminophenylboronic acid (3-APBA) and a number of diols in water solution or 
dispersion, and to follow the kinetics of enzymatic reactions producing catechol 
compounds, e.g. the O-demethylation of 3-methoxytyramine and the 2-hydroxylation of 
cyclodextrin-solubilised estradiol, which are operated by two members of the 
cytochrome P450 family, respectively CYP2D6 and CYP1A2. 
In the present study we have focused on the use of the boronic/diol complexation as a 
bioconjugation reaction, using hyaluronic acid (HA) as a model polymeric substrate. 
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan composed of 
alternating D-glucuronic acid and N-acetyl-D-glucosamine monomeric units. It is an 
ubiquitous component of virtually all extracellular matrices, although it is specifically 
abundant in the vitreous humour, vocal folds, synovial fluid, umbilical cord, dermis, 
subcutaneous tissue and cartilage 
9-13
 where it contributes to viscosity, tissue flow, tissue 
osmosis, shock absorption, wound healing and space filling 
9, 14
. Clinically, HA has 
been employed  in a number of applications, ranging from synovial fluid replacement, 
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to the management of skin lesions, and including vaginal dryness, nasal dryness, 
gingival inflammatory conditions, lubrication of eye and eye surgery 
15
. Recently, HA is 
increasingly looked at as the main component of carrier structures for controlled and 
possibly targeted drug delivery; see for example the recent review of Ossipov for HA 
carriers in cancer
16
. The advantages of HA as a carrier structure are numerous: 
 
1) HA is a natural product which has an essential role in the rheology of several body 
fluids, and its human form is identical to that of any other mammal;  
 
2) HA is non-inflammatory, at least in its high molecular weight form;  
 
3) HA cellular uptake is mediated by its interaction with cell surface receptors generally 
known as hyaluronan binding proteins or hyaladherins 
17
, the most common of which 
are CD44 and RHAMM 
18-22
. CD44 is particularly interesting: this receptor is 
constitutively expressed in a large number of cells and is involved in a number of 
functions: cell-cell aggregation, retention of pericellular matrix, matrix-cell and cell-
matrix signalling, receptor mediated degradation of hyaluronan, and cell migration 
20, 23
. 
However, CD44 affinity to HA appears to be inflammation-dependent, possibly through 
the cleavage of sialic acid residues
24, 25
. This opens the possibility to utilize HA-based 
structures for a selective delivery of active principles to inflammation-activated cells. 
 
4) HA is enzymatically degradable. Hyaluronidases are a group of rather unspecific 
enzymes, since they all degrade also chondroitin and chondroitin sulphate; all vertebrate 
hyaluronidases are hydrolysases (while bacterial ones are lyases) that degrade HA to 
low polymers and/or oligomers, which can be further degraded by other enzymes, e.g. 
β-D-glucuronidase and β-N-acetyl-D-hexosaminidase26, 27. In the human genome, six 
HYALs have been recognized: HYALs -1 to -4, HYALP1, and PH-20 which are 
distributed at various different sites in the body and are responsible for HA turnover 
13, 
28-30
. Having a large number of HYAL enzymes distributed throughout the body, 
ensures biodegradability of HA based carriers – the only limitation being that they are 
still recognizable by these enzymes. 
   
In the present work we have synthesised derivatives of HA bearing catechols (from 
dopamine), dimethylated catechols (acting as a negative control, from veratrylamine) 
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and boronic acids (from 3-aminophenylboronic acid, 3-APBA) as functional groups; the 
functionalisation was accomplished using a well-established procedure
31, 32
 based on the 
use of EDC ([3-(dimethylamino)propyl]ethylcarbodiimide) and sulphoNHS (N-
hydroxy2-sulphosuccinimide) as promoters of the reaction between the carboxylic acid 
groups of HA and primary amines (Scheme 3-1).  
 
 
 
Scheme 3-1. Synthetic process and structures of HA derivatives and their complexes. 
 
We have then tackled the issue of which group (boronic or catechol) would better allow 
a better conjugate performance (biocompatibility and degradability) for a given HA 
structure. The functional HA derivatives were then used in boronic/diol equilibria. 
Specifically, we have focused on boronic acid-containing HA due to its more favourable 
toxicity profile (see results and discussion) and studied its complexation with a number 
of diols: sugar diols, high molecular weight catechols (HA-dopamine and PEG-
dopamine) and low molecular weight catechols, some in situ enzymatically generated 
(dopamine, 2-hydroxyestradiol) and some dispersed in water with the help of 
solubilisers (quercetin, 2-hydroxyestradiol). As a comparison, the complexation of HA-
dopamine with 3-APBA was studied too. A complete list of the compounds used in 
these equilibria is provided in Scheme 3-2. 
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Scheme 3-2. Structures of diols (columns in the left and in the centre) and boronic acids (right column) 
used in this study. The binding constants of 3-APBA with all low molecular weight diols were already 
measured in a previous study8. 
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3.3 Experimental Section 
 
3.3.1 Materials 
 
High molecular weight hyaluronic acid sodium salt (HA) [MW = 1.10×10
6
 g/mol; wM  
= 1.02±0.22×10
6
 g/mol and gR =111±10 nm (static light scattering)] was purchased 
from Medipol SA, (Lausanne, Switzerland). Hydrochloric acid (32%) (HCl), N-(3-
dimethylaminopropyl)-N'-ethylcarbodiimide (EDC), N-hydroxysulphosuccinimide 
sodium salt (Sulpho-NHS), L-ascorbic acid, dopamine hydrochloride (DOPA), 3-
aminophenylboronic acid hydrochloride (3-APBA) and veratrylamine were supplied as 
high purity reagents (purity always ≥ 98%) by Sigma-Aldrich (U.K.) and used without 
further purification. Alizarin red S (ARS), D-(+)-mannose, D-(+)-glucose, pyrogallol, 
phloroglucinol, quercetin, tween 20, estradiol, pyrocatechol, (±)-epinephrine 
hydrochloride, DL-norepinephrine, Cytochrome P450 human 1A2, Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP), and sodium hydroxide pellets (NaOH) 
were supplied as high purity reagents (purity always ≥ 98%) by Sigma-Aldrich (U.K.) 
and used without further purification. Monomethoxy poly(ethylene glycol), Mn=2,000 
g/mol, functionalised with dopamine (PEG-DOPA) was synthesised by Dr. T. 
Kotsokechagia in a two-step reaction sequence (reaction of MeO-PEG-OH with p-
nitrophenyl chloroformiate and then reaction of the resulting MeO-PEG-(p-
nitrophenyl)carbonate with dopamine) and kindly provided for this study. 
Ovine testicular hyaluronidase (HAse, activity=9502 units/mg) was purchased from 
Calbiochem (Darmstadt, Germany). Human Cytochrome P450 2D6 Yeast reductase was 
supplied by Immuno diagnostic systems (U.K.). β-cyclodextrin sulphobutylether 
(Captisol) was supplied by Cydex Pharmaceuticals (U.S.). All solutions for binding 
studies were prepared in 100 mM PBS obtained by dissolving sodium dihydrogen 
orthophosphate dihydrate, disodium hydrogen orthophosphate dihydrate and sodium 
chloride, supplied by BDH (U.K.), in concentrations respectively of 2.3 g/L, 11.8 g/L 
and 9 g/L in water purified in a Milli-Q system (Millipore, U.K.). 
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3.3.2 Physico-chemical characterization 
  
UV spectroscopy. A BioTek Synergy 2 multi-mode microplate reader was employed to 
record absorbance spectra. The spectra of enzymatic reactions were recorded in the 
range 450-550 nm and at 37
 O
C, and were corrected by subtracting the possible 
scattering component of the buffer solution. All other spectra were recorded at 25 
o
C. 
The molar percentage of functionalised units were calculated on the basis of the 
previously measured values of molar extinction coefficient of dopamine 280 = 2610 L 
mol
-1
 cm
-1, veratrylamine ε277 = 2739 L mol-1 cm-1 and 3-APBA ε296 = 327 L mol-1 cm-1; 
The absorbance at the respective wavelengths could be related to the weight fraction of 
functionalised units (W ) and, through the molecular weights of the functionalised 
monomeric units ( MW ) and of the non-functionalised monomeric units ( HAMW ) it is 
then possible to calculate the molar fraction of functionilised units ( x ), using the 
following equation: 
HA
HA
HA
MWxxMW
x
LC
MW
WC
LA
)1(
280280280

   
 
1
H NMR spectroscopy.  Spectra were recorded on 0.5 wt.% polymer solutions in 
deuterated water using a 300 MHz Bruker spectrometer. Once the spectrum for the 
1
H-
NMR was obtained, the percentage of derivatisation was calculated by integrating the 
area below the peaks for the amine (e.g. dopamine) and the acetyl peak for HA and 
comparing these integrated values using the following equation: 
 
                          
                                    
 
                       
                                 
                         
 
 
Once the number of protons modified were obtained, the degree of derivatisation was 
calculated using the following equation: 
  
                                                        
  
Viscometry. The viscosity of HA solutions was measured with a falling-ball AMVn 
microviscometer (Anton-Paar, Hertford, UK) operating at 37°C and employing a 
capillary of 1.6 mm internal diameter used at an angle of 70°.  
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Static light scattering (SLS). 2 mL of 3, 2.2, 1.5, 0.8 and 0.1 mg/mL solutions of HA or 
HA derivatives in 0.1 M PBS were filtered 10 times through 0.22 µm hydrophilic PES 
filters and the absence of dust was confirmed by dynamic light scattering. SLS 
measurements were carried out at a constant temperature of 20°C with a Melles Griot 
HeNe class 3B laser (75 mW maximum power at 632.8 nm) coupled with a Brookhaven 
instruments goniometer and photodiode cascade detector. Measurements were 
performed at scattering angles from 30 to 140° with a 10° stepwise increase. Toluene 
was used as a calibration standard. The weight-average molecular weight ( wM ), Z-
average radius of gyration (Rg), and second virial coefficient (A2) values were estimated 
from the relation   
 
       
  
 
  
     
  
    
 
       where ∆R is the Rayleigh ratio 
and it is assumed that ∆R = K.Ic , K = 4π
2
n
2
(dn/dc)
2
//NAλ
4
, n the refractive index of the 
solvent, dn/dc the refractive index dependence on the solute concentration, and NA is 
Avogadro‟s number. dn/dc was 0.1518 ± 0.015 mL/g for HA, 0.1526 ± 0.01 mL/g for 
HA-BA and HA-BA:DOPA, 0.1579 ± 0.005 mL/g for HA-veratrylamine, 0.0885 ± 
0.012 mL/g for HA-DOPA and 0.1009 ± 0.011 mL/g for HA-DOPA:BA (see appendix, 
Table 3-5) as determined using a Bellingham and Stanley refractometer with a sodium 
lamp at 589.6 nm. By measuring the scattering intensity for a set of θ and c and 
correspondingly producing Zimm plots (see appendix, Figure 3-5), the values of Mw, Rg, 
and A2 were estimated.  
 
pKa determination. The pKa of HA-3-APBA (X2) was determined by titrating 2 mL of 
a 4.91 mg/mL solution of X2 (0.003 M boronic groups) with 10 mM NaOH solution in 
a 10 mL glass vial. 100 µL of 10 mM NaOH was added every minute, and the pH was 
recorded every 30 seconds. The solution was added until the point that the pH became 
stable and would not change any further on addition of further NaOH. The pKa was 
estimated to be 8.4 by plotting a graph of amount of NaOH added versus pH (see 
appendix, Figure 3-9) and finding the half equivalence point that is where half the 
amount of titrant has been added to neutralize the acid.  
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3.3.3 Synthesis of HA derivatives 
 
The conditions for the synthesis of dopamine-containing HA derivatives were optimized 
varying the molar ratios between different reactants (carboxy groups, EDC, sulpho-NHS 
and amines) and the ratios conducing to the highest yields (Table 3-1) were then 
employed for the preparation of veratrylamine and 3-APBA derivatives.  
In a typical experiment, a Radleys 6 chamber parallel reactor (each chamber – 50 mL) 
was used in which in each chamber the HA concentration was fixed (24 mL of a 6.15 
mg/mL stock solution of HA used, 7.34 mM COO
-
 groups) and the required 
concentrations of EDC, sulpho-NHS and amines were added in various chambers 
depending on the molar ratio needed.  
As an example, 570 µl of a 50 mg/mL EDC solution in deionized water (freshly 
prepared) were added to 24 mL of a 6.15 mg/mL HA solution (7.34 mM COO
-
 groups, 
3.68 mM EDC, for a 1:0.5 COO
-
 to EDC molar ratio).  The mixture was allowed to 
react for 30 seconds under continuous stirring prior to the addition of 1.66 mL of a 24 
mg/mL Sulpho-NHS solution in deionized water (3.68 mM sulpho-NHS, for a 1:1 
sulpho-NHS/EDC molar ratio). After 1 minute, variable volumes of a freshly prepared 
63 mg/mL solution of amine (dopamine, veratrylamine or 3-APBA) hydrochloride were 
finally added to different chambers to achieve the desired COO
-
 of HA : EDC : amine 
molar ratio;  in case of dopamine the amine solution contained ascorbic acid in a 1:1.5 
dopamine/ascorbic acid molar ratio. The mixture was allowed to react overnight under 
stirring at room temperature. The samples were then purified using ultrafiltration using 
membranes with MWCO = 10,000 g/mol and freeze dried. Average yields (weight of 
recovered material/weight of recoverable material) = 80 - 90% wt. A detailed list of the 
conversion of carboxy groups as a function of the molar ratios between reactants is 
provided Table 3-1. 
 
UV (deionized water): HA-Dopamine: 280 nm. HA-Veratrylamine: 277 nm. HA-3-
APBA:  296 nm. 
1
H-NMR (D2O): HA-Dopamine: δ = 6.58 – 6.63 (H-dopamine), 6.68 – 6.71 (H-
dopamine), 6.73 – 6.78 (H-dopamine), 4.8 (H-1 of GlcNAc), 4.3 – 4.5 (H-1 of GlcA), 
3.1 – 3.8 (H-2, H-3, H-4, H-5, H-6a, H-6b of GlcNAc, H-2, H-3, H-4, H-5 of GlcA), 
3.05 – 3.15 ( (benzylic) CH2 dopamine), 2.7 – 2.82 ( CH2 dopamine), 1.8 – 1.9 ppm 
(Acetyl H-8 of GlcNAc). HA-Veratrylamine: δ = 6.9 - 7 (3×H veratrylamine), 4.8 (H-
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1 of GlcNAc), 4.3 – 4.5 (H-1 of GlcA), 3.6 – 3.68 (2×CH3 veratrylamine), 3.4 – 3.55 
(CH2 veratrylamine), 3.1 – 3.8 (H-2, H-3, H-4, H-5, H-6a, H-6b of GlcNAc, H-2, H-3, 
H-4, H-5 of GlcA), 1.8 – 1.9 ppm (Acetyl H-8 of GlcNAc). HA-3-APBA: δ = 7.36 – 
7.42 (H APBA), δ = 7.49 – 7.6 (2×H APBA), 7.76– 7.81 (H APBA), 4.8 (H-1 of 
GlcNAc), 4.3 – 4.5 (H-1 of GlcA), 3.1 – 3.8 (H-2, H-3, H-4, H-5, H-6a, H-6b of 
GlcNAc, H-2, H-3, H-4, H-5 of GlcA), 1.8 – 1.9 ppm (Acetyl H-8 of GlcNAc). 
 
3.3.4 Enzymatic degradability of HA derivatives 
 
The concentration of the polymers was adjusted to provide an initial dynamic viscosity 
of about 20 mPa×sec; this corresponded to concentrations of 16 mg/mL for P1, 18 
mg/mL for P2, 3 mg/mL for T1, 16 mg/mL for T2, 5 mg/mL for X1, 9 mg/mL for X2 
and 1 mg/ml for the precursor HA. A 0.01 mg/mL enzyme stock solution was prepared 
in deionized water (95.02 units/mL) and polymers were tested in solution form at 37 
O
C. 
It is noteworthy that L-ascorbic acid was not added to P1 or P2 solutions in order to 
prevent any interference of the reducing agent with the degradation. An exponential 
decay model ( ( ) ( ) ( (0) ( ))
t
rel rel rel relt e
         ) was used to fit the time 
dependence of dynamic viscosity.  The parameter 1  is related to the reaction rate of 
enzymatic hydrolysis; however, direct comparison between different samples is not 
possible, due to their different concentrations, which provide a different concentration 
of degradable units. We have therefore calculated a “normalized reactivity” related to 
the reaction rate per enzyme-binding (negatively charged) disaccharidic unit, by 
dividing 1   by the molar concentration of non-derivatised units. 
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Table 3-1. Conversion of carboxylic groups to amides as a function of the molar ratios between 
reactands. The underlined conditions were selected for further characterization studies, those in bold for 
the studies of diol/boronic binding. 
Amine 
COO
-
: EDC: S-NHS: NH2 
Molar Ratio 
Degree of 
Derivatisation  
(mol %) 
Sample 
UV NMR 
Dopamine 1:0.5:0.5:0.5 8.4 8.5 P1 
1:2:2:2 12 13  
1:2:2:4 16 16 P2 
1:2:2:6 13 13  
1:2:4:4 13 14  
1:2:4:6 11 12  
1:4:4:4 14 15  
1:4:4:6 11 13  
1:4:6:6 13 13  
1:4:6:8 11 12  
1:6:6:6 13 14  
1:6:6:8 14 14  
Veratrylamine 
a
 
1:0.5:0.5:0.5 16 16 T1 
1:2:2:4 25 27 T2 
3-APBA 
a
 
1:0.5:0.5:0.5 17 17 X1 
1:2:2:4 24 25 X2 
a No ascorbic acid, due to the absence of oxidisable groups. 
 
3.3.5 Evaluation of cytotoxicity of HA derivatives on fibroblasts and 
macrophages 
 
In metabolically active cells, dehydrogenase enzymes produce NADPH or NADH that 
can reduce MTS (a tetrazolium compound) to formazan. By measuring the optical 
density (OD) of the latter, the cytotoxicity of a derivative in solution can be measured as 
the percentage of [ODmaterial – ODblank]/ODcontrol. Murine L929 fibroblasts and J774.2 
macrophages (ECACC, UK) were maintained as, respectively, adherent and semi-
adherent cell culture at 37°C in humidified atmosphere (5% CO2) in Dulbecco modified 
Eagle‟s minimal essential medium (DMEM, 25 mM glucose) supplemented with 2 mM 
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glutamine (Gibco), 10% heat inactivated fetal calf serum (FCS) (Invitrogen, UK), 100 
IU/ml penicillin and 100 IU/ml streptomycin (Gibco). For L929 fibroblasts cells 
splitting, trypsin-EDTA (Invitrogen, UK) consisting of 2.5% w/v of trypsin and 0.2% 
w/v EDTA in PBS was used, while J774.2 macrophages cells were detached by 
scraping. Both cell lines were adjusted to the required concentration of viable cells, by 
counting in a haemocytometer in the presence of 0.4% trypan blue. Upon confluence 
(~80%), cells were seeded on 96-well plates at a concentration of 4x10
4
 ml
-1
 and left to 
adhere for 24 hours in a humidified incubator at 37°C and 5% CO2. The following day, 
solutions of the HA derivatives [HA-Dopamine (P1=8.5%, P2=16%), HA-
Veratrylamine (T1=16%, T2=27%) and HA-3-APBA (X1=17%, X2=25%)] in full 
DMEM at variable concentration (10, 7.5, 5, 1, 0.5, 0.1 and 0.01 mg/mL) were added 
and left to incubate for 24 hours. The HA-Dopamine DMEM solutions contained also 
L-ascorbic acid (0.55 mg/mL and 1.03 mg/mL, respectively for P1 and P2) to prevent 
the oxidation of catechol groups. All solutions were then removed; the wells were 
washed with PBS, then serum-free DMEM including 4.8% CellTitre 96® Aqueous One 
Solution (Promega, Southampton, UK), and were left to incubate for 3 hours. The 
amount of soluble formazan produced by mitochondria of viable cells was then 
measured by recording the absorbance at 490 nm. Eight wells were exposed to each 
treatment (n=8) and the experiment was repeated three times. 
 
3.3.6 Evaluation of boronic/diol equilibrium constants 
 
Batochromic shift method: the mathematical model for the calculation of boronic/diol 
equilibrium constants from the batochromic shifts of ARS (corresponding to the 
liberation of free ARS from an ARS/boronic complex) was described in Chapter 2, 
pages 88 - 93. 
 
Experimental conditions: For competitive binding experiments in each well of a 96 
well plate (total volume of each sample = 250 L) 48 L of a 1 mg/mL ARS solution 
and 55 L of a 3.72 mg/mL HA-3-APBA (X2) solution (both in 0.1 M PBS) were 
mixed to obtain a 0.56 mM final concentration for both reagents (ARS and boronic in 
HA-3-APBA) and were allowed to react for 30 seconds; the colour of the solution 
correspondingly changed from red to orange. An amount of diol corresponding to HA-
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3-APBA/diol molar ratios ranging from 1:0.5 to 1:1000 was then added, producing a 
clear orange to red chromatic change at high HA-3-ABPA/diol molar ratios. The highest 
HA-3-APBA:diol molar ratio for veratrylamine and for phloroglucinol was 1:10 (0.0056 
M) and 1:100 (0.056 M) respectively, due to their limited solubility in water. All the 
absorbance values and the concentrations of the reagents were then corrected for the 
dilution. In simple binding experiments the same protocol was used, but the volumes of 
HA-3-APBA solutions were varied in a series of experiments and the absorbance values 
were monitored to obtain the intensities as a function of amount of added boronic acid.  
 
Reaction with pyrogallol: Owing to the quick oxidation of this electron-rich polyol, 
TCEP was added to the stock solution of pyrogallol in a molar ratio pyrogallol/TCEP 
1:1.5. Due to the decrease in pH following TCEP addition, a few drops of 0.1 N NaOH 
were added to the pyrogallol stock solution until pH = 7.4. 
 
Reaction with ascorbic acid: Due to the acidic nature of this diol, 1M PBS buffer was 
used to raise the pH to 7.4. 
 
Reaction with quercetin. Owing to the very poor solubility of quercetin in a water 
environment a Tween 20 (a oligo(ethylene glycol) (polyoxyethylene) derivative of 
sorbitol monolaurate widely employed in bioassays and pharmaceutical formulations) 
was used. For quercetin concentrations up to 1 mM a 1:1 Tween/quercetin molar ratio 
was sufficient to completely solubilise it in 0.1 M PBS buffer, since its UV-Vis 
absorbance reaches a plateau and does not increase with larger amounts of surfactant. 
The highest concentration of Tween 20 used is limited by its ability to hamper the 
binding reaction.  A maximum of 8% w/w of Tween 20 can be used without affecting 
the reaction kinetics. 
 
Reaction with polymeric derivatives. Typical experiments were performed with HA-
Dopamine (P2), HA-Veratrylamine (T2) and PEG-Dopamine using the above 
mentioned technique with both 3-APBA and HA-3-APBA. The molar ratio of 
boronic/diol was restricted to 1:2.5 to prevent highly viscous polymeric solutions.   
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Enzymatic Reactions. Typical experiments were performed in 96 well plates at 37 
O
C 
sealed with the help of PCR plate adhesive seals to prevent evaporation; three 
repetitions were carried out per sample in 0.1M PBS buffer. 
 
- Hydroxylation of estradiol. Estradiol can bind to boronic acid only upon the 
introduction of a second alcoholic function, which can be carried out by cytochrome 
P450 variant 1A2. Estradiol is barely soluble in the water medium that we have used for 
the diol/boronic reaction (0.1 M PBS) and thus requires a solubilising agent; since most 
surfactants would impair the activity of cytochrome P450, we have employed β-
cyclodextrin sulphobutylether, (i.e an anionic, very water soluble cyclodextrin: neutral 
cyclodextrins did not provide sufficient solubilisation, while most surfactants do) in 1:1 
molar ratio with estradiol. A stock solution of CYP1A2 was prepared by diluting 30 L 
of a 1000 pmol/mL solution with 375 L of 0.1 M PBS. To this CYP solution, 7.8mg of 
NADPH was added for its activation. 
48 L of ARS solution (final concentration: 0.56 mM) was added to each well, followed 
by 55 L of HA-3-APBA (final concentration: 0.82 mg/mL, 0.56 mM boronic moiety); 
the mixture was allowed to react for 30 seconds (stable change in colour from red to 
orange). On completion of this reaction, a calculated amount of estradiol (HA-3-APBA : 
estradiol molar ratios ranging from 1:0.1 to 1:4.5) was added to each well, followed by 
27 L of the CYP1A2 stock solution (corresponding to 2 pmoles of CYP1A2 calculated 
from the stock solution of 74 pmol/mL + 2.5mM final concentration of NADPH). 
 
- Demethylation of 3-Methoxytyramine. 3-methoxytyramine can bind to boronic acid 
only upon removal of its methoxy group, which can be carried out by cytochrome P450 
variant 2D6. A stock solution of CYP2D6 was prepared by diluting 20 L of a 500 
pmol/mL solution with 520 L of 0.1 M PBS. To this CYP solution, 8.34mg of 
NADPH was added which is needed for activation of the enzyme.  
The reaction of ARS with HA-3-APBA was conducted as described above. Appropriate 
amounts of 3-methoxytyramine, ranging from a HA-3-APBA : 3-methoxytyramine 
molar ratio of 1:0.5 to 1:3.2, were then added to each well, followed by 27 l of the 
CYP2D6 stock solution (corresponding to 0.5 pmoles of CYP2D6 calculated from the 
stock solution of 18.5 pmol/mL + 2mM final concentration of NADPH). 
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3.3.7 Reactions between polymeric species 
 
A typical experiment involved the use of a 30ml glass vial with HA derivatives 
employed at a concentration of 3mg/ml in 0.1M PBS with a total volume of 26.7ml. The 
reaction was assisted by continuous stirring for 1 hour. 
For the linkage of HA-3-APBA to dopamine, 13ml of a stock solution of HA-3-APBA 
(X1, 17% D, 0.00125M boronic) was first added followed by 5.85ml of dopamine 
solution (0.0125M, 3-APBA: dopamine molar ratio = 1:10). TCEP (0.0188M, 
Dopamine: TCEP molar ratio = 1:1.5) was added to the solution to prevent oxidation of 
dopamine.  
For the linkage of HA-Dopamine to 3-APBA, 6.67ml of a stock solution of HA-
Dopamine (P2, 16% D, 0.00116M dopamine) was first added followed by 2.83ml of 3-
APBA solution (0.0116M, Dopamine: 3-APBA molar ratio = 1:10) and finally TCEP 
(0.00174M, Dopamine: TCEP molar ratio = 1:1.5) was added to the solution.  
Purification for both the samples involved dialysis using 3500 Da molecular weight 
cutoff membranes against water containing dissolved sodium bicarbonate at pH 7.4. On 
completion of dialysis (monitored by conductivity) the samples were freeze dried and 
then evaluated for wM ,  Rg and A2 using SLS.  
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3.4 Results and Discussion 
 
3.4.1 Preparation of HA derivatives 
 
The functionalisation of HA with amine-containing molecules can be easily performed 
using water-soluble derivatives of carbodiimide (EDC) and N-hydroxysuccinimide 
(sulpho-NHS). This popular literature procedure
33, 34
 is based on the conversion of HA 
carboxylate groups into rather unstable O-acylisoureas, which can also react with 
alcohols in the HA structure, giving rise to branching and  cross-linking
35
. The O-
acylisoureas are thus transformed into amine-selective NHS esters, which in this study 
have allowed the functionalisation of HA in good yields, as witnessed by 
1
H-NMR 
(Figure 3-1) and UV spectra (Figure 3-2). 
There are a number of pathways in which this reaction proceeds leading to both 
favourable and side products (Scheme 3-3) depending on the amount and type of 
reactants used. The first step is the reaction of the carbodiimide, EDC, with a proton to 
form a carbocation, which in the absence of a dissociated carboxylic acid, hydrolyses to 
form a urea derivative. This is the main reason for using a freshly prepared solution of 
EDC
36
. In the presence of dissociated carboxylic acid, the carbocation can react with an 
ionized carboxyl group to form O-acylisourea. Depending on the presence or absence of 
nucleophile at this stage, different scenarios are possible.  
In the absence of a nucleophile, the O-acylisourea would reprotonate at the site of the 
Schiff base, and change into a carbocation which can partially hydrolyse to form urea or 
be attacked by the various bases which are present. Since an ionized carboxylic acid 
group is a very strong base, it can react with the carbocation to form carboxylic 
anhydride if the carboxyl group is cyclizable, which can readily react with amines, to 
form the corresponding amide. However, since the carboxyl group of HA is 
noncyclizable, the carbocation would react with the unionized amine to form the amide 
bond and with a water molecule to form carboxylate. Since the concentration of water is 
much higher in the system and most of the molecules of the amine are in the ionized 
form, this would lead to most of the carbocation forming the carboxylate, and hence 
giving a very low yield. This is the main reason for not using EDC on its own without a 
nucleophile. Also, the presence of excess carbodiimide, would favour the reaction of the 
carbocation with the excess carbodiimide to form N-acylurea as a byproduct which is 
unreactive towards primary amines and would be covalently attached to HA
37
. 
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In the presence of a nucleophile, such as NHS (we have used sulpho-NHS since it has 
good water solubility), the dissociated hydroxyl group of the NHS makes a nucleophilic 
attack on the O-acylisourea to form a succinimidyl ester which is more stable towards 
hydrolysis, and a urea derivative. The formation of N-acylurea is not possible since the 
succinimidyl ester cannot undergo N→O displacement. This succinimidyl ester is then 
attacked by a non-dissociated primary amine (dopamine, 3-APBA or veratrylamine) 
forming the amide bond and regenerating NHS.   
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Scheme 3-3. Carbodiimide mediated synthesis process of HA derivatives and the side reactions involved. 
The reaction of EDC with carboxylate groups leads to various side reactions depending on the presence or 
absence of a nucleophile such as formation of urea derivatives and re-formation of the carboxylate group.   
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The ratio between reactands influenced the functionalisation yield of HA with 
dopamine, although the use of large excess of promoters or amine did not necessarily 
correspond to an increase in the molar fraction of functionalised units (Table 3-1). Three 
points are evident from Table 3-1: the first that any increase in the molar ratio of EDC : 
Sulpho-NHS (1:1.5 – 1:2) does not vary the yield which means that the excess 
nucleophile present does not have any positive effect; the second point is that any 
increase in the molar ratio of EDC : amine (>1:2) does not necessarily show an increase 
in the yield as well; and the final point is that an increase in the COO
-
 : EDC molar ratio 
(>1:2) shows no change in the yield (13-15%).  
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Figure 3-1. 
1H-NMR spectra of (a) HA (1.1 MDa, bottom), EDC and Sulpho-NHS. (b) HA (1.1 MDa), 
dopamine and four HA-dopamine derivatives – P1, P2 and two others which have different molar ratios 
with excess reactants. (c) HA (1.1 MDa), 3-APBA, X1, X2, veratrylamine, T1 and T2. The spectra of the 
functional derivatives are always better resolved than that of the parent polymer. For example, the peak at 
4.3 – 4.5 ppm (H-1 of GlcA) is very broad and almost invisible for HA, while it is clearly visible for all 
derivatives.  We ascribe the better resolution of the latter spectra to the marked reduction in molecular 
weight during the functionalisation reaction. Reference to the numbering of carbon atoms is given in the 
experimental part, interpretation of NMR spectra. 
 
Therefore, two reaction conditions were selected, which offered a good compromise 
between high yield and low amounts of reactands; they were then adopted also for the 
reactions of HA with the other two amines (veratrylamine and 3-APBA), which 
exhibited considerably higher conversions than dopamine: 16 or 17% vs. 8.5% 
(polymers T1, X1 and P1, respectively, see Table 3-1 and Figure 3-1) for one set of 
conditions and 25 and 27% vs. 16% for the other (polymers T2, X2 and P2, 
respectively). The better reactivity may be due to the presence of ascorbic acid in the 
reaction with dopamine: the acidity of the reducing agent may partially protonate the 
primary amine, reducing its reactivity. It is worth pointing out that the reactions of HA 
(b) (c) 
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with dopamine carried out in the absence of ascorbic acid turned black in a few hours, 
as a consequence of the oxidation and polymerization of catechol groups (Scheme 3-4). 
 
OH
OH O
2
O
O
OH
2+
catechol o-benzoquinone
1/2
 
Scheme 3-4. Oxidation of catechol to o-benzoquinone. 
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Figure 3-2. UV spectra of the HA derivatives (1 mg/mL): HA-dopamine (P1 - 8.4% P2 – 16%), HA-
veratrylamine (T1 – 16%, T2 – 25%) and HA-3-APBA (X1 – 17%, X2 – 24%) showing the maximum 
absorbance at 280 nm for dopamine, 277 nm for veratrylamine and 296 nm for 3-APBA. Reference to the 
calculation for the degree of derivatisation is given in the experimental part, interpretation of UV 
spectroscopy. 
 
Figure 3-1 (a) shows the 
1
H-NMR spectra for HA (1.1 MDa) along with the spectra for 
the reactants EDC and sulpho-NHS. This provides a basis for comparing the spectra of 
the HA-derivatives presented in Figure 3-1 (b) and (c) to ensure purity and complete 
removal of excess reactants. As mentioned earlier, for the reaction of HA with 
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dopamine, various molar ratio of reactants were tested, and the spectra of few of them 
have been showed in Figure 3 (b) which clearly show from the integrals, the degree of 
derivatisation obtained. We selected the acetyl group of HA for comparing the integral 
as it has its own individual distinct peak and it does not participate in the reaction which 
ensured that its value is unchanged before and after the reaction. For the integral of 
dopamine, we selected the 3 hydrogen protons present on the aromatic ring since, they 
are distinct and do not interfere with any peak of HA.  
There is a substantial increase in the derivatisation percentage between P1 (molar ratio 
COO
-
:EDC = 1:0.5) and P2 (molar ratio COO
-
:EDC = 1:2), and this is owing to the 
quadruple increase in the amount of EDC, sulpho-NHS and dopamine. This is also seen 
in the UV spectra (Figure 3-2 shows the UV spectra for samples P1 and P2 at 1 mg/mL) 
and the degree of derivatisation obtained from the UV spectra (using the equation 
provided in section 3.3.2, UV spectroscopy) corresponds to the values obtained by 
NMR. However, on increasing the reactants any further, the integral do not seem to 
increase in the same manner, which might be due to the side reaction which leads to the 
reforming of the carboxylate groups.  
Figure 3-1 (c) shows the 
1
H-NMR spectra for HA-3-APBA and HA-veratrylamine 
derivatives along with their respective reactants. In the case of 3-APBA, we have 
selected the 4 hydrogen protons present on the aromatic ring since they are in the region 
of 7 – 8 ppm and do not interfere with the peaks of HA. We can see a clear distinction 
between the integrals of X1 and X2 owing to the increase of reactants. In the case of 
veratrylamine as well, we have selected the 3 hydrogen protons present on the aromatic 
ring, and have not opted for the aliphatic spacer or the methyl groups since they seem to 
be shadowed by the peaks of HA; and a very clear difference is visible in the 
derivatisation percentages of T1 and T2. The degree of derivatisation obtained in both 
these cases is also comparable to the values obtained using UV spectroscopy (Figure 3-
2, samples X1, X2, T1 and T2). 
A common thing which is visible in all the spectra is the absence of the side product 
urea (usually present around 1 ppm), as well as any excess EDC or sulpho-NHS which 
have been removed during dialysis.  
It must be noted that all reactions determined a clear decrease in HA molecular weight, 
as shown by static light scattering (Table 3-2). A huge difference in the Mw of the HA 
derivatives is noticeable as compared to the parent HA which is common due to 
degradation of the HA during the reaction with EDC and sulpho-NHS. One main point 
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is that between the three HA derivatives (P2, T1 and X1) having the same degree of 
derivatisation, the Mw is similar which denotes that the degradation of HA is 
independent of the type of primary amine used for the reaction. Literature suggests that 
HA can be hydrolysed by acids and bases and is more sensitive towards bases. The 
degradation rate constant at pH 13 is approximately 50 times larger than at pH 2. 
Therefore, it is highly probable that base-catalysed hydrolysis cleaves the 1→4 and/or 
1→3 glycosidic bond of HA, resulting in low-molecular fragments as seen in Table 3-
2
38-40
.  
The decrease in Mw has caused a decrease in Rg as well but it is not directly 
proportional, as a tenfold decrease in the Mw of HA has caused only a twofold decrease 
in the Rg. An Rg of 111.2 ± 10 nm for HA of 1 million g/mol is in accordance with 
literature values of 120 nm for 1 – 1.2 million g/mol. Also an Rg of 55 ± 5 nm for all the 
HA derivatives (P2, T1 and X1) is in accordance with literature values of 55 nm for 
0.236 million g/mol
41
.  
The second virial coefficient is a property describing the interaction strength between 
the molecule and the solvent. For samples where A2 > 0, the molecules tend to stay in 
solution. When A2 = 0, the molecule-solvent interaction strength is equivalent to the 
molecule-molecule interaction strength and the solvent is described as being a theta 
solvent. When A2<0, the molecules will tend to crystallize or aggregate. In our case, all 
the A2 values (for HA and its derivatives) are positive indicative of intermolecular 
repulsion
42
. 
A decrease in the molecular weight of HA usually reduces the A2 denoting a 
destiffening and contraction of the coil which is seen clearly in the derivatisation of 
HA
43
. It has been suggested that this might be related to the accessibility and number of 
hydrogen bond forming groups as HA molecules in solution are in a dynamic process of 
forming and breaking of hydrogen bonds involving the C2 hydroxyl group of glucuronic 
acid, the acetamido oxygen of N-acetylglucosamine and the oxygen of carboxylic 
groups of a second glucuronic acid. These interactions in high molecular weight HA 
might be intramolecular due to the large volume occupied by the molecule and physical 
entanglements of the chain; whereas with a decrease in the molecular weight, the 
volume occupied by each chain decreases and the molecules begin to experience 
intermolecular interactions which compete with intramolecular ones, resulting in a 
decrease in A2
42
. 
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The values of A2 for P2 and X1 presented in Table 3-2 are in accordance with the 
literature values for similar molecular weight pure HA which denotes that the 
derivatisation does not hamper the conformational properties of the HA
43, 44
. The A2 for 
T1 seems to be more of an anomaly since we do not expect it to be much different from 
the other HA derivatives.  
The detailed discussion of the complexes (P2/3-APBA and X1/dopamine) has been 
presented in section 3.4.3 Part B (Evaluation of boronic-diol equilibria on HA 
derivatives). 
 
Table 3-2. Results of static light scattering measurements: weight average molecular weight ( wM ), 
radius of gyration (Rg) and second virial coefficient (A2) for HA, its functional derivatives
a and their 
complexes. 
Polymer 
Functionalisation 
(mol %) 
wM  
(g/mol) 
Rg 
(nm) 
A2 
(cm
3
mol/g
2
) 
HA 0 1.02 ± 0.22×10
6
 111.2 ± 10 4.60 ± 0.07×10
-3
 
P2 16 1.86 ± 0.27×10
5
 55.7 ± 5.2 2.30 ± 0.21×10
-3
 
T1 16 2.34  ± 0.28×10
5
 54.0 ± 5.3 8.17 ± 0.42×10
-3
 
X1 17 2.74 ± 0.30×10
5
 55.8 ± 2.4 2.62 ± 0.15×10
-3
 
P2/3-APBA = 1.08 ± 0.09×10
5
 30.0 ± 6.6 2.11 ± 0.09×10
-3
 
X1/dopamine = 2.22 ± 0.14×10
5
 38.7 ± 8.0 3.15 ± 0.07×10
-3
 
a All the polymers showed statistically indistinguishable results. 
 
3.4.2 Evaluation of degradability and cytotoxicity 
 
An ideal bioconjugate should show negligible cytotoxicity and should also be either 
excreted or degraded at the end of its therapeutic action, in order to avoid possible 
problems from long-term accumulation. HA is inherently non-cytotoxic, but it is rapidly 
enzymatically degraded in vivo: its half-life time can be as low as half a day
10
. An ideal 
HA-based bioconjugate should maintain the biocompatibility and degradability, 
however reducing the rate of the latter. This is, however, a rather general effect: the 
introduction of functional units on the carboxy groups is indeed expected to decrease 
the rate of enzymatic degradation, as it happens for a number of HA esters, such as the 
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HYAFF family
26, 45
. Mammalian hyaluronidases bind to HA utilizing its anionic 
carboxylic groups, with a binding region spanning at least an hexasaccharide 
sequence
27, 46
; the introduction of even few non-anionic groups sharply decreases the 
number of all-ionic hexasaccharidic sequences, thus dramatically affecting the 
degradability of HA derivatives.  
Here we have compared the degradability and cytotoxicity of derivatives containing 
boronic acid (X1 and X2) to those of dopamine derivatives (P1 and P2), using 
veratrylamine ones (T1 and T2) to differentiate effects deriving from the aromatic 
nature of catechols from those of REDOX origin. 
 
We have examined the effect of hyaluronidase (from ovine testes: broad spectrum 
hydrolase catalyzing the cleavage of the (14) glycosidic link) through a semi-
quantitative but rapid test, monitoring the viscosity of the water solutions of HA 
derivatives. All of them showed a significant response, with a marked decrease of the 
viscosity (see appendix, Figure 3-6).  
We here have employed two different parameters for a comparison of the degradability 
of the polymers (Figure 3-3). 
A) Using the rather rough assumption that the decrease in viscosity during degradation 
is mostly related to a reduction in molecular weight, we have employed the ratio 
between initial and plateau viscosity (0) ( )rel rel    as an indication of the maximum 
extent of enzymatic degradation. With the exception of T1 (16% veratrylamine, 
statistically indistinguishable from HA), the derivatives showed a markedly lower 
extent of degradation than their parent polymer, decreasingly with increasing 
functionalisation. 
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Figure 3-3. Relative decrease in dynamic viscosity (bottom, black squares) and “normalized reactivity” 
(top, empty circles) for HA (right) and two HA derivatives for each functional group introduced. The two 
parameters provided a rather similar picture of strong reduction of enzymatic degradability upon 
functionalisation. n=3. 
 
B) The degradation kinetics of the polymers more closely reflects the efficiency of 
enzyme/substrate binding. Fitting the viscosity data with a simple exponential kinetic 
model, we have calculated a “normalized reactivity” (see experimental section), a 
sensitive parameter exhibiting a reduction of up to almost two orders of magnitude upon 
functionalisation. For veratrylamine and 3-APBA, similar percentages of 
functionalisation similarly affected the “normalized reactivity”, decreasing with 
increasing amounts of functional groups. The presence of dopamine, on the contrary, 
appeared to cause a dramatic reduction in degradation rate also at 8.5 mol % of 
functional groups, which we can possibly ascribe to the REDOX reactivity of catechols. 
 
The cytotoxicity of the HA derivatives was then evaluated utilizing the MTS test of 
metabolic activity on L929 fibroblasts and J774 macrophages. Macrophages are 
characterized by higher endocytic activity than fibroblasts, and produce larger amounts 
of the main receptor for HA internalization (CD44)
47
; it was therefore expected that 
they offer a more sensitive model for the cytotoxicity of HA-based systems. However, 
no sound difference was recorded between the two cell lines (Figure 3-4). Furthermore, 
some moderate negative effects on cell viability were recorded only for dopamine-
containing polymers (Figure 3-4); with both cell lines, these polymers showed IC50 
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values in the range of 1-3 mg/mL, with no apparent reduction in cell viability below 0.5 
mg/mL. The other HA derivatives showed even less cytotoxicity (IC50 > 5 mg/mL or 
simply not recorded in the range of concentrations evaluated, i.e. above 1% wt.), which 
was particularly low for the 3-APBA derivatives. It appears therefore that the 
methylation of OH groups has significantly increased the tolerance of both cell lines to 
the presence of catechols. 
 
 
 
Figure 3-4. Viability of fibroblasts (left) and macrophages (right) after 24 hours of exposure to different 
concentrations of the HA derivatives.  
 
The boronic acid derivatives showed a very favourable toxicity profile; they also 
preserved significant degradability, while their slower kinetics in comparison to the 
parent polymer would be beneficial in the perspective of a prolonged circulation. We 
have therefore focused on HA-boronic derivatives, and specifically on X2 for further 
investigations. 
Comparing the degradability and the cytotoxicity results, we come to the conclusion 
that in general, the higher the derivatisation percentage, the less favourable is the 
derivative as its degradability decreases and its cytotoxicity increases. The tests for HA-
dopamine derivatives showed that they had the worst degradability and were the most 
cytotoxic as compared to the other derivatives; this is mostly due to their oxidation 
potential. The HA-veratrylamine derivatives showed a better degradability (especially 
T1) and cytotoxicity profile than the HA-dopamine derivatives, owing to the 
methylation of the diol, while the HA-3-APBA derivatives showed an equivalent 
degradability but the best cytotoxicity profile. One of the main aims of synthesising a 
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HA based polymeric carrier which has good degradability, longer circulation time and 
least cytotoxicity has been achieved with the HA-3-APBA derivatives.  
  
3.4.3 Evaluation of boronic-diol equilibria on HA derivatives 
 
The boronic/diol equilibrium constants were obtained by utilizing a previously 
developed method based on the batochromic shifts in the absorbance spectrum of 
Alizarin red S (ARS), which is a diol-containing dye with an absorption peak at 519 in a 
free form that shifts to 480 in the boron-complexed form. The binding equilibrium of 
ARS to a boronic acid-containing compound is governed by a constant K1, which is 
readily calculated from the hypsochromic shifts of ARS. Using 3-APBA and the HA 
derivative X2, we have obtained K1 = 5150 ± 200 M
-1
  for ARS – APBA and of ARS-
HA-BA (K1) is 2550 ± 150 M
-1
. When exposing these two complexes to other diols, a 
competitive equilibrium is established and from the resulting batochromic shift of ARS 
it is possible to calculate the constant K2 for the binding of the boronic acid to the 
second diol. From the results provided in Table 3-3 it is possible to highlight the 
following points: 
 
A) We have used three negative controls: phloroglucinol, which has three aromatic 
non-vicinal OH groups; veratrylamine and T2, which feature methylated catechol 
units. As it happens with 3-APBA, no binding was recorded also for X2, ensuring 
therefore that the polymeric HA structure does not directly interfere in the 
equilibrium. 
 
B) The boronic/diol complexation has an effect on the macromolecular dimensions of 
HA derivatives. A distinct shrinkage (Rg reduced from around 55 nm to less than 40 
nm) was recorded both for P2 reacting with 3-APBA and for X1 reacting with 
dopamine (Table 3-2, bottom). Upon formation of the boronic/diol complex, the 
number of polymer-bound anions increase, due to the quaternarised boron atoms; 
the modest protonation of dopamine or 3-APBA at neutral pH does not 
counterbalance this effect. Therefore, on the grounds of the increased electrostatic 
repulsion between chain segments, one would expect an expansion of the HA coil, 
rather than its shrinkage. 
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C) With the exception of ARS, all diols bind more strongly to the macromolecular 
derivative X2 than to the low molecular weight compound 3-APBA. On the other 
hand, generally one would expect the polymer matrix to decrease the binding 
strength at least due to steric hindrance. 
 
D) In two cases, catechols were generated enzymatically from non-reacting precursors: 
respectively, 2-hydroxyestradiol from estradiol and dopamine from 3-
methoxytyramine. The kinetics of the two enzymatic reactions, respectively an 
hydroxylation and a demethylation, can be followed through the competitive 
equilibrium of the newly formed diols with the ARS/3-APBA and ARS/X2 
complexes (see appendix, Figure 3-7). The calculation of the kineitic parameters (
maxv  and MK ) is based on the assumption that the complexation is considerably 
quicker than the enzymatic reactions; therefore, a slow boronic/diol complexation 
would provide different values of the kinetic parameters of the enzymatic reactions. 
In our case (Table 3-4) the use of 3-APBA or X2 as reporters for the enzymatic 
reactions were indistinguishable, suggesting the kinetics of the complexation not to 
be heavily affected by the presence of the macromolecular chain. 
 
E) Despite both reagents being polymeric and multifunctional, in the complexation 
between P2 and X2 no gelation or increase in viscosity could be recorded (see 
appendix, Figure 3-8). 
 
In summary, the macromolecular HA backbone does not participate to the boronic/diol 
complexation, but does not hinder it and even appears to favour it. The reduction in the 
dimension of the macromolecular coil could indicate the presence of attractive 
interactions between boronic esters and macromolecular backbone that counterbalance 
and possibly overwhelm the increased electrostatic repulsion between the anions. The 
absence of rheological effects of the complexation between polymeric partners can also 
be interpreted along these lines, with a collapse of the macromolecular structures around 
the boronic esters that will favour strong aggregation of a very limited numbers of 
partners rather than weaker aggregation involving several macromolecules. 
A possible mechanistic explanation of this effect is that the HA backbone may cause a 
decrease in the pKa of the boronic acids. The opposite effect has been observed in 
synthetic polymers such as poly(N-isopropyl acrylamide)
48
, where the decrease in 
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acidity is related to the closer proximity among boronic acids. However, to our 
knowledge no literature report exists about the acidity of boronic acids linked to 
strongly H-bonding polymeric substrates, such as HA. We have used an empirical 
equation validated by Wang
49
, which sets the optimal pH as the numerical average 
between the pKa of diol and boronic acid, and calculated optimal pH values for 3-APBA 
and for X2, with the latter pKa calculated to be 0.5 units lower than that of 3-APBA 
(Table 3-3, 5
th
 and 7
th
 column). Following this, the optimal pH for all diols except ARS, 
would be closer to neutrality for X2, i.e. they would bind the HA derivative more 
strongly than 3-APBA. The reverse applies for the more acidic diols. Indeed this is what 
is experimentally recorded for ARS and all other diols. 
Using the estimated pKa value of 8.4 from the titration plot of X2 (see appendix, Figure 
3-9), we believe that due to the increased acidity and therefore increased reactivity of 
HA-bound boronic acids, it is possible to rationalize all our experimental observations.  
Comparing the results from Table 3-3 and Table 3-4, we come to the following 
conclusions: HA-boronic derivative X2 binds to 1,2-diols better than 3-APBA due to a 
lower pKa, which brings the optimal pH of binding to most diols closer to physiological 
pH. This is an excellent finding, as X2 is reasonably reactive towards diols, and does 
not affect the binding strengths negatively due to the presence of the polymeric chain. It 
also signifies that, since the optimal pH of binding is closer to physiological pH, the 
release of the diols would be at a less acidic pH than that of the diols bound to 3-APBA. 
The enzymatic reactions also show that the polymeric chain does not hamper the 
reactivity of the enzyme towards the substrates, and proves that the analytical method 
works in the case of polymeric chains as efficiently as it does for small molecules. The 
binding of X2 with other polymeric-diols proves that our carrier could be used for 
transporting big molecules as well; however studies with proteins and other big 
molecules have not been performed. This helps us achieve one the main aims of the 
project, which was to study the conjugation of diols to our polymeric carrier in order to 
ensure a decent reactivness towards diols.  
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Table 3-3. Equilibrium constants (K1 for ARS and K2 for all other diols) for various diols with HA-BA 
and 3-APBAa at pH 7.4 in 0.1 M PBS buffer. SD are calculated over n = 3. The values of optimal pH for 
binding are calculated using the 3-APBA actual pKa and the estimated pKa of X2 to be 8.4. 
Diol 3-APBA
 
 X2 
Class Name pKa K (M
-1
) 
Opt. 
pH
b
 
K (M
-1
) 
Opt. 
pH
b
 
 ARS 4 5150 ± 200 6.5 2550 ± 150 6.2 
N
eg
at
iv
e 
co
n
tr
o
ls
 
Phloroglucinol 8.5
50
 0 8.7 0 8.5 
Veratrylamine = 0 = 0 = 
T2 = 0 = 0 = 
A
ro
m
at
ic
 d
io
ls
 
Pyrocatechol 8.62
51
 1490 ± 70 8.8 1844 ± 110 8.5 
Dopamine 8.89
52
 1555 ± 66 8.9 1955 ± 117 8.6 
Dopamine from 3-
methoxytyramine 
8.89
52
 1550 ± 73 8.9 1839 ± 110 8.6 
Epinephrine 8.55
53
 1445 ± 65 8.7 1910 ± 114 8.5 
Norepinephrine 8.6
54
 1545 ± 66 8.8 1969 ± 118 8.5 
2-hydroxy 
estradiol from 
estradiol 
c
 
9.4
55
 955 ± 38 9.2 1061 ± 67 8.9 
A
ro
m
at
ic
 
p
o
ly
o
ls
 
Pyrogallol 
d
 9.1
56
 1796 ± 78 9.0 2325 ± 140 8.8 
Quercetin 
e
 7.6
57
 1240 ± 98 8.3 1312 ± 115 8.0 
S
u
g
ar
 d
io
ls
 Mannose 12.13
58
 5.85 ± 1.2 10.5 6.43 ± 0.85 10.3 
Glucose 12.3
58
 3.75 ± 0.4 10.6 3.98 ± 0.31 10.4 
Ascorbic acid 
f
 11.8
59
 6.4 ± 0.94 10.4 7.04 ± 0.83 10.1 
P
o
ly
m
er
ic
  
d
io
ls
 P2 (8.9) 
g
  1440 ± 61 (8.9) 1717 ± 103 (8.6)  
PEG-Dopamine (8.9)
 g
 1025 ± 42 (8.9) 1432 ± 86 (8.6) 
a with the exception of P2, T2 and PEG-dopamine, all the 3-APBA were obtained in a previous study. 
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b the optimal pH was calculated according to Yan et al.49 as ( ( ) ( )) / 2
optimal a a
pH pK boronic pK diol    
c  in the presence of sulphonated β-cyclodextrin to solubilise the steroid. The end point of the enzymatic 
reaction was used to calculate the value of the equilibrium constant, assuming complete conversion of 
estradiol. 
d  in the presence of TCEP to avoid pyrogallol oxidation. 
e in the presence of Tween 20 to solubilise quercetin. 
f in 1 M PBS. 
g due to the structural similarity, we estimate the pKa of this catechol groups to be substantially analogous 
to that of dopamine. 
 
Table 3-4. Comparison of the kinetic parameters for the CYP2D6-mediated demethylation of 3-
methoxytyramine and for the CYP1A2-mediated 2-hydroxylation of estradiol, using the complexation of 
the products to 3-APBA and X2 as a reporter of the enzymatic reactions. 
Substrate Reporter 
MK   
(M) 
maxv  
(pmol/pmol 
P450/min) 
Hydrolase 
activity 
(CLint)
 a
 
(L/pmol 
P450/min) 
 
Estradiol 3-APBA 3800 ± 650 65 ± 13 0.017 
Previous 
data 
Estradiol X2 3570 ± 990 56 ± 11 0.015 
This 
study 
3-methoxytyramine 3-APBA 281
 
 ± 8 49 ± 4 0.18 
Previous 
data 
3-methoxytyramine X2 285 ± 6 54 ± 3 0.19 
This 
study 
a CLint (intrinsic clearance = MKv /max ) is a common measure of the enzymatic activity in the cell. 
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3.5 Conclusions 
 
In an attempt to evaluate the feasibility of the use of boronic/diol complexation for the 
purpose of bioconjugation, we have synthesised and conducted a semi-quantitative 
evaluation of the toxicity and degradability of boronic acid- or catechol-containing 
derivatives of hyaluronic acid. The more favourable toxicity led us to prefer the use of 
the first ones. We have then further compared the performance of a boronic acid-
containing HA derivative (X2, 25% mol of carboxy groups bearing phenylboronic acid 
residues) to that of the low molecular weight 3-APBA in the complexation to a library 
of diols. Rather surprisingly, the presence of this macromolecular backbone did not 
hamper the complexation, which could have happened either because of steric hindrance 
or of increased proximity between mutually repelling anionic boronic esters. On the 
contrary, the equilibrium constants to the vast majority of diols slightly increased (5-
15%) and clear reductions in the macromolecular size were recorded too. We have 
attributed these effects to an increase in the acidity of the boronic acids, which 
rationalize the results in terms of differences of the optimal pH for binding. 
The negligible toxicity, reasonable degradability and good binding strength (Kd around 
500 µM for catechols) are encouraging in the perspective of applying HA-boronic acids 
as carrier structures for the delivery of diol-functionalised payloads. 
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3.6 Appendix 
 
 
Table 3-5. Raw Data for Refractive Index of HA and its derivatives used for the calculation of dn/dc. 
 Refractive index for concentration of  
Sample 
3  
mg/mL 
2.2 
mg/mL 
1.5 
mg/mL 
0.8 
mg/mL 
0.1 
mg/mL 
dn/dc
a
 
(mL/g) 
HA 1.33488 1.33472 1.3346 1.33452 1.3344 
0.1518 ± 
0.015 
X1, 
X1/dopamine 
1.33485 1.3347 1.33455 1.33447 1.33438 
0.1526 ± 
0.01 
T1 1.33411 1.33399 1.33389 1.33381 1.33365 
0.1579 ± 
0.005 
P2 1.33465 1.33457 1.3345 1.33445 1.33439 
0.0885 ± 
0.012 
P2/3-APBA 1.33452 1.33445 1.33436 1.3343 1.33423 
0.1009 ± 
0.011 
a A plot of RI (y-axis) vs Concentration in g/mL (x-axis) gives a straight line, the slope of which is the 
dn/dc. 
 
 
 
 
 
Figure 3-5. Zimm Plot for parent HA (left) and for P2 (right). 
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Figure 3-6. Left: typical behaviour of the dynamic viscosity of HA and HA derivatives as a function of 
time upon exposure of water solutions. The concentration of the solutions were adjusted to obtain 
comparable values of the dynamic viscosity prior to degradation: HA, 1 mg/mL; P1, 16 mg/mL; P2, 18 
mg/mL; T1, 3 mg/mL; T2, 16 mg/mL; X1, 5 mg/mL; X2, 9 mg/mL. Right: values obtained from 
exponential fits of the viscosity curves (averages over three samples). 
 
 
 
 
 
Figure 3-7. Michaelis-Menten plots for the two enzymatic reactions followed in this study, using the 
complexation of the catechol product with 3-APBA or X2 as a reporter. The dashed line shows the result 
of a hyperbolic fitting on the X2 data. Left: demethylation of 3-methoxytyramine. Right: hydroxylation of 
estradiol.  
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Figure 3-8. The storage (G‟) and loss (G”) moduli of a mixture of X2 and P2 (both 5 mg/mL) in 10 mM 
PBS (frequency 1 Hz) as a function of time after mixing. No sign of increase in viscosity or build-up of 
an elastic character can be seen and the solution shows no sign of significant aggregation. 
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Figure 3-9. pKa determination for X2 using 10 mM NaOH 
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4. Conclusion 
 
Aims and Hypotheses. The two main aims of this thesis were to study the 
complexation of independent and polymer-conjugated boronic acids with diols in simple 
and complex systems (including enzymatic systems) using the batochromic shifts of the 
optical reporter ARS, and to prepare suitable HA derivatives for using boronic/diol 
complexation as a bioconjugation reaction. 
The hypothesis of this project is that any non-toxic, non-immunogenic, non-excretable 
and biodegradable polymer like HA is capable of being transformed into a drug delivery 
carrier by conjugation with a boronic acid, and can be used to deliver diol containing or 
catechol-containing/conjugated drugs/peptides/proteins by boronic-diol reversible 
complexation chemistry. Once injected into the body, the high molecular weight 
polymer would allow for a long circulation time and/or solubility of the drug, while 
possibly keeping it inactive while bound. The conjugate would then undergo 
endocytosis using cell surface HA receptors and, due to the reversible nature of the 
boronic-diol complexation chemistry, the acidic pH of the late endosome or lysosome of 
tumours and inflammatory tissues would release the drug. The HA-boronic would then 
undergo degradation by hyaluronidase enzymes. This would allow for an efficient 
delivery of bioactive molecules e.g. targeting it to inflammatory cells. 
 
Research Conclusions. Various bioconjugation techniques have been presented in 
Chapter 1, out of which the two main pH-sensitive ones are boronic-diol and acetal 
linkages. Acetals, like boronic-diol linkages, hydrolyse at acidic pH and hence have 
been used for drug delivery of anticancer drugs. The main advantage the boronic-diol 
technique has is that the hydrolysis can occur quickly at less acidic pH‟s like 5.5 – 6 of 
the endosome as compared to acetals which have a slower release and require a much 
more acidic medium of around pH 5 which is found in lysosomes. Another advantage is 
that the equilibrium constants for boronic-diol conjugates are low, providing easier 
decomplexation.  
Boronic acids can be linked to polymers like HA which contain carboxylic acid and 
hydroxyl groups by various different functionalisation techniques, some of which have 
been reviewed in Chapter 1. One of the main reasons for choosing a polymer like HA 
is its biodegradability in vivo by hyaluronidase enzymes which needs to be retained 
even after functionalisation. The carboxylic acid group of HA is preferred for 
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functionalisation since there is only one group per repeating unit, hence allowing for 
minimum structural changes to the HA.  
A new technique for studying the complexation of boronic acids with diols (catechols, 
flavonoids, sugars, etc.) using ARS as an absorbance reporter has been presented in 
Chapter 2. In terms of equilibrium constants, the results obtained with this method are 
comparable to those of fluorescence-based assays. The main advantage of this method is 
its application to boronic-diol reactions in complex systems, such as in a self-
emulsifying system (Tween 20 + quercetin) and during enzymatic reactions (for 
example: conversion of estradiol to 2-hydroxyestradiol using CYP1A2). Accounting for 
the diversity of systems the batochromic shift method works for, it can be assumed that 
it would act as a good reporter for these reactions in a biological environment. 
Note: the two examples of enzymatic reactions have a specific relevance: the use of a 
colorimetric test to follow hydroxylation of cyclodextrin-complexed estradiol by 
CYP1A2 to 2-hydroxyestradiol could possibly allow to follow tumour development as 
the 2-hydroxy derivative is non-cancerogenic and tumour-inhibiting because of its rapid 
monomethylation by COMT.  
We have also presented for the first time the demethylation of 3-methoxytyramine by 
CYP2D6 to dopamine, which is a major drug for Parkinson‟s disease. We have shown 
that CYP2D6 is able to regenerate dopamine from its COMT-derived inactivation 
product, suggesting that the efficacy of catecholamine-based PD therapy may be 
influenced by the interplay between these two enzymes and by their polymorphisms.  
In Chapter 3 we have presented the synthesis of HA derivatives (-boronic, -dopamine 
and -veratrylamine) using a simple amine coupling technique. HA-boronic was 
synthesised to serve as a drug delivery carrier for diol containing bioactive molecules 
using boronic-diol complexation chemistry while HA-dopamine (and its control HA-
veratrylamine) can be used for cell and/or other surface functionalisation (for example: 
titanium dioxide surfaces) for biomedical devices.  
The study of the cytotoxicity of the HA derivatives on fibroblasts and macrophages 
revealed that HA-boronic was the least toxic, maintaining the highest cell viability even 
at remarkably high concentrations. All the derivatives showed a lower degradability 
than their parent polymer, decreasing with increasing degree of derivatisation. In terms 
of drug delivery carriers, this ensures a prolonged circulation time and recognition by 
the degrading enzymes. These results suggest the possibility of a rather long circulation 
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time (stability against degradation) without remarkable toxic effects, and are therefore 
encouraging in view of the application of HA-boronic as a drug delivery carrier.  
The equilibrium constants obtained for the complexation with HA-boronic were 
comparable to those obtained with 3-APBA, ensuring adequate binding of the diols to 
the carrier, and signs of coil contraction were seen with SLS. 
 
Future work. Future work should be focused on studying the uptake of these 
bioconjugates by cells through receptor mediated endocytosis, followed by the release 
of the drug and the breakdown of the polymeric carrier in vitro. Once a particular drug 
is selected for delivery, the process of bioconjugation can be optimized for optimal pH 
of binding and the kinetics for release on reducing pH, followed by the studies of uptake 
of the bioconjugate by cells and the release of the drug in vitro at first and then in vivo. 
Future studies could also involve the synthesis of microgels for drug delivery which 
would be pH responsive using the boronic-diol chemistry by using a boronic-derivatised 
polymeric carrier crosslinked to a diol containing drug. 
Various diol containing drugs can be delivered using this strategy and it might be useful 
for studying the conjugation and release of these drugs depending on their application; 
for example: anti-inflammatory drugs such as catechol, 3- and 4-methylcatechol, 4-tert-
butylcatechol, etc. can be delivered to leukocytes where they could be released and 
possibly reduce inflammation while the HA would be degraded enzymatically. Various 
anticancer drugs like 2-hydroxyestradiol, 3-(8‟(Z), 11‟(Z)-pentadecadienyl) catechol, 
caffeic acid, Cis 3,4-dihydroxycinnamic acid, 3,4-dihydroxybenzaldehyde, etc. can be 
delivered to tumour cells using the HA carrier where they could possibly induce 
apoptosis and block cell cycle while the HA could be degraded by the hyaluronidases. 
Also antihistamines like vitamin C, etc. can be delivered to vascular smooth muscle, 
glandular cells, endothelium and mast cells where they could prevent histamine release 
and increase the detoxification of histamine leading to treatment of allergies and/or 
control of inflammation.  
 
